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SUMMARY
This thesis describes work which I performed as a research fellow
in the Dept of Clinical Surgery, Royal Infirmary of Edinburgh,
under the supervision of Mr O.Eremin esq., Senior Lecturer,
studying the production of autologous human monoclonal antibodies
with reactivity against human breast carcinoma cells. A review of
the relevant literature concerning the immunology of breast cancer
and the production and uses of monoclonal antibodies was
performed.
In the experimental work, axillary node lymphocytes from patients
undergoing surgery for carcinoma of the breast were fused with
the human myeloma cell line LICR/L0N/HMy2. Resulting Hybridomas
were characterised by performing chromosome counts and
investigating cell surface markers. Supernatants of these
hybridomas were investigated for the presence of immunoglobuliun
and the reactivity of that immunoglobulin with breast carcinoma
cells investigated. Efforts were made to improve the rate of
hybrid production by introducing four variables into the fusion
experiment, viz. the prestimulation of lymphocytes with pokeweed
mitogen, the addition of feeder cells, the use of azaserine in the
selective medium, and the alteration of cell numbers. Of these
only the addition of azaserine was seen to improve the rate of
hybrid production. The results of this work are discussed in
relationship to the published literature.
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ABBREVIATIONS USED.
AEC 3-Amino 9-diethyl Carbizole.
DMSO Dimetyhyl Sulphoxide.
EBV Epstein Barr Virus
FCS Foetal Calf Serum.
HAT Hypoxanthine,Aminopterin and Thymidine.
HAzT Hypoxanthine,Azaserine and Thymidine.
ig Immunoglobulin.
McAb Monoclonal Antibody.
NSS Normal Swine Serum.
PAP Peroxidase anti-peroxidase Complex.
PBS Phosphate Buffered Saline.
PEG Polyethylene Glycol.
PWM Pokeweed Mitogen.
SAR Swine anti-rabbit immunoglobulin Antibody.
SIg Surface immunoglobulin.
SRBC Sheep Red Blood Cell.
TBS Tris Buffered Saline
TCM Tissue Culture Medium
SECTION 1.
AIMS OF THE THESIS.
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AIMS OF THE THESIS.
The aim of this study was to investigate the production of
autologous human monoclonal antibodies (McAbs) with reactivity
against breast carcinoma cells by the cellular fusion of axillary
node lymphocytes from patients undergoing surgery for breast
cancer with the human myeloma cell line LICR/L0N/HMY2 (hereafter
designated Hmy2).
Firstly, this study aimed to investigate ways in which the
efficiency of hybridoma production might be improved, by
investigating the beneficial effects of four variations of the
fusion experiment. These variations are 1) the prestimulation of
lymphocytes with pokeweed mitogen (PWM),2) the addition of feeder
cells to the fused cell culture 3) the use of an alternative
selective medium and 4) variation of the cell numbers used in the
fusion experiment.
Secondly, this study aimed to investigate the means by which
hybridomas and their secreted antibodies might be most
appropriately characterised.
SECTION 2.
INTRODUCTION AND REVIEW OF THE LITERATURE.
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2.1. Breast Cancer. A Brief Review of the Clinical Problem.
Carcinoma of the breast is a major cause of morbidity and
mortality in females living in industrialised affluent western
societies . In Scotland, 1175 women died of breast cancer in
1981 , this accounting for approximately 20% of all female cancer
deaths (Anon, 1981). During the years 1975-1979 over 2000 new
cases of breast cancer were registered annually, accounting for
about 20% of all female cancer registrations (Anon,1981). It has
been estimated that 1 in 14 women in the western world will
suffer from breast cancer at seme stage in their lives(Baum
1981) . The methods used to treat this disease have increased
as understanding of the natural history of breast cancer has
evolved during the course of this century. These methods are
briefly summarised as follows.
2.1.1.Surgery.
A variety of operations have been employed as primary treatment
of breast cancer. Surgery has aimed to remove the tumour together
with a variable amount of surrounding tissue ( breast, muscle),
as well as a variable number of the axillary nodes.
Halsted (1897) described in detail the operation of radical
mastectomy which still bears his name. This operation consisted
of the removal of the breast ,the underlying pectoral muscles
and the axillary contents. Halsted introduced this radical
operation in an attempt to reduce the high rate of local
%
recurrence associated with more conservative surgery at that
time. This operation became standard treatment for carcinoma of
the breast for many years.
This form of radical surgery was based on the premise that breast
cancer spread initially from the primary tumour to the axillary
nodes and finally to distant sites as metastases. As is discussed
later in this chapter this is now thought not to be the case, but
rather breast cancer is thought to disseminate early in the course
of the disease . Hence the surgical treatment of breast cancer has
become less radical and the operations of modified radical and
simple mastectomy and , more recently, lumpectomy , have
superceded radical mastectomy as the operations of choice for
primary breast cancer.
2.1.2.Radiotherapy
Radiotherapy was the next mode of treatment introduced into breast
cancer therapy and was originally used as an adjuvant to radical
mastectomy. McWhirter et al. (1948) proposed that radical
radiotherapy was an equally suitable method of treating axillary
lymph nodes as surgical removal and,therefore,suggested simple
mastectomy followed by axillary radiotherpy as an alternative to
radical mastectomy. This regime was adopted by many surgeons in
this country but not in the U.S.A. These techniques were employed
in the belief that carcinoma of the breast spread radially
outwards and that it would be possible,by aggressive local
treatment, to remove all tumour cells during the early stages of
the disease before distant metastases occurred.
q
This theory was challenged when long term follow up studies of
patients were published. Notable amongst these was the work of
Brinkley and Haybittle (Brinkley et al.,1975) who showed that women
who had undergone radical mastectomy for clinically localised
breast cancer had an increased incidence of death from metastatic
disease up to 30 years post surgery. This and other studies laid
the foundation of our current understanding of the behaviour of
breast cancer as a disease which disseminates early in the course
of the disease although actual distant recurrences may not appear
for many years subsequently ( Forrest,1981). Thus it became clear
that improved survival would not cane about by employing
increasingly aggressive local therapy but that some form of
systemic therapy may also be required to treat tumour cells which
had disseminated early in the course of the disease.
2.1.3. Endocrine therapy.
Beatson (1896) first described oophorectomy in the treatment of
patients with advanced or recurring breast cancer with apparent
beneficial results. A relationship between carcinoma of the breast
and the ovaries therefore was established. Recently,Jensen et al.
(1971) demonstrated that some breast cancers contained cytoplasmic
(and probably nuclear) receptors for oestrogen which were
comparable to receptors found in other oestrogen sensitive
tissues.This receptor site is a cytoplasmic protein which
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binds oestrogen and translocates the hormone into the nucleus
where it promotes cell protein synthesis and cell division.These
discoveries have led to a wide variety of endocrine manipulations
being employed in breast cancer therapy, including
oophorectomy (Henley 1947), adrenalectomy (Higgins et al.?1953),
hypophysectomy (Forrest et al.,1955), and the administration of
drugs with hormone related activity e.g. the
anti-oestrogen, tamoxifen.
2.1.4.Chemotherapy
Chemotherapy using cytotoxic agents has been widely used in the
treatment of advanced breast cancer, usually employing a
combination of such agents (Bisel 1980). More recently
peri-operative chemotherapy has been advocated as adjuvant
treatment in patients with operable breast cancer in an attempt to
decrease the incidence of tumour recurrence.(Rossi et al 1981).
In summary, the treatment of breast cancer has become more
complex. Factors such as the histological type and grade of the
tumour, the degree of nodal invasion by the tumour,the measurement
of oestrogen receptor status and the careful preoperative search
for distant metastases may all be taken into account when planning
treatment programmes for individual patients. The conducting of
properly controlled clinical trials allows the merits of each form
of treatment to be accurately assessed.
2.1.5.Survival Rates.
What effect have these alterations to the treatment of primary
breast carcinoma made to the survival of patients suffering from
this disease? When discussing survival data it is important
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to bear in mind the concept that breast cancer is a disease which
disseminates early but may recur late. Thus Brinkley and Haybittle
(Brinkley et al 1975) recorded an 82.8% five year survival (age
corrected ) in a group of 704 patients with operable stage I disease,
but this figure dropped to 46% at 25years, many of these patients
dying of the disease.
Comparable results were obtained by Langlands (Langlands et al 1979)
from a bigger series of 3878 patients. The benefits of adjuvant
chemotherapy have yet to be assessed on a long term basis.
2.1.6.Screening.
One method of improving this gloomy outlook has been to attempt
to detect the disease at an earlier stage using large scale
screening programmes of the population at risk. Such programmes
involve clinical and mammographic examinations and are currently
under evaluation. Shapiro (1977) concluded from the initial results of
the Health Insurance Plan breast screening programme in New York that
screening might improve the prognosis of breast cancer patients
under 50 years of age although the results in the older population
were as yet uncertain. Comparable screening programmes are taking
place at selected centres in the U.K. including Edinburgh , but the
effects of breast screening on the overall mortality of breast cancer
remains unclear.
Whatever the results of these screening programmes the fact
remains that a large number of women presenting with breast
cancer are still going to die of the disease. There is therefore
a strong case in favour of exploring new avenues of treatment of
this disease.
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2.2.EVIDENCE OF AN IMMUNE RESPONSE TO BREAST CANCER.
There is a considerable volume of clinico-pathological and
experimental evidence to suggest that human breast carcinoma
provokes an immune response in the host individual. This response
is thought to involve both cellular and humoral immune
mechanisms. This chapter will outline seme of the studies
characterising this response as it relates to the work of this
thesis.
2.2.1 Cell-Mediated Immune Response
Evidence of a cell-mediated immune response to breast carcinoma
cells comes from a variety of in-vitro and in-vivo experiments,
including skin hypersensitivity to tumour cell extracts,the use of
a "skin window" to directly examine and grade the cellular
response and the inhibition of leucocyte migration/adhesion by
tumour cell extracts. For ethical reasons skin hypersensitivity
tests and skin window tests cannot be used on healthy subjects as
controls. This does to some extent make the results of these tests
more difficult to evaluate.
Skin hypersensitivity tests involve injecting preparations of
tumour cells intradermally and then measuring the degree of
reaction produced by this injection. This gives a measure of the
cell mediated response to the injected material. Hollinshead et al.
(1974) used a skin hypersensitvity test to determine the cell
mediated immune response to extracts of breast cancer cells.
Soluble extracts from both breast carcinomas and normal
V3
breast tissue were separated firstly on a Sephadex column and secondly
by polyacrylamide gel electrophoresis. These extracts were then
injected into both breast cancer patients and control patients
suffering from non-breast,non-gynaecological cancers. It was found
that one of the fractions obtained on the Sephadex column produced a
positive reaction in breast cancer patients whether derived from
breast carcinoma or normal breast.Further separation of this fraction
however by electrophoresis isolated a protein fraction from breast
carcinomas which produced a positive skin reaction whereas the
equivalent fraction from normal breast did not. In addition the tumour
fraction produced a positive reaction in the control patients whereas
the fraction derived from normal breast did not. This study showed
that breast cancer cell extracts could produce positive skin reactions
in patients with breast and other cancers. This study has the
disadvantage that only a small number of patients were included in the
study.
Black et al.(1973) used a skin window technique to assess the reaction
to tissue sections of autologous tumour. An abrasion was made on the
patient's forearm and this was covered with a glass slide containing a
section of the patient's own tumour. After a period of time the slide
was removed and the cellular response to the section of tumour could
be examined microscopically. Forty per cent of breast cancer
patients showed a positive reaction to sections of autologous tumour
by this technique,whereas only 10% of this group reacted to sections
of normal breast. This reaction was demonstrable 1-2 years after
mastectomy and was more frequently present in patients whose lymph
nodes showed the features of sinus histiocytosis.The same author
IW
(Black et al.,1978) used both the skin window and leucocyte
migration tests as measures of immune response of breast cancer
patients to breast tumour cells. A wide variation of results was
seen in the patients studied and the conclusion of the study was
that the presence of a positive skin window or leukocyte migration
test might be of prognostic significance.
One criticism of these studies is that the processing of breast
tumour tissue either by preparing soluble membrane extracts,or
cutting sections and fixing them on slides may alter the nature
of expressed antigens and hence these tests may not be an accurate
reflection of what happens in vivo.
Andersen et al., (1964) described the leukocyte migration test as a
measure of cellular immunity. This assay involved measuring the
inhibition of leukocyte migration induced by breast cancer cells,
this inhibition being a measure of the cell mediated immune
response to that antigen. This test was found to be positive in
five of eight patients with breast cancers tested with extracts of
autologous tumour. None of these patients reacted with extracts
of autologous normal breast nor did the leukocytes of any healthy
donor react with breast carcinoma extracts.lt was concluded that
these five patients demonstrated an in-vitro cellular immune
response to breast cancer cells.
McCoy et al. (1974) reported the results of the leukocyte
migration inhibition assay in 26 breast carcinoma patients using
homogenised breast carcinoma extracts. Twenty of these
latter patients produced a positive reaction to autologous tumour
whereas none of these patients reacted to extracts of either
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normal breast or benign breast tumours.There was,however,some
crossover reaction in that breast cancer extracts did produce
a reaction in a number of normal controls. It was found that
the leukocyte inhibition assay compared well with the results
of skin hypersensitivity tests in these patients.This study
provided further evidence of a cell-mediated immune response
to breast cancer cells in some but not all the breast cancer
patients studied. Tsang et al. (1980) demonstrated that
leukocyte adherence inhibition occurred when peripheral blood
lymphocytes of breast cancer patients were treated with
autologous tumour extracts. This did not happen using the
blood of healthy controls.
These and other studies have demonstrated some evidence of a
cell mediated immune response to cancer cell extracts in
breast cancer patients.
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2.2.2 The Humoral Immune Response to Breast Cancer.
Humphrey et al.f (1974),assessed the reactivity of serum of breast
cancer patients with preparations of breast carcinoma cells using
both immunodiffusion and complement fixation techniques. Serum was
obtained from patients with both benign and malignant breast
tumours and healthy controls. A positive reaction using a
homogenised breast carcinoma preparation was found in 25% of
patients with fibroadenoma, 34% of patients with fibrocystic
disease and 46% of patients with carcinoma. None of the 54 healthy
controls produced a positive reaction. The breast carcinoma
patients who produced a positive reaction were found to react to
preparations of a variety of different tumour types as well.
Howard et al.(1979) reported the presence of an antibody in pooled
AB serum from healthy donors which bound to breast cancer cells as
assessed by an immunoperoxidase technique.This serum also bound to
breast tissue showing the features of epitheliosis, and the
authors suggested that this technique was specific enough to be
of value in the histological diagnosis of breast cancer. It
was,however, possible that the inmunoperoxidase assay used in
this study was detecting endogenous immunoglobulin in the breast
tumour sections and not bound immunoglobulin from the AB serum.
Edynak et al.(1971) described the binding of sera of breast cancer
patients to a variety of cultured breast carcinoma cell lines
using immunofluorescence. It was found that the sera bound
particularly well with a nuclear antigen on one of the breast
cancer cell lines. Sera from patients with medullary carcinoma
showed the highest degree of binding to the breast carcinoma cell
lines.
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Normal human sera showed a much lower degree of binding to the
breast carcinoma cell lines whilst the positive sera from breast
cancer patients did not react with a variety of other tumour and
normal cell lines. One criticism of this study was that only
cultured cell lines were used as targets and, as will be
discussed,the antigenicity of such lines is known to vary with
time in culture, it was also possible that the sera was bound to
HLA or other non tumour-specific antigens. Wasserman et al.(1975)
found a higher incidence of autoantibodies (anti-nuclear, -smooth
muscle,-glomerular and anti-mitochondrial ) in the sera of 100
breast cancer patients compared with normal controls. This may
not, however, represent an immune response to breast cancer but
instead be a reflection of increased cell breakdown within the
tumour. Nordquist et al.(1977),demonstrated the binding of sera of
breast cancer patients to the cultured breast cancer cell line
BT-20 and showed,using immunofluorescence, an increased incidence
of binding of breast cancer sera compared with sera from healthy
controls or patients with benign breast disease. Sheikh et al.
(1979) used immunofluorescence to detect binding of patient's sera
to sections of their own breast tumours. Sera from 45 out of 104
patients with ductular carcinoma reacted with sections of both
their own and other p^tie-hts tumours, whereas sera from patients
with lobular carcinoma did not react with sections of ductular
carcinoma. In addition ,the positive sera were found to react with
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other tumour types. Edynak et al.(1972) used similiar techniques
to detect binding of the sera of twenty two of twenty four breast
cancer patients to sections of autologous tumour,whereas this only
occurred in the sera of four of twenty healthy controls.The
positive breast cancer sera failed to react with a variety of
other cell types. It was concluded in this study that there were
anti-breast carcinoma cell antibodies in the serum of many breast
cancer patients. Priori et al.(1971) obtained breast carcinoma
cells from fresh mastectomy specimens and tested the sera from
breast cancer patients, those with benign breast disease, healthy
controls and other cancer patients for reactivity against these
cells using immunofluorescence techniques. The sera of 30 of 42
breast cancer patients reacted with these cells although there was
seme cross reactivity with the sera of both benign breast disease
patients and also one with an osteosarcoma.
These studies suggested that there were factors in the sera of at
least some breast cancer patients which appear to bind to breast
carcinoma cells in vitro. This provided sane evidence of a host
humoral immune response to breast cancer cells. These serum
factors, presumably antibodies secreted by B-cells sensitised by
tumour associated antigens,have yet to be characterised fully.
These studies do have sane technical limitations. The use of
immunofluorescence made the precise histological localisation of
the antibody binding site difficult. In addition this method did
not provide permanent records which would be available for
subsequent comparisons. As has been mentioned both the
fluorescence and immunoperoxidase techniques used may detect
cytophilic immunoglobulin in the tissue sections as well as tumour
reactive immunoglobulin from the patients serum.
It is concluded that there is evidence of both a cellular and
humoral immune response to breast carcinoma cells in some but not
all breast cancer patients.
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2.2.3. Clinico-pathological Evidence of an Immune Response to
Breast Cancer.
The following studies describe sane of the clinico-pathological
evidence for a host immune response to breast cancer cells .In
sane instances attempts have been made to correlate these features
of a host response with the course and prognosis of the disease.
Black et al,(1953) compared the histology of axillary lymph nodes
with survival in 226 patients with breast cancer, in particular
looking at the presence of sinus histiocytosis and follicular
proliferation. Each of these features was scored on a system of
0-4. It was found that the presence of sinus histiocytosis
correlated with a good 5 year survival compared with patients
whose nodes did not show this feature. This beneficial effect was
seen even in patients with axillary lymph node metastases at time
of diagnosis. The same author (Black et al.,1955) described the
presence of sinus histiocytosis as being a measure of the host's
immune response. Further work was reported comparing the value of
sinus histiocytosis, tumour infiltrating lymphocytes and tumour
histology as independent prognostic indicators. Although the
presence of a high concentration of tumour infiltrating
lymphocytes appeared to confer a favourable prognosis only a
small number of patients were included in the study. It was
suggested that the presence of sinus histiocytosis and perhaps
tumour infiltrating lymphocytes were independent prognostic
markers for breast cancer. This conclusion might be criticised
since approximately 12% of the patients in the study had no record
made of their axillary node histology.
1\
Berg (1952), however, was unable to detect any correlation between
the presence of sinus histiocytosis in axillary lymph nodes and
prognosis in patients treated for breast cancer. The same author
(Berg,1971) found it difficult to relate tumour morphology to the
presence of an immune response. Hamblin (1968) examined both
tumour infiltrating lymphocytes and node histology retrospectively
and found that their presence had prognostic significance which
appeared to be largely independent of other known prognostic
variables. Dire et al.(1963) found that the presence of sinus
histiocytosis in the axillary nodes appeared to produce an
improved ten year survival. Crile (1967,1968) reported a series
comparing radical mastectomy (with axillary node clearance) with
simple mastectomy (the axillary nodes being left in situ) for
women with no clinically detectable axillary metastases at the
time of surgery, and found that this latter group had a somewhat
improved prognosis. The authors concluded that uninvolved axillary
nodes provided some form of protection against the spread of
cancer. This concept is open to criticism since it is difficult to
detect axillary metastases by palpation alone. Cutler et al.(1969)
examined a group of 100 patients with bilateral palpable lymph
nodes in a series of 2000 patients with breast cancer and found
that in those patients with no histological evidence of axilllary
metastases, those with bilateral palpable nodes had an improved
survival compared with those with no palpable nodes. This study
suggested that bilateral palpable nodes
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hyperplastic and tumour free, represented a beneficial host
immune response.Tsakraklides et al,(1974)examined the histology of
regional lymph nodes and compared this to survival in patients
with breast cancer. A correlation was found between nodes
exhibiting lymphocyte predominance and good survival and
lymphocyte depletion and poor survival. The authors concluded that
lymph node architecture reflected the state of the regional
immune response which might affect survival. Anastassiodes et al.
(1966) examined the presence of sinus histiocytosis in axillary
nodes and described the presence of sinus histiocytosis as a sign
of the host's immune response. Tsakraklides et al (1975) examined
the relative T and B cell populations in the axillary nodes of
mastectomy patients and compared these with the histological
appearence of the node and the response of the lymphocytes to
mitogen stimulation. A wide variation in all these parameters was
observed suggesting a wide range of host immune response to breast
carcinoma.
Bloom and Richardson(1970) described the follow up over 20 years
of 1411 patients with breast carcinoma of whom 104 had medullary
tumours (tumours of high malignancy but with heavy lymphocytic
infiltration) . This group of patients had a much improved five
year survival compared with the rest of the group, and this
applied to patients with both positive and negative axillary
nodes. It was concluded that medullary cancer, in spite of its
high malignancy, had a favourable prognosis because of the immune
response it elicited. This study of a large series of patients
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over a long (20year) follow up provided important evidence to
suggest that a strong immune response may be a favourable
prognostic feature. Ownby et al.(1983) measured peripheral blood
lymphocytes and eosinophils in breast cancer patients,and found
that those patients with a high lymphocyte or eosinophil count had
a significantly longer time to reccurrence than those with
lowcounts, suggesting that the level of the immune response may
affect the time to recurrence.
Eremin et al, (1976) defined the lymphocyte subpopulations in
normal human lymph nodes, inflammatory nodes and axillary nodes
from mastectomy patients. T and B lymphocyte subpopulations were
characterised using a variety of surface markers and rosetting
techniques, and the values obtained compared with the findings in
the peripheral blood lymphocytes from the same patients. Whilst no
difference was found in the blood lymphocytes of the three groups,
significant differences were found in the nodes. Regional tumour
nodes were found to have an increased percentage of B cells and
decreased percentage of T cells compared with normal nodes,
although the total lymphocyte counts were elevated. Comparable
changes were found in inflammatory nodes and tonsils, both
responding presumably to viral and bacterial antigens. In a later
report,(Eremin et alf>L980), lymphocyte subpopulations were studied
in association with changes of microarchitecture of the node.
Increased paracortical thickening and sinus histiocytosis were
associated with a relatively increased T-cell count whilst
lymphoid follicles were enlarged in those nodes with an increased
B- cell count. The changes in the T- and B-cell populations in the
regional tumour nodes were seen to be similiar to those seen in
nodes subjected to continuous antigen stimulation ie chronic
inflammatory nodes. This provides sane evidence that the axillary
nodes draining breast cancers are involved in a local immune
response and are subjected to repeated persistent antigenic
stimulation, although the nature of the antigen is uncertain.
These studies suggest that there is a host immune response to
breast cancer. This response appears to involve both cellular and
humoral immune mechanisms . The presence and extent of this
response has been investigated for its effect on prognosis but no
definite relationship between the immune response and prognosis
has been established. The presence of an immune response implies
that breast carcinoma cells possess antigen(s) which are
recognised as foreign by the body's immune surveillance system,
thus precipitating the response.The nature and specificity of
these antigens remains unclear.
Black et al. (1976) compared the antigenicity of precancerous
nastopathy, in situ carcinoma and invasive carcinoma using the
skin window technique,and found that a positive response was
obtained more regularly and to a greater extent in those patients
with preinvasive disease. Cross reactivity between benign and
malignant breast tumours was also seen in the work of Humphrey et
al. (1974), Priori et al. (1979),and Avis et al , (1976) .The same
effect has been shown by workers using monoclonal antibodies as
will be described in subsequent chapters.
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It has been postulated that the tumour associated antigens
inducing an immune response might represent de-differentiation
antigens which might also be expressed on benign breast tumours.
Hollinshead et al.(1974) attempted to isolate the protein fraction
of soluble membrane antigens which was unique to breast carcinoma,
and succeeded in isolating one protein band which ,as has been
described, appeared to have these properties. Kufe et al(1983)
used a variety of monoclonal antibodies to detect breast carcinoma
cells at various stages of differentiation and concluded that
cancer-associated antigens may only be exposed at certain stages
of the cell cycle. Leung et al« (1979) investigated the presence of
mammary tumour glycoprotein(MTGP) which was initially obtained
from the cytoplasm of 7 breast tumours tested but in none of 54
normal tissues. In a larger series MTGP was found in 76.2% of all
cancers and it was postulated that this molecule might represent a
specific marker for breast cancer.
Rosen et al , (1982) examined the value of pregnancy specific
glycoprotein as a marker for breast cancer but found that it had a
wide distribution in normal tissues. Old(1981) concluded that
whilst the evidence for tumour antigens was extensive and varied
»*• was nevertheless indirect , and tumour specific antigens
have yet to be defined directly and specifically.
It is concluded that there is considerable indirect evidence of
an immune response to breast cancer,and that breast carcinoma
cells do possess tumour-associated antigens not usually expressed
by normal differentiated cells.. Axillary lymph nodes have been
shown to be similiar to those undergoing persistent antigenic
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challenge, and to contain increased populations of B cells. It is
proposed that axillary lymph nodes of breast cancer patients do
contain B lymphocytes which have been specifically sensitised by
tumour associated antigens and that these B cells therefore have
the potential to secrete antibody with specificity for breast
carcinoma cells . This forms the theoretical basis on which this
study into the production of human monoclonal antibodies with
reactivity against breast carcinoma cells is based. The following




2.3.1. The Initial Experiments
The production of monoclonal antibodies (McAb) of predefined
specificity was first described in the now well known work of
Kohler and Milstein in the mid 1970"s. In their initial studies
into the diversity of antibodies, (Kohler et al.,1975) two antibody
secreting mouse cell lines were fused together, using inactivated
Sendai virus to promote cell fusion. These fused cells ,or
hybridomas, were grown in selective medium, and their secreted
products investigated. These hybridomas had a chromosome count of
just less than that of the sum of the two parent cell lines,
indicating that these cells had arisen by fusion of both parent
cells. The secreted products of these cell lines and of the
original parent cell lines were investigated by
Immunoelectrophoresis. The hybrids were found to secrete
immunoglobulins which were different from those secreted by
either parent cell. However, when the secreted immunoglobulins of
both parent cells and hybrids were reduced to their constituent
light and heavy chains,it was demonstrated that the hybridomas
were secreting the same chains found in both parent cells. It was
deduced therefore that the new immunoglobulins secreted by the
hybridomas arose by different combinations of the various chains
secreted by both parent cells. No new immunoglobulin chains were
secreted by the hybridomas.
Earlier studies (Milstein et al.,1974) had shown that the V (
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(variable) and C (constant) regions of each antibody chain were
coded for by one mENA molecule. It was concluded therefore that
fusion of two secreting cell lines produced no scrambling of the V
and C regions of each immunoglobulin chain. The production of new
immunoglobulins was concluded to be an intracellular event,in that
simple mixing of the two parent cell lines resulted in no new
antibody formation. Whilst these hybridomas secreted a variety of
immunoglobulins, the specificity of these molecules remained
unknown.The next important step was to modify this experimental
model to secrete antibody of predefined specificity. This was
achieved (Kohler et al 1976(a)) by fusing an antibody secreting
murine myeloma cell line with a lymphocyte which had been
sensitised by a known antigen, in the hope that the resulting
hybridoma would secrete antibody against that antigen. A Balb/c
mouse was immunised by the injection of sheep red blood cells
(SRBC's) which were known to provoke a strong immune response in
these mice. After a few days the animals were sacrificed and their
spleens removed. The spleen cells were then fused with the mouse
myeloma cell line P3-X63 Ag8. The resulting hybridomas secreted
immunoglobulin chains different from the myeloma cell line, and it
was concluded that the hybrid was secreting immunoglobulin chains
coded for by the parent lymphocyte. The chromosome count of these
hyridomas was slightly less than the sum of the two parent cells
but greater than twice the chromosome number of Balb/c cells
indicating that these hybrids did not result from the fusion of
two spleen cells.
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The resulting hybridomas were cloned on agar and the reactivity of
their supernatants was tested for their reactivity to SRBC's by a
complement mediated lysis test. Several hybrids were found to
secrete antibody with specificity against SRBC's ie antibodies of
predefined specificity had been produced by the fusion of a
sensitised lymphocyte with a myeloma cell line.
In their second report (Kohler et al 1976 (b)) further work was
described which showed that these antibodies of predefined
specificity were truly monoclonal. Using similiar techniques to
those already described,mice were immunised with either SRBC's or
trinitrophenyl (TNP) bound onto fowl immunoglobulin, and the
spleen cells of these mice fused with the mouse myeloma line.
Supernatants were tested for their reactivity by their ability to
lyse 1) SRBC's and 2) SRBC's coated with TNP. Hybridomas positive
for lysis were then cloned on agar and these clones were tested
for anti-SRBC activity. These supernatants were also characterised
by immunoelectrophoresis. It was shown that the positive
hybridomas and clones secreted immunoglobulins with different
light and heavy chains from those secreted by the parent myeloma
cell line,as well as chains from the myeloma cell line . By
repeated cloning it was possible to produce a cell line which
secreted only the new immunoglobulin chains and none of the
myeloma chains. This hybridoma clone secreted antibody with the
maximum activity against SRBC's and it was concluded that these
clones were producing pure or monoclonal antibodies of predefined
specificity.
30
In summary, the following stages are involved in the production of
monoclonal antibodies.
1) A myeloma cell line which transmits the properties of stable
growth and antibody secretion in culture.
2) A lymphocyte sensitised by the appropriate antigen and capable
of antibody production.
3) The successful fusion of these cells to produce stable
hybridomas.
4) The means to detect antibody production by hybridomas and the
characterisation of these antibodies.
5) Selective growth of fused cells , so that fused cells will grow
in conditions in which the parent cells will die.
6) Cloning of the hybrid cultures to ensure that the antibody
produced is truly monoclonal.
The work of Kohler and Milstein represents the foundation of McAb
production. The following sections will describe how these
techniques have been modified and advanced by other workers in the
production of a large variety of monoclonal antibodies.
2.3.2. The Mouse Model.
Myelcroa Cell Lines.
Kohler and Milstein used a myeloma cell line derived from a Balb/c
mouse for fusing with lymphocytes. This cell line was selected
for resistance to 8 azaguanine,thus making it suitable for use in
selective medium as will be described. It had,however,the
disadvantage of secreting an IgG immunoglobulin chain of its own.
Many workers (Kohler et al.,1976(b) , Fazekas 1980 (b),Goding
1980) have commented on the difficulties posed by using a
secreting myeloma cell line for McAb production. The resulting
hybridomas would have the potential to secrete a number of
different immunoglobulin molecules from a variety of combinations
of the chains produced by both parent cells. The isolation of the
hybridoma(s) secreting immunoglobulin chains derived from only the
spleen cell requires considerable effort. There are obvious
advantages in using a myeloma cell line which does not secrete
immunoglobulin chains of its own but which, when fused with a
lymphocyte, will still transmit the properties of perpetual
growth and antibody production in culture (Goding 1980). . Such
variants of mouse myeloma cell lines have been successfully
produced and used for McAb production.
Kearney et al,(1978) produced a non-secreting variant by repeated
cloning of a mouse myeloma line and testing the supernatant of
each clone for antibody production. These variants were
successfully used to produce McAbs by fusion with a splenic
B-cell. Continuous culture of these variants did not produce any
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revertants throughout the period of testing-ie immunoglobulin
production was not resumed by these cells and this mutation
appeared to be stable. Hybridomas resulting from this
non-secreting variant did secrete immunoglobulin, but none of the
chains secreted by the hybrids was similiar to any of the original
myeloma chains. Kohler et al. (1976(a)) produced two non secreting
variants of the M0PC21 myeloma cell line which were successfully
used for McAb production. Such spontaneously occurring mutants
were estimated to occur with a frequency of 10~3 to
10""Vcell/generation in the myeloma cell culture and these mutants
were not seen to revert to antibody production at a later date.
Schulman et 31,(1978) likewise produced a non-secreting murine
myeloma cell line variant which was successfully fused to mouse
spleen cells to produce antibody secreting hybrids.
In summary non-secreting murine myeloma cell lines have been
produced which can be used to form hybridomas which secrete
antibody derived only from the spleen cell and this represents a
considerable advance in McAb production.
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2.3.3.The Spleen Cell
Kohler and Milstein demonstrated by Immunoelectrophoresis the
production of new immunoglobulin chains by hybridomas of spleen
cells and myeloma cells , concluding that this new
immunoglobulin must be derived from the spleen cell. It was
concluded that the spleen cell was therefore a cell which had been
specifically senstised by the appropriate antigen and primed to
secrete antibody- ie it had the properties of a B lymphocyte.
2.3.4.Immunisation Schedule.
The immunisation schedules described below outline the regime used
to immunise mice with the appropriate antigens prior to sacrifice
of the animal and removal of the spleen for use in fusion
experiments. Kohler et 31,(1976(3), 1976 (b)) reported that there
was a considerable variation in the efficiency of hybridoma
production. This could be related to the immunisation schedule
used and the time interval between the last booster injection and
the removal of the spleen. These findings suggest that there is an
optimum immunisation schedule for McAb production. Stahli et
al(1980) investigated this aspect of McAb production and concluded
that succesful fusion required a high frequency of blast cells in
the spleen cell preparation which could be achieved by adjusting
the immunisation schedule. Andersson et al. (1978), reviewing the
evidence that altering the immunisation schedule could improve the
rate of hybrid production, attempted to simulate this effect by
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prior stimulation in-vitro of the B cell population. The mitogen
used was lipopolysaccharide which had been shown to stimulate
specifically the B-cell population (Kearney et al.,1975). The
rates of hybrid production using mitogen stimulated spleen cells
was found to be comparable with that obtained using an optimum
immunisation schedule.
It is concluded from these studies that the successful production
of McAbs requires lymphocytes which are at the correct stage of
differentiation-ie at the blast cell stage when they are actively
dividing and are committed to antibody production.
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2.3.5.Cell Fusion
The fusion of two mononuclear cells to form a single cell which
inherits the properties of both parent cells is central to the
work of McAb production.
Fusion between cells of similiar type was shown to occur
spontaeously when grown together in in-vitro culture(Littlefield
1964). The rate of fusion,however, between the two mouse
fibroblast cell lines used in this study was very low. Efforts
were made,therefore,to find agents which would promote cell
fusion. Harris et al,(1965) reported the use of Sendai virus,
inactivated by ultraviolet light,to promote fusion between human
HeLa cells and mouse Ehrlich cells. Yerganian et al.(1966) also
was succesful in using inactivated Sendai virus to promote fusion
of dwarf hamster cells.
Sendai virus was regarded as a useful fusogen and was successfully
used in the production of McAbs by early workers (Kohler et aly
1975,1976(a) . There are problems, however, associated with the
use of Sendai virus. Its use is limited to laboratories with the
facilities to produce inactivated Sendai virus. Its fusion effects
tend to be variable and there is always the possibility that
virus particles will be incorporated into the hybridomas and hence
alter their characteristics. For these reasons Pontecervo (1975)
sought to develop a more suitable fusing agent. It had been
observed that polyethylene glycol (PEG) promoted fusion between
plant fibroblasts . This substance was investigated for its
ability to promote fusion between mammalian cells. PEG was
successfully demonstrated to promote fusion between mouse and
hamster cells and between human fibroblasts and lymphocytes.
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PEG has since been confirmed to be a stable and reliable fusogen
and has now superceded Sendai virus in the production of McAbs.
White et al.(1980) investigated the cellular mechanism of cell
fusion using electron microscopy.In these studies it was shown
that the' fusogen' promoted fusion between the membranes of the
two parent cells with no leakage of contents. Fusion of the nuclei
did not occur until both cells underwent the next division. This
offers an explanation as to why it is important to have both
parental cells actively dividing at the time of cell fusion.
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2.3.6.Selective Growth of Hybridcmas.
It is important that, when cell fusions are performed, the
hybridomas will grow in culture medium in which both parental cell
lines will die. It has been estimated that cell fusion occurs
approximately once for every 10^ parent cells used (Kohler et al
1976(a), Fazekas et al, 1980(a)). Therefore after fusion, there
will be only a few hybridomas mixed in with several million
unfused parent cells, and clearly these hybrids would be
impossible to isolate if all the parental cells also grew in the
culture medium. Two systems of hybrid selection have been
described and these will now be discussed.
a) Selective Drug Resistance.
This method depends upon the fact that cells selected for
resistance to certain drugs lack specific enzymes which are
essential for cell growth.If the two parental cells are selected
so that they lack complementary enzymes then neither cell line
will survive in culture but hybridomas of these cells will survive
as they will inherit enzymes from both parents. Littlefield (1964)
described resistance to two such enzymes in a cell fusion
involving two fibroblasts. One parental cell line was selected for
resistance to 8 azaguanine . These cells were shown to lack the
enzyme Guanylic acid -ionosinic acid pyrop'nosphorylase. The second
cell line was selected for resistance to 5 bromodeoxyuridine, and
was shown to lack a thymidine kinase. It was shown that neither of
these cells would survive in culture medium containing
hypoxanthine, aminopterin and thymidine (HAT). By mixing cultures
of the two cell lines and growing this mixture in selective
medium, it was found that some colonies of cells survived. These
cells were shown to contain approximately twice the DNA,RNA and
chromosome content of the parent cells. These cells were also
shown to contain both the enzymes thymidine kinase and guanylic
acid pyrophosphorylase. It was concluded that these cells
represented fused cells which had survived by inheriting enzymes
from both parent cells. Reading (1982) described this method in
more detail.Cells selected for resistance to 8 azaguanine lack a
functional hypoxanthine phosphoribosyltransferase( which is the
same enzyme as guanylic acid pyrophosphorylase) and cells
selected for resistance to 5 bromodeoxyuridine lack a thymidine
kinase. Both of these cells are unable therefore to utilise the
"salvage" pathways for purine and pyrimidine synthesis although
they can still manufacture these substances de novo. The addition
of aminopterin, a folate antagonist which inhibits dihydrofolate
reductase, blocks this de novo synthesis. Cells grown in HAT
containing medium will fail to multiply and will die. The fused
cells however inherit these enzymes from both parents and are
able to utilise the hypoxanthine and thymidine in the selective
medium to produce purines and pyrimidines by the "salvage"
pathway and will survive and grow,
b)Irreversible Biochemical Inhibitors.
Wright (1978) proposed this alternative method of cell selection,
in which cells were treated with different biochemical inhibitors
to stop their growth. If two cell lines are treated with different
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complementary biochemical inhibitors then neither will be able to
survive in cell culture,whereas fused cells by inheriting
molecules from both parents will be able to survive. A wide
variety of inhibitors was suggested by the authors and experience
of using two of these was described- iodoacetamide and
diethylpyrocarbonate. Whilst these inhibitors were successful in
allowing selective growth of hybrids, this system had a number of
disadvantages which were noted by the author.This system was
unpredictable and difficult to use, and the incorporation of these
inhibitors might alter the characteristics of the cells. The
system does have the obvious advantage of not requiring selective
medium. Littman et al (1983) used this system to produce
human-human McAbs by fusing peripheral blood lymphocytes with a
variant of the GM1500 human myeloma cell line,using
diethylpyrocarbonate. It was concluded that the use of selective
drug resistance and HAT medium was more efficient in terms of
hybrid production.
The system of selective drug resistance has been most widely
accepted and has been widely employed in McAb production.
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2.3.7. Feeder Cells.
Fazekas et al, (1980(a) was interested to discern why the cell
fusion technique of Kohler and Milstein produced such variable
results. It was concluded by the author from his experiments that
the chief indicator of a successful fusion was the presence in the
culture tray of active macrophages, these macrophages being
derived from the spleen cell population. This phenomenon was
investigated by obtaining mouse peritoneal macrophages and adding
these to half of the wells in the fusion experiment.The addition
of macrophages in this manner was found to improve markedly the
rate of hybrid production. The same good results were obtained by
adding rat or guinea pig macrophages to mouse hybridomas. The same
author(Fazekas 1980(b)) postulated that macrophages were required
to remove the cell debris that accumulated as parental cells die
off. These products,if left,may inhibit hybridoma growth. Also,the
macrophages may produce and secrete substances which promote cell
growth. Reading(1982) emphasised the importance of"feeder "cells
for successful hybridoma production and pointed out that the
addition of feeder cells decreased the number of medium changes
required and hence decreased the risk of contamination.
Various cell types have been successfully used as feeder cells-eg
mouse peritoneal macrophages(Fazekas et al.,1980 (a), Edwards et al->
1982,Schulman et al.,1978), irradiated human fibroblasts (Kennett
et al.,1978) ,and mouse thymus cells(Andersson et al.^978,Lernhardt
et al.,1978,Schlom et aL.,1980).
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Astaldi (1980,1981) pointed out how little was known of the
mechanism by which feeder cells act. The efficiency of mouse
peritoneal macrophages as feeder cells was compared with the
supernatant from a culture of human endothelial cells (HECS)
obtained from a piece of umbilical vein.This supernatant was found
to be at least as effective as macrophages in improving hybridoma
production, and attempts were made to isolate the effective
component of this supernatant. This was thought to be a molecule
of molecular weight 750,000 which bound onto the hybridoma cells.
It is possible that feeder cells act either by phagocytosis of
cell debris and/or the provision of growth substances which
stimulate hybrid growth.
2.3.8. Human Monoclonal Antibodies.
Since the pioneering work of Kohler and Milstein ,the technique of
immunising mice with the appropriate antigen and using the spleen
cells of these animals for McAb production has been widely used
for the preparation of McAbs. McAbs have been raised to a wide
variety of antigens of various types including molecules eg
Trinitrophenol, (Kohler et al.)1976(a)), virus particles such as
influenza (Fazekas et alo1980(a)), cell membranes (Greene et al.,
1980) and whole cells (Fazekas et al.?1980(a)) . Such antibodies
have found a wide variety of uses in many branches of medical
science,and the production of these antibodies has attracted
considerable financial investment. The use of mouse-mouse
hybridomas does have some disadvantages however, if used in the
clinical situation . These are as follows.
Firstly, if a mouse is immunised with human tumour cells (whole or
extracts), the mouse is likely to be sensitised to both a large
number of species-specific as well as tumour specific antigens
(Milstein 1982, Kaplan et al.;1982). As has been discussed, the
precise nature of tumour-specific antigens is unclear and it is
impossible to immunise the mouse with a pure preparation of
tumour-associated antigen. The resulting hybridomas are therefore
likely to have a wide range of cross reactivity with normal human
tissues and a great deal of cell cloning will be necessary to
isolate a clone producing a tumour specific antibody (Burtin et al
1982) .
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Ashall et 31^(1982) produced a McAb by immunising mice with
extracts of a human laryngeal cell carcinoma and the resulting Cal
antibody was originally thought to be specific only for cancer
cells. When this antibody was further investigated it was also
found to react with a range of normal tissues as well.
Stepleweski (1980) used both melanoma and colonic carcinoma cells
as immunogens and found that only a few of the resulting MABs
reacted with the appropriate cell line selectively.There was
considerable cross reactivity with many of the McAbs with normal
human tissues. Minna et al.;(1981) encountered similiar problems
attempting to produce McAbs against lung cancer cells, as did
Brown(1982) .
Secondly,antibodies produced by mouse/mouse hybridomas will
secrete mouse immunoglobulins and there is a significant risk that
these will produce hypersensitvity reactions if administered to
patients repeatedly (Marx,1982, Bron, 1985). Miller(1981) noted a
mild hypersensitivity reaction after repeated injections of a
murine McAb to a patient with T cell leukaemia. Larson et al«>
(1983) discovered the presence of anti-mouse antibodies in the
serum of patients who had been given murine McAbs.In two patients
a second injection of murine McAb rapidly disappeared from the
circulation and this was associated with a large rise in the level
of anti-mouse Immunoglobulin in their peripheral blood. Thus even
if adverse hypersensitvity reactions are avoided there is
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the possibility that the usefulness of these antibodies will be
severely limited by the formation of anti-mouse antibodies in the
host individual.
One method of overcoming these problems has been to try to produce
human/mouse hybridomas by fusing a sensitised human lymphocyte
with a mouse nonproducer myeloma cell line.It was hoped that
these hybrids would secrete human McAbs and that they would be
more specific in their activity as the parent lymphocyte was
immunised in vivo. Whilst the feasibility of this technique has
been demonstrated (Schlom et al ->1980,Sikora et al., 1981), it is
associated with various problems. These hybrids tend to be
unstable and to preferentially lose human chromosomes (Olsson et
al .>1980,Sikora et al., 1982(c)). This method requires early and
frequent cloning of all hybrids to produce a stable hybrid. It is
possible that these hybrids selectively retain chromosome 14
(responsible for the human immunoglobulin heavy chain) as
suggested by Croce et alv (1979,1980(b)) . Gigliotti et al.-)(1984)
produced mouse-human MAbs against tetanus toxoid, diphtheria toxin
and the capsular antigen of Haemophilus influenzae,but found that
most hybrids lost their ability to secrete immunoglobulin .
Many workers are agreed that the ideal solution to these problems
would be the development of antibody secreting human-human
hybridomas, the development of which will now be discussed. Bloom
et al>,(1974) first demonstrated the feasibility of fusing together
two human lymphocytes. These cells were fused using
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inactivated Sendai virus and were grown in selective medium. The
fused cells retained a stable chromosome number and secreted
immunoglobulins derived from both parent lymphocytes.Both parent
cells contained chromosome markers and both of these markers
appeared in the fused cells confirming that fusion of the two
different cells had occurred.
The first two reports of the production of human/human McAbs of
predefined specificity were made almost simultaneously. Olsson et
al,,(1980) described the successful fusion of human spleen cells
(taken from patients with Hodgkins disease undergoing splenectomy
as part of a staging laparotomy ) with an 8 azaguanine resistant
variant of the human myeloma cell line U266. These patients were
immunised prior to fusion with dinitrochlorobenzene (DNCB). Five
hybrids were obtained from three fusion experiments and these
secreted antibody with activity against dinitrophenol. Croce et
al,,(1980(a)) fused peripheral blood lymphocytes frcm a patient
with subacute sclerosing panencephalitis with a human myeloma cell
line, and obtained hybrids which secreted antibodies with activity
against measles virus antigen.
Following these two reports several groups of workers have
reported the production of human McAbs . Shoenfield et al,(1982)
prepared autoantibodies by fusing the peripheral blood lymphocytes
frcm patients with autoimmune diseases with a human myeloma cell
line. Sikora et al.(1983(a)) fused lymphocytes frcm a variety of
tumours with the human myeloma cell line LICR/D0N/HMy2 in an
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endeavour to produce anti tumour antibodies. The same author reported
on the successful attempt to produce autologous McAbs with some
activity against human glioma cells (Sikora 1982(b)).Littman et al.
(1983) fused peripheral blood lymphocytes from a patient suffering
from systemic lupus erythematosus with a variant of the GM1500 cell
line in an attempt to produce monoclonal autoantibodies.
The production of human-human McAbs has proven to be more difficult
than the corresponding mouse McAbs. These problems include the low
rate of hybrid production (Sikora et al JL982(c)),the small amounts
of immunoglobulin secreted by these hybrids and the difficulties of
collecting and separating the lymphocytes which had been sensitised
in vivo to the appropriate antigen .Various aspects of the fusion
system have therefore been investigated in an attempt to overcame
these difficulties.
The human myeloma lines which have been used so far have two
disadvantages. Firstly they produce hybrids which secrete low amounts
of immunoglobulin. Olsson et alv (1980) demonstrated immunoglobulin
secretion of only 3-llug/day from hybrid cultures using the U266
line. Edwards et al.)(1982) described immunoglobulin secretion of
0 .l-3ug/day from hybrids derived frcm the LICR/LON/Hmy2 line.
Secondly these myeloma lines secrete immunoglobulin of their own
which complicates the analysis of hybrid secretion. For example the
U266 line secretes an igE (Olsson et al..> 1980) whilst the
LICR/LON/Hmy2 secretes an IgG (Edwards et alv1982).The desirability
of having a nonsecretor human myeloma line for the production of
human McAbs has been stated by Marx (1982) who commented on the fact
that "Cancer Institute officials hope to be able to budget
$0.5million to remedy this deficiency"(ie the absence of a
nonsecretor myeloma).
2.3.9. Epstein Barr Virus Transformation
An alternative approach to cell fusion in the production of human
McAbs has been proposed. This involves the transformation of
sensitised lymphocytes with Epstein-Barr virus (EBV). EBV
transforms B lymphocytes causing them to undergo blast
transformation,divide and secrete antibody.EBV is readily obtained
from a transformed marmoset line which secretes the active virus
(Miller et al.,1973) and this technique has been used to produce
human McAbs. Slaughter et al,(1978) used EBV to transform
lymphocytes from patients with rheumatoid diease to produce
monoclonal rheumatoid factor. Steinitz et al,(1979) transformed
blood lymphocytes from patients with high naturally occurring
anti nitrosonitrophenol(NNP) activity, and produced antibodies
with activity against NNP. Watson,D.B. et al.(1983) attempted to
produce anti-melanoma antibodies by EBV transformation of tumour
infiltrating lymphocytes. Rosen et al*(1977) measured the increase
in IgM and igG secretion following EBV transformation of normal
human and foetal lymphocytes. Steinitz et al,(1980) produced
monoclonal rheumatoid factor by the EBV transformation of
lymphocytes from patients with rheumatoid disease. Kozbor et
al(1982) pointed out the extremely low rate of immunoglobulin
production obtained by EBV transformed cells per se and attempted
to combine EBV transformation with cell fusion.Lymphocytes were
first transformed with EBV and then fused with an oubain resistant
variant of the myeloma cell line GM 1500. The potential advantages
of this will be discussed in a later chapter.
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2.3.10. Monoclonal Antibodies and Breast Cancer.
This chapter will discuss studies already reported which
have attempted to produce McAbs with activity against human
breast carcinoma cells.
Schlom et al. (1980), Wunderlich et al#(1981), and Teramoto et al.
(1982) fused axillary node lymphocytes of breast cancer patients
with a murine non-producer myeloma cell line using mouse
thymocytes as feeder cells. Supernatants of the resulting
hybrids were screened for the presence of human immunoglobulin
using a radioimmunoassay and these antibodies tested for
activity against breast carcinoma cells by an immunoperoxidase
technique. A total of 301 hybrids grew frcm 1460 wells using
lymphocytes frcm 16 patients. Fifty one hybrids (17%) secreted
human igG or IgM but only 23 of these remained stable in
culture.Of these latter hybrids one was selected , cloned and
the antibody further investigated.This antibody stained
approximately 50% of cancer cells in sections of the patients
own breast tumour. The percentage of cells stained and the
intensity of staining varied widely throughout the tumour. The
antibody did not react with surrounding normal breast tissue or
stroma, but did react with cancer cells in axillary node
metastases. The antibody reacted with a number of other breast
cancers, and to a lesser extent both normal breast tissue and
benign breast tumours from different patients. There was some
degree of cross reactivity with other tumour types e.g.bronchial
alveolar cell carcinoma and medullary carcinoma of thyroid, but
none with a selection of normal tissues.
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This study demonstrated the feasibility of using axillary
lymphocytes to produce McAbs with activity against breast cancer
cells. It is of interest that the staining reaction varied widely
throughout the tumour-this may be an artefact or may represent
variability of antigen expression within the tumour . The antibody
did show some activity against juxtatumoural normal breast cells
in some patients and also against some benign breast tumours This
suggests that these cells are in a stage of de-differentiation and
are beginning to express the tumour-associated antigen or
alternatively indicates that the antibody is not specific for
tumour cells. The cross reaction with other tumour types may
indicate a cross reactivity with other antigens having a similiar
epitope or it may be that the antigen recognised by the McAb is
not specific to the breast cancers but is shared by other
tumours. This study also indicated the instability of most
mouse-human hybrids although the one hybrid investigated had
survived more than 300 days in culture.
Ashall et al « (1982) and McGee et al (1982) described the
production of the Cal antibody, obtained by immunising mice with
extracts of a human laryngeal cell carcinoma. This antibody was
seen to bind to a wide variety of human tumour types using an
immunoperoxidase technique. Initial work suggested that this
antibody bound quite specifically to breast carcinoma cells.
Subsequent investigation by different workers,however,has
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failed to confirm this. While it was originally suggested that
this antibody recognised a tumour-specific antigen subsequent work
showed that this antibody also bound to a variety of normal
tissues.
Yuan et al. (1982) and Hendler et al (1981) produced a murine McAb
by immunising mice with the cultured human breast carcinoma cell
line ZR75-1. Of the twenty antibodies produced one was shown by
immunofluorescence to bind onto the ZR75-1 cell line and not to a
variety of normal human cells. This antibody showed positive
binding to 3 out of 6 other cultured human breast carcinoma cell
lines. When tested against sections of breast tumours positive
binding to tumour cells was detected in 54% of tissue sections
although the degree and intensity of binding varied considerably.
The antibody also bound cells in 84% of fibradenomas and 82% of
fibrocystic disease. It was suggested by the authors that this
antibody only reacts with well differentiated,oestrogen receptor
positive cancers. This antibody may recognise antigens which are
present in benign tumours and well differentiated carcinomas but
these antigens may disappear as the tumour becomes less well
differentiated. The technique of using cultured breast carcinoma
cells as immunogen is open to criticism. Breast carcinoma cells
are very difficult to grow in culture and the few established
cultured cell lines available have been distributed widely
amongst laboratories with the risk of contamination with viruses
and other cells. It has been demonstrated that these cell lines
can alter their characteristics markedly with repeated passages in
culture and therefore these lines may not represent the most
appropriate immunogen.(Hand et al.p.983).
Colcher et al, (1981) used a membrane extract of cultured breast
carcinoma cell lines (MCF7, BT20,ZR75-l)as immunogens to produce a
murine MAb which showed some activity against the parent cell
lines. The antibody also showed binding to a number of other
tumour cell lines of different origins but did not react with cell
lines derived from normal tissues. This study did not include a
record of the reactivity of this antibody to sections of breast
tumours which limits its usefulness. It lends some support to the
suggestion by Ashall et al (1982) that many tumour types share
common antigens although the presence of such common antigens
remains to be confirmed. Greene et al (1980) used a purified form
of the extranuclear oestrogen receptor protein from the MCF7
breast cancer cell line as immunogen and produced an antibody with
a variable activity against cells which possessed receptors for
oestrogen. Foster et al. (1982) used the human milk fat globule
membrane as immunogen in the production of murine McAbs. Four
antibodies were obtained which bound,to a variable extent and
degree of intensity, to both normal and malignant breast
tissue.This variable degree of uptake suggested a heterogeneity
of antigen expression throughout the tumour cell population.The
binding pattern of these McAbs to breast cancers did not seem to
correlate with the degree of differentiation of the tumour which
led the authors to suggest that these antibodies may provide
different markers from tumour histology and therefore be useful
probes for investigating the functional status of breast cancers.
Taylor-Papidimitrou et al. (1981) likewise used the human milk fat
globule membrane as immunogen and obtained antibodies which
reacted with both normal and malignant breast cell
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lines.These McAbs also showed some binding to pharyngeal and
colonic cancer cell lines. Arklie et al . (1981) further
investigated the specificity of this McAb against a variety of
tissue sections of normal and lactating breast , benign and
malignant breast tumours and found that the antibody bound well to
both lactating breast and sane carcinomas. Sane degree of binding
was also seen with a number of benign tumours suggesting that this
antibody recognised tissue-specific rather than tumour-specific
antigens. In the case of tumours,the antibody stained well
differentiated tumours better than poorly differentiated ones and
lobular tumours better than intraduct tumours. Some binding to
other tumour types e.g. adenocarcinoma of lung and ovary was also
detected. Papsidero et al.(1983) used the cultured breast cancer
cell lines MCF7 and SK-BR3 as immunogens. Of the resulting murine
McAbs two were selected which bound to the parent lines . When
tested against sections of breast tumours, neither of these
antibodies was found to bind selectively to breast carcinoma
cells. This study demonstrated the difficulties of using cultured
cell lines as immunogens. Menard et al,(1983) was likewise unable
to produce a specific anti-breast cancer McAb using MCF7 as
immunogen. Adams et al,(1983) prepared a murine McAb by immunising
mice with a soluble extract of the MCF 7 cell line. This McAb was
found to bind to a cytosol preparation of the MCF 7 cell line and
it was suggested that this McAb may provide a means of measuring
the oestrogen receptor status of breast cancers. King et al,
(1984) described a panel of murine McAbs which were raised
against oestrogen receptor protein, and which identified nuclear
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oestrophilin in sections of breast tumours ,using an
immunoperoxidase technique. Heterogeneity of McAb binding was
noted throughout the tumour cell populations. Hand et al, (1983)
investigated the binding patterns of four murine McAbs on 39
specimens of breast carcinomas and found that the pattern of
staining varied widely both within and between tumours suggesting
that breast carcinomas do possess a wide variety of antigenic
heterogeneity. Sikora et al. (1983(a)) fused lymphocytes from
axillary nodes of mastectomy patients with the human myeloma line
LICR/L0N/Hmy2. Binding of the resulting McAbs to breast carcinoma
cell lines was weak and no binding of these McAbs to sections of
actual breast tumours was demonstrated by immunohistological
staining. Capone et al,(1983) produced murine McAbs by immunising
mice with cells derived from breast tumour specimens,and these
McAbs were found to bind to breast tumour cells and a variety of
other epithelial tumour types,but not to a variety of normal human
tissues. Breast tumours were then xenografted into nude mice.
Subsequent injection of this McAb was found to dramatically
decrease the size of the xenografted tumour causing considerable
tumour necrosis. By radiolabelling this McAb specific targeting of
the McAb to the xenografted tumour was demonstrated. However no
attempt was made to xenograft normal human tissues , or other
types of tumour to determine whether this effect was specific to
breast tumours or not. Peterson et al' (1983) demonstrated a high
degree of variability of antigen expression in populations of
breast carcinoma cells by using a McAb to a single cell surface
component of the breast epithelial cell.
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In conclusion a wide variety of McAbs of both mouse and human
origin have beeen developed but none of these has been shown to
possess absolute specificty for breast carcinoma cells. These
studies do demonstrate 1) the feasibility of using axillary node
lymphocytes of breast cancer patients to produce anti-breast
cancer McAbs, 2) some potential uses for anti-breast cancer McAbs
(such as the measurement of oestrogen receptor status),and 3)
the fact that there appears to be a wide variability of antigen
expression within and between breast tumours, with some cross
reactivity with benign breast disease. It is also possible that
antigens on breast cancer cells may be shared by a variety of
other tumour types.
2.3.11. Clinical Applications of Monoclonal Antibodies.
The potential clinical application of McAbs has been investigated
in both experimental and clinical situations. This chapter will
discuss three main areas in which McAbs may be of value in the
management of malignant disease. These are 1) the investigation of
tumour antigens and tumour behaviour 2)the detection of occult
tumour deposits and 3)the selective killing of tumour cells.
2.3.12. The Investigation of Tumour Antigens and Their
__
Relationship to Tumour Behaviour.
As has been discussed there is evidence that breast tumours (and
other tumours) possess tumour specific or tumour associated
antigens although the precise nature of these antigens is as yet
unknown. McAbs may have a role in characterising these antigens
and defining their distribution throughout the tumour. Such work
may provide important markers for cancer cells thus giving more
information about the behaviour of the tumour which may be of
prognostic significance.
Foster et al .(1982) and Burchell et al. (1983) described the
distribution of the anti-milk fat globule membrane antibody in a
variety of breast tumours and concluded that the antigen
recognised by this antibody was independent of tumour histology,
oestrogen receptor status or other known variable. It was
concluded that this antibody may provide information of prognostic
significance. Similiar heterogeneity of antigen expression has
been demonstrated using McAbs in melanoma cell lines (Bruggen et
al 1983, Suter et al, 1983), colorectal carcinomas ( Daar et al.;
1983) and gastric carcinoma (Hockey et aL, 1984).
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Leinard et al. (1985) reviewed the heterogenous expression of
oestrogen receptor in breast tumours and metastases using McAbs.
This heterogeneity occurred within individual tumours and was seen
to alter in the same tumour after a period of time and after the
introduction of hormonal therapy, suggesting that the expression
of oestrogen receptor was constantly changing. This supported the
theory that malignant cells are continually mutating and altering
their antigenic characteristics . McAbs have been of value in
defining the heterogeneity of antigen expression within tumour
cell populations. This heterogeneity, which has been described as
being independent of the cell cycle (Edwards 1985) , is of
importance since it may limit the clinical potential for McAbs.
Edwards (1985) discussed the nature of the heterogeneity of tumour
cell antigens and postulated that this may be due to alterations
of the carbohydrate portionof the membrane glycoproteins en cell
membranes. He postulated that it may be possible to raise McAbs
against the constant protein fraction of these glycoproteins
although this has not yet been done. Baldwin (1985) discussed the
problem of using McAb /cytotoxic drug conjugates to treat cancer
and concluded that a "cocktail" of McAbs may well be required to
identify all tumour antigens. Neville et al.(1985) discussed the
implications of tumour cell heterogeneity, and likewise concluded
that there is a need for a panel of McAbs to treat cancer
adequately. McAbs have been used in a diagnostic role when routine
histology has failed to provide an accurate diagnosis. Kemshead et
al. (1983(a)) described the use of a panel of McAbs in the
diagnosis of a series of small round cell tumours in children. In
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each case McAbs provided the accurate diagnosis where routine
histological examination of the tumour specimen could not define
the precise diagnosis. Debus et al. (1984)described the staining
pattern of a number of murine McAbs raised against various types
of cytokeratins to a variety of tumour sections of different
origin. Different staining patterns were discerned depending upon
the type of tumour section used -e.g. squamous carcinomas stained
differently from adenocarcinomas. It was proposed that these
antibodies may be of value in distinguishing tumour types and
discerning their histological origin. Ghosh et al.(1983) described
the use of McAbs to detect tumour cells in histologically negative
aspirates from pleural and peritoneal effusions. Gatter et al.
(1982) used a panel of McAbs to distinguish anaplastic carcinoma
from high grade lymphoma. A number of cases were described in
which these McAbs provided an accurate diagnosis where normal
histological assessment was unreliable. These studies illustrate
some of the ways in which McAbs are being used to define tumour
antigens and characterise more precisely different tumours.
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The Detection of Occult Tumour Deposits.
By labelling antibodies with radioactive tracers it may be
possible to use tumour-specific antibodies in the detection of
both primary and secondary tumours.Labelling of antibodies can
either be achieved internally by growth in medium containing H.'
leucine ,or by conjugating the McAb with a radioactive tracer such
as 1^31#it is important l)that the means of labelling the antibody
does not affect the binding pattern of the antibody,and 2)that
the tracer is securely bound to the antibody,has a short half life
and is easily detected by external scanning. For these reasons
labelling is usually performed with radioactive iodine. Pressman
(1980) reviewed the techniques available for labelling and
concluded that labelling with 1^31 was an appropriate technique.
Cuello et al .(1982) internally labelled McAbs by growth in 3H
lysine and found that the labelled antibody had the same binding
pattern as the unlabelled antibody concluding that internal
labelling did not affect the activity of the antibody. Ghose et
al.(1975) reported that the conjugation of il31 to a polyclonal
antibody did not affect the activity of that antibody.
Radiolabelled antibodies have been used in both animal and human
studies to detect tumour deposits. Ballou et al.(1979) used an
I125 labelled mouse McAb to detect a mouse teratocarcinoma
successfully by external scintigraphy.
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Xenografts of human tumours in immunosuppressed mice have
been used to detect the binding of anti-human tumour
McAbs.This technique does have the disadvantage of failing
to demonstrate whether the McAb recognises a tumour-associatedantigen
or a species-specific antigen. Herlyn et al.(1983) conjugated mouse
McAbs,raised against human colonic carcinoma,with radioactive iodine
and then injected this antibody into mice containing xenograft tumours
of human colon.The latter were obtained by the intraperitoneal
injection of human colon carcinoma cells. The animals were sacrificed
after injection of the antibody and the activity measured in various
tissue types. It was concluded that a high proportion of the antibody
was bound to the xenografted tumour,especially if only the F(ab)2
fragment of the antibody was used. Similar results were obtained by
Mach et al.(1974) using a polyclonal anti-CEA antibody conjugated with
ll31. Moshakis (1981(a),1981(b))iodinated a mouse McAb with activity
against human teratoma cells using i125 and used this antibody to
detect tumour binding in a xenografted mouse. A high degree of
antibody binding to tumour,compared with other tissues,was noted using
autoradiography of the tissue samples. Warenius et al.(1981) attempted
to target an anti HLA mouse McAb to a human tumour xenografted to a
mouse. The antibody appeared however to have a higher uptake in the
mouse liver than the tumour. It was deduced that this was due to
circulating tumour antigen forming immune complexes in the blood,
these complexes being subsequently concentrated in the liver. This may
present a major problem in using radiolabelled
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antibodies to detect tumours -i.e. the injected McAb may
fail to reach the tumour. This may occur because of
circulating antigens in the blood which will bind the McAb
or else the McAb, being a foreign protein, may itself become
bound to circulating host antibodies. Colcher et al.(1983) used an
ll25 iodinated McAb to detect a human breast cancer xenografted onto a
mouse. The best uptake was found if only the F(ab)2 fragment of the
antibody was used.
The following studies describe seme of the human work performed with
radiolabelled McAbs. Sears et al.(1981,1982(a)) described the ex-vivo
perfusion of the human colon with radiolabelled murine McAb with
activity against colorectal carcinoma cells. It was suggested that
this may provide a useful model to assess the in vivo activity of such
antibodies. Such a model, however, failed to take into account any
binding of the antibody whilst in the circulation, nor dids it provide
information about the binding of the antibody to other tissues in vivo
i.e. it failed to define the in-vivo specificity and homing properties
of the antibody. The results of the above studies were not
promising. Three out of the six colons perfused showed preferential
binding to the tumour, two showed binding to normal and tumour
tissue,whilst one failed to show any binding of antibody at all.
Smedley et al.(1983) injected a rat McAb raised against human colon
carcinoma cells radiolabelled with il31 into 27 patients. Scintigrams
were performed 48 hours after injection of antibody and tumour uptake
in areas of known disease was recognised in 13 out of 16 patients with
colorectal cancer and 3 out of 4 patients with breast cancer. The
quality of the imaging however was poor.
Brown (1985) injected 125j_Conjugated McAbs into mice xenografted
with human soft tissue sarcoma and found that the maximum uptake
of McAb by the xenograft occurred at 7 days. Sears et al.(1982(b))
reported a series of four patients who received injections of
mouse McAbs. Anti-mouse immunoglobulin antibodies were detected in
three of these patients but no adverse reaction was noted
clinically. One patient, on the other hand, received multiple
injections and developed a mild hypersensitivity reaction after
the 4th injection. Eykes et al.(1980) injected polyclonal sheep
anti CEA antibody labelled with i!31 into a series of patients
with large bowel cancer.Four out of five primary tumour sites and
8 out of 11 secondary deposits were identified on the subsequent
scans, which helped to confirm the potential feasibility of using
radiolabelled antibodies as diagnostic agents. Larson et al.
(1983)injected a murine McAb with anti melanoma activity labelled
with i!31 into six melanoma patients. This technique successfully
identified 22 out of 25 lesions larger than 1.5cm in diameter.
Whilst no adverse clinical reactions were noted, anti mouse
immunoglobulin antibodies were subsequently identified in the
serum of three patients. Berche et al.(1982) injected murine
monoclonal anti CEA antibody labelled with 1^31 into patients with
colorectal carcinoma. External scintigraphy successfully
identified 16 of 17 sites of known tumour, 5 of these deposits
having volumes of less than lOcrn^. Mach et al.(1983) used an ll31
labelled murine McAb with activity against colon carcinoma cells
to detect by tomoscintigraphy 34 out of 63 known deposits of
colon carcinoma in 52 patients.
Farrands et al , (1983) used a murine McAb labelled with il31
to detect an osteosarcoma by rectilinear scintigraphy.In
conclusion,these studies,which are all preliminary in nature
involving small groups of patients,have shown the feasibility of
using radiolabelled antibodies to detect sites of tumour
deposits. The sensitivity of the techniques needed to be improved,
however, since these antibodies identified only large tumour
deposits currently detected by existing techniques. Neville et al.
(1985) described the conjugation of Ullndium to McAbs and
concluded that this was a preferable isotope to 125j for use in
the immunodetection of breast tumours.
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2.3.14. Tumour Therapy.
The use of McAbs as a means of selectively killing cancer
cells has the potential of being one of the major advances in cancer
therapy. McAbs have been looked upon as the potential "magic
bullet". The following paragraphs will describe some of the work that
has been reported investigating the potential use of antibodies as
selective cancer cell cytotoxic agents.
Antibodies may induce the death of the target cell in the
presence of complement. This has been demonstrated in
vivo. Berche et al.(1982) described the administration of a murine McAb
with activity against a T-cell differentiation antigen in a patient
with adult T-cell leukaemia. Immunofluorescence studies did show
strong antibody binding to the T-cells. Following the administration
of the antibody on two occasions the white cell count fell
dramatically but then rose over the ensuing 24 hours. Also, a mild
hypersensitivity reaction was noted 5 days after treatment. Thus
while the antibody produced a marked effect en the leukaemia cell
population, this effect was transient. Nadler et al.(1980) injected a
mouse McAb with activity against leukaemia cells (AB89 antigen) into a
leukaemia patient and showed that the resultant effects,as measured
by serial blood counts,was both small and transient. This McAb had
been shown to produce complement-mediated lysis of these cells in
vitro. Bast et al-(1983) described the selective killing of leukaemia
cells, diluted X100 with normal human bone marrow cells,by a
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murine McAb in the presence of complement. Watson,J.V. et al
(1983) described a chamber which could be implanted
subcutaneously in which hybridomas secreting antibody could grow.
The hybridomas could not pass out of the chamber into the tissues
whereas the McAb could freely disperse. This chamber was used to
grow autologous human hybridomas secreting antibody with activity
against glioma cells in a patient with a glioma. No beneficial
effect was observed however in the patient's clinical course.
Miller et al, (1982) described the administration of murine anti-B
cell McAb to a patient with advanced B-cell leukaemia. After 8
doses of the McAb over a four week period the patient remained in
remission for six months. Buckman et al,(1982) used a murine McAb
to eliminate cancer cells from bone marrow in-vitro,in the
presence of complement. Gore et al#(1983) detected killing of the
MDA-MB cultured breast carcinoma cell line (using a Cr^l release
assay) by the administration in vitro of an anti-MDA McAb in the
presence of killer lymphocytes derived from human bone marrow.
Kaszubowski et al> (1984) produced a murine McAb against colonic
carcinoma cells which were found to be toxic to these cells in the
presence of human complement.
Whilst the effect of administration of McAbs on their own has
found some success, they may be of great value for use as carrier
molecules to deliver cytotoxic agents selectively to cancer cells.
Ghose et al, (1978) commented that early work conjugating
conventional cytotoxic drugs to polyclonal antibodies had been
disappointing. A study was reported in which ricin A chains were
conjugated to a McAb which was
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then shown to be toxic to mouse macrophages and rat Kupffer cells
in vitro. This demonstrated that antibody could take the place of
the B chain of ricin to bind the A chain to cells. However this
conjugate was found to be less toxic than free ricin.
Levy et al (1975) provided further evidence of the feasibility of
these techniques by conjugating daunomycin with polyclonal
anti-tumour antibodies and showing that these conjugates were
toxic to tumour cells in vitro. Gilliland et al.(1980) described
the use of ricin A chain conjugated to mouse McAb with activity
against colorectal carcinoma cells. The activity of this antibody
conjugate on a culture of colorectal cancer cells was measured by
a leucine labelling method which measured the level of protein
synthesis in the target cells. The antibody conjugate markedly
decreased the protein synthesis of the target cells. It was also
found that conjugation of the ricin A chain did not appear to
affect the specific binding patterns of the McAb. Seto et al.
(1982) demonstrated the selective in-vitro killing of MM 46 cells
by murine anti-MM46 McAb conjugated with ricin A chain. The same
effect was then demonstrated in-vivo by developing xenografts of
these cells within the peritoneal cavity of mice. Tumour
regression was demonstrated in these animals following the
administration of anti-MM46 McAb/ricin A chain conjugate.
Colombatti et al.(1983) demonstrated selective killing of Thy 1-2
bearing cells in-vitro by anti-Thyl-2 McAb conjugated either to
gelanin or ricin A chain.
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Krolick et al, (1980) conjugated ricin A chains to antibodies
against igG and IgM and tested these conjugates for their ability
to kill B-lymphocytes. The ricin A chains were also conjugated
with ll25.The degree of toxin binding to the cells was then
measured by a radioimmunoassay, and the effect of the toxin by
measuring protein synthesis. The antibody conjugates were tested
against a variety of normal and malignant B -lymphocytes and it
was found that the conjugates bound only to those cells bearing
the appropriate surface marker. Youle et al, (1977) conjugated
McAbs with activity against the Thy 1-2 antigen with whole
molecules of ricin. The antibody conjugate was found to bind
selectively to THY1-2 antigen bearing cells only in the presence
of lactose. The B chain of ricin is said to bind to cells via
galactose bearing receptors on the cell surface, this binding
being blocked by lactose. If no lactose was present the antibody
conjugate bound nonselectively to a variety of cells, this
presumably because the ricin was attached to the cell by the B
chain rather that the McAb. Thorpe et al(1978) investigated the
use of polyclonal anti-lymphocytic serum. From this the IgG was
separated out and conjugated with diphtheria toxin. The toxicity
of this conjugate was tested against the CLA4 cell line (a
lymphoblastoid cell line) using radiolabeled leucine to measure
protein synthesis. Toxicity of the conjugate was found to be
greater than the toxin alone or a simple non-conjugate mixture of
toxin and antibody. Seon (1984) used a McAb/ricin A chain
conjugate to demonstrate selective killing of T-leukaemia cells
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in vitro, and postulated that this antibody/toxin conjugate may be
of value in clearing bone marrow of tumour cells in vitro.
Blythman et al. (1981) described the conjugation of ricin A chains
with anti THYl - 2 McAb. The activity of this conjugate was
measured in mice innoculated with THYl - 2 bearing leukaemia
cells. Using this system most untreated tumour bearing animals
were dead within 39 days whereas the survival of animals treated
with the conjugate was significantly increased. Animals treated
with a simple mixture of A chain and McAb behaved in the same way
as those treated with A chain alone indicating that the antibody
required to be conjugated with the McAb to exert a beneficial
effect. Kishida et al. (1983) conjugated a murine McAb with ricin A
chain and described selective killing of leukaemia cells in
culture using this conjugate. In addition the lives of nude mice
xenografted with leukaemia cells were significantly prolonged
after the administration of this conjugate.
The above studies have demonstrated the feasibility of using toxin
- antibody conjugates to selectively kill tumour cells. The
potential clinical benefit of using antibody/toxin conjugates will
depend upon the uniformity of antigen expression within the tumour
cell population and the ability of enough antibody to bind to each
cell to allow the absorption of an adequate amount of toxin
(Bagshawe 1983) . More recently, conventional cytotoxic drugs
have been conjugated to McAbs successfully by using an
intermediate carrier molecule. Rowland et al» (1985) conjugated
Vindesine to a murine McAb and produced regression of xenograft
tumours (melanoma, osteogenic sarcoma, and colorectal carcinoma)
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in mice, using the appropriate McAb. Baldwin (1985(a)) described
the conjugation of methotrexate with a murine McAb using dextran
as the carrier molecule. This conjugate was used to treat a
xenografted osteosarcoma in a mouse , and was found to be more
effective in producing tumour regression than administration of
methotrexate alone. The same author (Baldwin 1985(b)) described
the conjugation of other cytotoxic agents (Adriamycin, Vincristine
and Cyclophosphamide) to McAbs . These conjugates were shown to be







Axillary lymph nodes were obtained from patients undergoing
surgery for carcinoma of the breast. All of these patients had
operable T1-T2 tumours with no detectable evidence of distant
metastases at the time of surgery on the basis of screening
investigations performed which included a haematological /
biochemical profile (full blood count, E.S.R., serum urea and
elecrolytes,liver function tests, calcium, phosphate, albumin),
chest x-ray, isotope bone and liver ultra-sound scan. A record
was made of the patients age,tumour size ,type of operation, lymph
node histology and oestrogen receptor status from all patients
whose nodes were used in this study. Lymph nodes were obtained
following three types of operation-1) simple mastectomy followed
by axillary node sample (removal of four axillary nodes) 2)
mastectomy followed by clearance of all axillary contents and 3)
lumpectomy followed by lower axillary sample or clearance (ie
clearance up to the lower border of the axillary vein). Further
information about these patients is contained in appendix 2 .
Following the surgical removal of the axillary contents the nodes
were immediately dissected out of the axillary fat in an aseptic
manner in the ante-roan of the operating theatre. Nodes which were
macroscopically uninvolved by tumour deposit were then selected
out. In cases where only a few nodes were obtained these nodes
were bisected, half being retained for use in this study, the
other half being submitted for histological evaluation
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In cases where many (more than ten) nodes were obtained one node
was set apart for use in this study.
Nodes were placed in sterile normal (N) saline and transported to
the laboratory within 1-2 hours.
On arrival in the laboratory lymphocytes were separated from the
nodes in the tissue culture hood as described by Eremin et al
(1976). A 5 ml syringe with a 21g needle was filled with
TCM-A/2%FCS. The node was placed in a sterile petri dish and
punctured with the needle. The node could then gently ballooned
with the culture medium. This process was repeated several times
at different sites on the node and by so doing the lymphocytes
were readily washed out through the puncture holes. The lymphocyte
suspension in the petri dish was then aspirated and centrifuged at
250g for 5 minutes. The lymphocyte pellet was resuspended in
TCM-A/2% FCS and re-centrifuged. This washing process was repeated
twice more and then the cells were suspended in TCM-A/10XFCS. A
drop of cell suspension was then placed in a counting chamber and
the number of morphologically viable lymphocytes counted.The cell
suspension was then stored at 4°C until used in a fusion
experiment. This was always performed within 24 hours of
obtaining the node ( the timing of the fusion experiment being
dependent on the availability of a suitable HMy2 culture) , unless
the lymphocytes were prestimulated with pokeweed mitogen(PWM).
3.1.2. The Myeloma Cell Line.
The myeloma cell line used in this study, LICR/L0N/HMy2 .hereafter
designated HMy2, was kindly donated to the laboratory by the
Ludvig Institute for Cancer Research in Cambridge.
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The HMy2 line was cultured in TCM-B/10%FCS. Stock cultures of this
line were maintained in 100ml glass bottles at 37°C. On the day
prior to fusion the myeloma culture was subcultured by splitting
the stock culture into three bottles and adding fresh TCM-B/10%FCS
to each bottle. One of these bottles was kept as a stock culture,
the other two being cultured overnight and used the following day
for the fusion experiment when the maximum number of cells would
be in the log phase of growth.
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3.2. Cell Fusion.
Cell fusion was accomplished using polyethylene glycol(PEG) as
»
fusogen (Pontecervo,1975). The fusion procedure is based on that
described by Sikora et al. (1983(a)). Cell fusions and all
subsequent feeding of culture plates was performed in an Envair
microbiological safety cabinet,class II.(plate 1).
For a standard fusion 5x10*7 lymphocytes were fused with 5x10^ HMy2
cells. The two cell suspensions were centrifuged separately at
400g for 5 min. and resuspended in 15 ml of TCM-B with no added
serum. They were then recentrifuged and this washing process
repeated three times. The two cell suspensions were then mixed in
a 50ml conical tube (Corning) and centrifuged at 400g for 5
min.. After pouring of the medium the tube was left to stand for 5
min. to allow any medium on the sides of the tube to settle to the
bottom. This collection of medium was then gently aspirated with a
fine bore pipette to ensure that the cell pellet was completely
dry .The cell pellet was broken up by gentle flicking of the tube
and 0.5 ml of PEG solution A (see appendix 1) was added dropwise.
The cell suspension was gently mixed with the PEG by gently
stirring with the tip of a pasteur pipette for 20 sec. followed by
gentle rocking of the tube. One minute after the addition of PEG
sol.A, 0.5ml of PEG solution B was added dropwise and the tube
gently rocked for 3-4 min.. Four ml. of TCM-B/10%FCS were then
added dropwise following which the cell suspension was gently
aspirated into a wide bore 25ml. glass pipette and distributed
evenly over the 2ml. wells of two 24 well tissue culture plates
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(Nunc). An additional 1.0ml of TCM-B/10%FCS was added to each well
and the plates, labelled, were placed in a 5%C02,95% humidity
incubator (Leec) at 37°c.
3.2.1. Management of Cultures.
On the day following fusion 1.5ml of medium was removed from each
well using a pasteur pipette attached to a continuous suction
device and replaced with 1.5 ml of fresh selective medium
(TCM—B/l0 %FCS with either HAT(Hypoxanthine,Aminopterin and
Thymidine) or HAzT(Hypoxanthine,Azaserine and Thymidine))(see
Appendix 1 for details). This feeding process was continued every
2 days for the first week after fusion and weekly thereafter(or
earlier if the medium began to turn yellow before one week).Hybrid
growth was recognised first by microscopic and then by
macroscopic examination of the wells of the plate. Microscopically
hybrids appeared as clumps of growing cells in a field of cell
debris. Shortly after this clumps of growing cells could be seen
macroscopically in these wells. The wells were fed as required
until the concentration of the hybridoma cells was sufficient to
turn the colour of fresh medium yellow within 24 hours. At this
stage the hybridoma culture was divided equally among 3 new wells
in a clean plate as well as the original well and these were fed
until they too contained actively growing clumps of hybrid
cells .At this stage attempts were made to grow the hybridomas in
bulk culture in a 50ml tissue culture flask (Nunc) as described by
Edwards et al (1982). Whilst TCM-B was initially used in the flask
cultures it was difficult to prevent the medium turning alkaline
in the flask even when the flask was gassed with GO2 • The
75
culture medium was therefore changed from TCM-B in the culture
plate to TCM-A in the flask culture. Hybrids were found to
tolerate this change in medium .
Cells from three of the four wells containing hybridoma cells were
transferred to the flask which contained 5 ml of TCM-A/10%FCS with
the appropriate selective medium and after gassing with CO2 the
flask was incubated at 37°c in the ordinary incubator. The flask
cultures of hybrids were fed and divided as necessary. The
supernatants of these cultures , containing any immunoglobulin
secreted by the hybrids were collected whenever the culture medium
turned yellow. These supernatants were stored at 4°C in a solution
of lOmM Hepes buffer /0.1% sodium azide to preserve the pH of the
supernatant and to prevent the denaturing of any antibody present
(Sikora et al.,(1983(a)).
Hybrids were maintained in full selective medium for the first 15
passages in flask culture and then the Aminopterin or Azaserine
was emitted,leaving the cells in medium with added Hypoxanthine
and Thymidine for a further 10 passages. After this the cells
were grown in ordinary TCM-A/10%FCS with no additives.
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3.3. Pokeweed Mitogen Stimulation.
Pokeweed mitogen (PWM) is a plant lectin which has been shown to
selectively stimulate the B-cell population of lymphocytes
although this effect has been shown to depend on the presence of
T-cells (Keightly et al.,(1976) . It has been postulated that
prestimulation of lymphocytes prior to fusion with PWM will
increase the efficiency of hybrid production as more lymphocytes
will be actively dividing at the time of fusion. (Warenius et alu
1983) . Preliminary experiments were therefore conducted to measure
the effects of PWM stimulation on axillary node lymphocytes.
PWM. Preliminary Experiments
Experiments to measure the effects of PWM stimulation were
performed in both a "macro" and a "micro" system - both of these
being identical except for the number of cells involved. These two
methods were used because of the requirements of the different
techniques used to measure the effects of PWM stimulation as will
be described.
Whilst human AB serum is often preferred for mitogen experiments
because FCS possesses some weak mitogenic effects on its own, PCS
was used throughout in these experiments to closely simulate the
actual treatment of lymphocytes prior to fusion.
In the macro system axillary node lymphocytes were centrifuged at
400g for 5 min. and resuspended in TCM-A/10%FCS at a
concentration of 2x10^ cells/ml. PWM was added to 4 ml of this
suspension to give final PWM concentrations of 1,4,and 16ug/ml. In
addition control tubes with no added PWM were included in each
group of experiments. The cultures were fed every second day by
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the addition of 2 ml of fresh medium. In the micro system washed
axillary node lymphocytes were suspended in TCM-A/10%FCS to a
concentration of 1.25xl06 cells/ml. Using a pasteur pipette two
40ul drops of the cell suspension were dispensed into each of the
96 wells of a microtitre plate. An additional 40ul of TCM-A/10%FCS
was then added to each well ,followed by 40ul of PWM to give final
PWM concentrations of 2,4,8,16,and 32 ug/ml. Control wells with no
added PWM were included in each plate. The plate was then coverd
in Transpaseal and incubated at 37°C.
Different techniques were employed to measure the effects of PWM
stimulation, these being summarised by Nespoli et al. (1978).
1) Cell Counts.
Lymphocytes were counted both before and after PWM stimulation
in a slide chamber using phase contrast microscopy. Counts were
made of the total and large blast cell count by two independent
observers and the mean count recorded. It was thought that cells
stimulated by PWM would progress to the stage of blast cell
formation and hence the effects of PWM stimulation could be
measured by a relative increase in the number of large cells
morphologically resembling blast cells.
2) Measurement of Surface Immunoglobulin (SIg) Bearing Cells.
Attempts were made to determine whether FWM stimulation of
B-lymphocytes could be determined by measuring the increase in
the percentage of surface immunoglobulin (SIg) bearing cells. As
lymphocytes are stimulated by PWM the B-cells pass through the
blast cell stage to form plasma cells. Since PWM may stimulate
T-lymphoblasts,cell counts alone are not reliable and SIg bearing
cells were therefore enumerated.
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The measurement of Slg-bearing cells was performed by two
techniques, a) an immunoperoxidase technique and b ) the formation
of anti-human Fab rosettes. The details of these two techniques
are described in detail in subsequent paragraphs.
In brief, the iinmunoperoxidase technique used rabbit anti human
IgG and igM antibodies (Dako) to determine Slg-bearing cells on
cytocentrifuge preparations of PWM-stimulated lymphocytes, Sig
bearing cells cells showing up as a red-brown colour compared with
the blue counterstain. Results were expressed by counting 200
cells and expressing the number of Sig cells as a percentage (see
section 3.8.2. for details of immunoperoxidase method).
Anti-human Fab rosettes were prepared as described in section
3.6.2. and again counts were made of 200 cells.
3) Tritiated Thymidine Uptake.
This assay measured the uptake of thymidine into cell cultures.
As the uptake of thymidine is directly related to the level of
cell division this assay can provide a direct measure of the level
of cell division produced by PWM stimulation. This assay has the
advantages of being sensitive and of measuring directly the effect
of PWM which is most relevant to cell fusion experiments -ie the
amount of cell division produced in the lymphocyte culture.
After a period of incubation in PWM, in the micro system, the
wells of the microtitre plates were pulsed with % thymidine
(Amersham),(37 BQ or 1 u Ci) by adding 25ul of the stock solution
to each well. The wells were again covered with Transpaseal and
incubated for 18 hours at 37°C. Following this the cells were
harvested using a Titertek cell harvester onto a glass fibre
disc. The disc was dried and then placed in a container to which
was added scintillation fluid. The scintillation fluid used was 4g
P.P.0.(2,5 diphenyloxazole (Kochlight))in one litre of Toluene
(Fisons). The activity of each container was measured in a Beta
counter (Nuclear,Chicago,Mark 1) . Counts were made for 2 minutes
for each well and a mean count of each group of triplicate wells,
with standard deviations, recorded.
3.4. Feeder Cells
The beneficial effects of feeder cells in the production of
hybridomas was investigated by the use of two types of feeder
cells. Since this study concentrated on the production of
human-human hybridomas it was decided to use only human feeder
cells to prevent any overgrowth of cells from a different
species. The feeder cells investigated were peripheral blood
monocytes and thymocytes.
3.4.1. Monocytes
Monocytes were obtained from the peripheral blood of healthy
women age 18-70 years who were not known to be suffering from any
inflammatory or neoplastic disease. Samples were all obtained with
the informed consent of these women. 30 ml of blood was removed
into a syringe containg 30 units of preservative free heparin .
The heparinised blood was then diluted 1:3 in phosphate buffered
saline (PBS) and layered onto Ficoll-Hypaque (Specific gravity
1.007) (30ml diluted blood onto 10 ml Ficoll Hypaque in a
siliconised glass tube). These tubes were then centrifuged at 400g
for 40 min. at 20°C (centrifuge MSE Mistral GL), thus separating
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the lymphocyte/monocyte population at the interface of the
Ficoll-Hypaque from the granulocytes and erythrocytes at the
bottom of the tube, as described by Boyum (1968). The
lymphocyte/monocyte layer was carefully pipetted from the
interface and washed twice in TCM-A/2%FCS at 400g for 10 min. and
used as described in section 4.5.1..
3.4.2. Thymocytes.
Thymocytes were obtained from samples of thymus gland from
children under the age of 5 undergoing open heart surgery at the
Royal Hospital for Sick Children, Edinburgh. A part of the thymus
gland is routinely removed in such children to allow exposure of
the heart. Samples of thymus were placed in sterile saline in the
theatre and transported directly to the laboratory where
thymocytes were removed in the same way that lymphocytes were
removed from the lymph nodes. By this means large numbers of
thymocytes were obtained and these were washed four times by
suspension in TCM-A/2%FCS and centrifugation at 400g for 5
min..At the time of cell fusion thymocytes were added directly
to each of the wells of the plate ,10^ cells/well immediately




The effect of varying the cell input into the fusion system was
investigated as follows. In the standard experiment 5xl07
lymphocytes were fused with 5x10^ HMy2 cells, a lymphocyte/myeloma
cell ratio of 10:1. The effect of reducing this ratio to 5:1 and
1:1 was investigated by increasing the number of HMy2 cells used
for the fusion. Three 50ml conical tubes were set up each
containing 2.5xl07 lymphocytes from the same lymph node. To these
were added respectively 2.5x10^ , 5.0x10^ and 2.5xl07 HMy2
cells.These three mixtures were then fused under identical
conditions and each tube distributed over one 24 well plate. All
plates were fed with HAT medium,with no feeder cells and no
prestimulation of lymphocytes with PWM.
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3.6. Characterisation of the Hybridomas.
The hybridomas were characterised by measuring their chromosome
count and by characterising their surface markers using a
rosetting technique.
3.6.1. Karyotyping.
Cells were karyotyped by arresting the cells in metaphase using
colchicine and then swelling the nuclei with hypotonic KCL as
described by Moorhead et al (1969).
The technique is summarised as follows.
1) On the day prior to karyotyping the hybridoma culture was fed
with fresh medium and incubated overnight to ensure that a large
number of cells would be dividing.
2) Colchicine was added to the cell suspension to give a final
concentration of 7.5xl0-^ M and the cells incubated for a further
4 hours at 37°C.
3) The cells were then centrifuged at 400g for 5 minutes , washed
twice in TCM-B with no added serum and resuspended in 0.5 ml of
this medium.
4) 0.5 ml of 0.075 M KC1 was added slowly and the cells carefully
mixed. The time was noted at the start of this additiion. A
further 3.5 ml of KC1 was added slowly and the tube left to stand
for 3 minutes.
5) The cells were then centrifuged at 200g for 6 minutes and
resuspended in 0.25 ml of KC1. Total time in KC1 was 10 minutes.
6) 4 ml of fresh fixative (Acetic acid/Methanol 1:3) was added
slowly and clumps of cells gently broken up. The tube was left to
stand for a further 15 minutes. The cells were then centrifuged
at 100 g for 6 minutes and the above fixation process repeated.
7)The cells were resuspended in 1 ml of fresh fixative,and a drop
of cell suspension was dropped from a height of 6 inches onto a
cleaned chilled wet glass slide.Excess liquid was blotted off and
the slide gently dried in air. The slides were stained with
Giemsa for one hour then examined microscopically. Chromosomes
were counted from at least 3 different nuclei and the mean of
these counts recorded.
3.6.2. Surface markers.
The surface markers of hybridomas were evaluated by a sheep red
blood cell (SRBC) rosetting reaction, to demonstrate that these
hybrids were B-cells and not T-cells. This was to confirm that the
hybrids had arisen by fusion of a HMy2 cell with a B and not a T
lymphocyte.
T-cells form spontaneous rosettes with SRBC's. B-cells are
identified by using SRBC's coated with the antibody sheep
anti-human Fab to detect surface immunoglobulin.(Eremin et al
1976).
a) T-Cell Rosette Indicators.
1)Sheep red blood cells (Clun Forrest, less than one week old)were
washed in PBS at 1600g for 5 minutes.
2) The SRBC's were then suspended in PBS to give a 10% solution.
3) To 50ul of 10% SRBC's was added 500ul of neuraminidase (at
0.Olunits/ml) in PBS.
4) The SRBC solution was then incubated at 37°C for 20 minutes.
5) Cells were then washed in PBS four times and resuspended
in 50 ul of TCM-A/10%FCS and 450ul of FCS absorbed against SRBC'S.
6) The indicators were then stored at 4°C until use.
b) Sheep anti Human Fab (B-Cell) Rosettes.
Indicators for these rosettes were made by conjugating polyclonal
anti human Fab with SKBC's using chronic chloride by an identical
method to that described in section 3.7.1.
c) Rosettes.
To make rosettes lOOul of the appropriate indicator cells were added
to an LP3 tube followed by lOOul of the hybridoma suspension. The
rosettes were then incubated ,T rosettes for one hour at room
temperature, B rosettes at 4°c for 30 minutes. Following this the
tubes were gently rotated to resuspend the cells . One drop of cell
suspension was then placed on either end of a siliconised glass slide
followed by one drop of stain(Toluidine Blue) and covered with a
siliconised cover slip.Rosettes were read by counting 200 cells which
had stained blue, and recording the number which had formed
rosettes(defined as 4 or more attached red cells).
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3.7. Characterisation of Supernatants.
3.7.1. Estimation of Immunoglobulin
The presence of antibody in these supernatants was detected by an
agglutination reaction involving SRBC's coated with an appropriate
antibody using chromic chloride. The first step in this assay was
to couple the antibody to the SRBC and this was performed as
follows.
1) The SRBC's were washed six times in PBS (400g for 5 minutes).
The cells were then suspended in PBS to make a 10% suspension.
2) The appropriate volume of red cell suspension to be coupled was
then mixed with an equal volume of 0.25% trypsin(pH 7.0, at
37°C)and left in a 37°C water bath for 30 minutes , with
occasional inversion. After 30 minutes the cell suspension was
centrifuged and washed twice in PBS at 400g for 5 minutes.
3)The cells were resuspended in trypsin inhibitor in an equal
volume to that of the packed red cells.This mixture was left to
stand for 10 minutes at room temperature then centrifuged and
washed twice in 0.9% NaCl. The cells were then ready for
coupling.
4) Coupling was performed in Falcon 2054 tubes. 25ul of a 1%
solution of the antibody to be coupled (rabbit anti human igG and
rabbit anti human igM (Dako Denmark, code nos.A090 and A091) were
added to the tube followed by 25ul of packed trypsin treated red
cells. 50 ul of chromic chloride (0.2% pH 5.0) was then added
slowly whilst the tube was continually shaken. After 30 seconds
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the tube was capped and rotated slowly for 60 minutes at room
temperature on a Matburn rotator .
The cells were then washed in PBS 3 times (400g for 5 minutes)and
resuspended to a final concentration of 1% in PBS. The two cell
indicators, one coupled with rabbit anti human igG and the other
with rabbit anti human igM were then ready for use in the
agglutination reaction.
Agglutination Reaction
For each batch of cell indicators produced, control agglutination
reactions were performed to test the adequacy of the coupling.
Thus each set of indicators was tested against sheep serum ( a
negative control to test for non-specific agglutination of the
cell indicators) and normal human serum (a positive control).
Agglutination tests were performed on microtitre plates (Nunc).
First, one drop of each supernatant or control serum was added to
each well in serial dilutions starting at neat and then in 1 in 4
dilutions serially along the first 11 wells of the row. One drop
of the cell indicator was then added to each well and the plates
left to stand for If-2 hours. The agglutination reaction was then
recorded on a scale of 0-3+.
3.7.2. Measurement of the Concentration of Antibody.
The concentration of IgG or IgM in the supernatant was measured as
described by Watson,D.B. et al , ( 1983) using the above
agglutination technique. Normal human serum was obtained and the
levels of IgG and IgM were measured by the Dept. of Clinical
Chemistry, Royal Infirmary, Edinburgh. This normal serum was then
agglutinated in serial dilutions until no further agglutination
was observed. Since agglutination requires an adequate amount
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of antibody,it is presumed that the dilution at which no further
agglutination occurs represents the dilution at which there is
insufficient antibody present. The hybrid supernatant was then
agglutinated in serial dilutions until it too failed to produce an
agglutination reaction.The concentration of antibody in the
supernatant could then be calculated as follows.
Sc = Cc where Sc = supernatant concentration
Sd Cd Sd =supernatant dilution
Cc = control concentration
Cd = control dilution.
3.8. Screening of Supernatants for Reactivity to Breast Carcinoma
Cells.
3.8.1.The Radio-immuno Assay l)
This assay was used in an attempt to detect binding of antibody in
the supernatants of hybridomas to a variety of cultured cell
lines, derived from both breast carcinoma cells and other cell
types. It is based on the techniques described by Sikora et
al(1983(b)). The cell lines used were MCF-7 and MDA_MB (breast
cancer cell lines) , CLA4 (a lymhoblastoid cell line) and DET6 (a
HeLa subline)(see appendix 1 for details of these cell
lines).These cells were cultered as monolayers (apart from CIA4
which grew as a suspension culture) until a sufficient cell
density was obtained . The cells were then removed from the
flasks by trypsinisation and washed by centrifugation in PBS five
times. The cells were then resuspended at a concentration of 5x10^
cells/ml. The assay was performed using flexible polyvinyl u-well
microtitre plates. These were pretreated with poly-L-lysine(0.1%
solution in PBS) ,50ul/well for one hour at roan temperature. The
poly-L-lysine was then removed and 50 ul of the appropriate cell
suspension added per well. The cells were allowed to settle at 4°C
for one hour and then the plates were carefully immersed in 0.25%
glutaraldehyde in PBS, avoiding air bubbles,and left for 5 minutes
at 4°C. This process caused adherence of the cells to the wells
of the plate as described by Stocker et al» (1979). Sane authors
(Posner et al.,1982, Lansdorp et alJ-980) suggest that the use of
glutaraldehyde in this way increases the degree of non-specific
binding in this assay.
The glutaraldehyde was then flicked out and the plate immersed in
PBS for 5 minutes at 4°C and then for 5 minutes at roam
temperature,to wash out excess glutaraldehyde. The plates were
then dried on absorbent paper.
lOOul of blocking buffer( PBS+0.1% sodium azide +1% bovine plasma
albumin) was then added to each well and left for 60 minutes at
37°C. This was to block any non specific binding sites on the
surface of the plastic of the wells to which antibodies might
adhere.
50ul of the test supernatant or appropriate control was then added
to each well and incubated for 45 minutes at roam temperature. The
supernatant was removed by flicking the plate and the wells washed
5 times with PBS to remove all free supernatant.
The plates were then dried on paper and 50 ul of mouse anti human
Ig Kappa or Lambda chains (Bethseda Resaearch Labs cat. nos.31040
and 31030) at a 1/5000 dilution was added to the wells and
incubated for 45 minutes at room temperature. The plates were
again washed five times in PBS and dried.
50ul of il25 conjugated rabbit anti mouse antibody(Dako) was then
added per well and incubated at room temperature for 45 minutes.
The plates were finally washed five times with PBS and dried. The
plates were then cut up into individual wells and the bound
radioactivity measured in a gamma counter (Wallac). Each cell type
was set up in triplicate with each of the hybridoma or control
supernatants and the results calculated as the mean of the counts
of each of the three triplicate wells.
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Iodination of rabbit anti mouse immunoglobulin used in the
radioimmunoassay.
This procedure was performed in the fume cupboard in the grade B
laboratory in the Dept. of Surgery. Prior to performing this
procedure I attended a course of lectures on the correct
management of radioactive materials organised by the University of
Edinburgh. I acknowledge with thanks the supervision and advice
given by Mr.j.Ashby during this procedure.
Materials used.
1) lmCi (37mBq) of 125j sodium Iodide (Cat.no. IMS 30, Amersham
International).
2) Chloramine T lmg/ml in distilled water.
3) Saturated tyrosine solution (Millipore filtered).
4) 1% bromophenol blue in distilled water.
5) Sephadex G50 column.
6) Phosphate buffered saline
7) PBS + 1% bovine serum albumin + 0.1% Sodium Azide.
PROCEDURE.
1) Add 50ul of antibody to the vial if 125 j and immediately add
lOul of Chloramine T.
2) Close vial, mix and leave for 90 sees.
3) Add 50ul of saturated tyrosine.
4) Add 10ul of brcmophenol blue.
5) Load into Sephadex column.
6) Elute 200ul fractions into LP3 tubes with PBS.
7) Pool the fractions with the highest counts on the gamma counter
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3.8.2. The Immunoperoxidase Technique.
This technique was employed as well as the radio-immuno assay to
detect the binding of MAbs to breast carcinoma cells. This assay
is designed to detect sites of binding of McAbs to target cells
using the enzyme horseradish peroxidase.Horse-radish peroxidase
can then be detected by the addition of an appropriate reagent
which will turn red-brown thus allowing sites of McAb binding to
be detected microscopically.This assay has the advantage that it
can detect binding of MAbs to sections of breast tumours as well
as cultured cell lines, thus giving an estimate of the possible
in-vivo site of reactivity of the antibody. (Naiem 1982).There are
several methods by which the peroxidase technique can be
performed. The enzyme horseradish peroxidase can be conjugated
directly onto the McAb thus giving the "direct" assay.
Alternatively, the enzyme may be bound onto a polyclonal antibody
raised against the enzyme and then this "peroxidase-
anti-peroxidase" complex can be bound onto sites of McAb binding
by using an appropriate intermediate antibody. This indirect
assay, whilst somewhat more complex, is said to increase the
sensitivity of the assay many fold ( Taylor, 1978) and was the
method used in this study. A variety of target cells were used
which were prepared as follows.
1) Cytocentrifuge preparations were made of both cultured breast
cancer cell lines and also of cell suspensions derived from tumour
specimens. The former consisted of both MCF7 and MDA-MB (see
appx.l).
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The latter were prepared by finely mincing fresh breast tumour
tissue with a scalpel blade, incubating this minced tissue in
collagenase for 16 hours at 37°C and then straining through a
muslin filter.(Eremin et al 1982). The resulting cell suspension
was then washed twice in TCM-A/10%FCS, incubated for 12 hours at
37°C, then washed and resuspended to a final concentration of
106 cells/ml.
In addition cytocentrifuge preparations were also made of tumour
cell suspensions in which Fc rosettes(to identify macrophages) had
been formed. Fc rosette indicators were produced as follows.
1) Ox rbc's, inagglutinable and less than one week old, were
washed x6 in PBS and resuspended in 2% PBS.
2) 500ul of 1/10 rabbit IgG prepared against ox rbc's in PBS was
added to 500ul of ox rbc suspension.
3) Cells were then incubated for 45 min. at room temperature.
4) Cells were washed x2 in PBS, resuspended in TCM-A/10%FCS and
stored at 4°C. Rosettes were then formed as described in section
3.6.2(c).
These cell suspensions were added to the chambers of the
cytocentrifuge (Shandon Cytospin 2)(1 drop/chamber) and
centrifuged at 800 rpm for 5 min.. The resulting slides were
air-dried and fixed in acetone for 10 min. .Prior to use in the
peroxidase assay these slides were rehydrated in water at room
temperature for 30 min..
2)Paraffin sections of breast tumours were obtained from both the
Dept of Clinical Surgery and the Department of Pathology,
Edinburgh University. These sections came from patients from whan
nodes had also been obtained to perform fusion experiments. The
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slides were dewaxed prior to use in this assay by immersion in
xylol for 10 min., followed by washing in alcohol in
concentrations of 100%,70%,20% and 0% in water.The slides were
then treated with trypsin. This was because it has been suggested
(Curran et al 1977) that the fixation methods used on paraffin
sections may "mask" a variety of antigens .Pretreatment with
trypsin was thought to "unmask" these antigens and hence make
the assay more sensitive. Slides were therefore washed in 0.1%
trypsin (pH 7.6) at 37°C for 15 min..
Immunoperoxidase Staining.
1)Slides were first incubated in methanol/3%H2<32 for 30 min. at
room temperature to block any endogenous peroxidase activity in
the target cells. It has been suggested that false positive
background binding in this assay might be due in part to the
presence of endogenous peroxidase in the target cells and that
this activity might be blocked by incubation in H2O2(Heyderman et
al 1977) .
2) Slides were washed in tris-buffered saline(TBS)for 10 min. at
room temperature and then incubated in 20% normal swine serum
(NSS) in TBS at room temperature for 20 minutes to block any non
specific binding sites on the glass slide. Swine serum was chosen
because it would not react with any of the other antibodies used
in this assay.It was obtained from the local abbatoir and
heat-inactivated for one hour at 56°C prior to use.
3) The slides were rinsed in TBS/2%NSS for 15 min. and then the
hybrid supernatant was added to the slide and incubated at room
temperature for 30 min. in a moist chamber.
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4)Following a 15 min. wash in TBS/2%NSS the second antibody (rabbit
anti human IgG(sigma) or IgM(u) (Dako) 1/100 dilution in TBS) was
incubated for 30 min. at roan temperature.
5)The washing process was repeated and then Swine anti Rabbit
immunoglobulin (Dako) was added, again for 30 min..
6) Finally the slides were washed and incubated with the
peroxidase/antiperoxidase complex(rabbit,Dako) for 30 min. at roan
temperature.
7)The slides were washed again and the peroxidase stained by the
addition of Amino-Ethyl Carbizole (0.5ml diluted in 9.5ml of acetate
buffer) to which 2 drops of 30 vol H2O2 had been added immediately
before use. This stained the peroxidase a red-brown colour and the
slide was then counterstained in haemotoxilyn.
This assay is summarised in figure 2.
FIGURE 2.









BREAST CANCER TARGET CELL.
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•^c^. Cloning of Hybridomas.
Hybridoma cultures were subcultured on the afternoon prior to
cloning to ensure that most cells were actively growing and
dividing by the following day. For cloning, hybridomas were
suspended in TCM-A/10% FCS, and cell counts performed. The
hybridoma culture was diluted by an appropriate amount to give
suspensions of 100,50 and 25 cells/ml. One 25ul drop of each
suspension was then added to the wells of a 96 well microtitre
plate to give 4,2 and 1 cells per well. Two drops of TCM-A/10% FCS
were then dispensd into each well and the plates cultured in the
CO2 incubator (Leec) at 37°C. Culture medium was changed
regularly, and the cell cultures observed under inverse phase
microscopy. When the cells were seen to be growing in clumps, they
were transferred to the 2ml wells of the 24 well tissue culture
plates (Nunc) and fed with regular medium changes. Finally the
hybridomas were transferred back to the 50ml tissue culture





The results of the fusion experiments are given in the following
paragraphs. Fusion experiments were labelled with the prefix
"FE"(Fusion Edinburgh)followed by the number of the experiment.
Since most fusion experiments involved more than one plate, the
plate number was then added. Finally the wells of the plate were
denoted by the grid system on the plate,each well being denoted by
a number on the "x"axis and a letter on the "y" axis. Thus a
hybrid would be defined by a title such as FE30/4/A2. The lymph
nodes used in the experiments were labelled by the prefix
T.N.L.E.(Tumour Node Lymphocyte Edinburgh) followed by the
appropriate number.
Initial fusion experiments had been performed in the laboratory
prior to the commencement of this study, these being labelled FE1
to FE19. Whilst the details of these experiments are not included
in this thesis since the work was not done by me, the hybridomas
obtained from these experiments were characterised by me and these
results are included within this thesis.
4.1.1. Scoring System.
Fusion experiments were scored by recording the number of hybrids
obtained per 24 well plate. NO time limit was set after fusion at
which the plates were scored, because of the widely varying times
after fusion at which hybrids appeared. All plates were therefore
fed and cultured as described until such time as infection of the
plate by moulds ,yeast or bacteria was seen to have occurred at
which time the plate was discarded. However an arbitrary minimum
time limit was set. All plates had to survive this period in
culture before they were included in the results,those which
failed to do
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so being counted as technical failures. This lower limit was
arbitrarily set at 24 days, being the earliest time at which a
hybrid appeared (59/3/A3) .
4.2. Results- Fusion Experiments.
The results of the fusion experiments performed in this study are
described first ,as the introductory group of experiments, then as
the overall results of the main group of fusion experiments, and
finally as the groups of fusion experiments evaluating the
different options employed in an endeavour to improve the rate of
hybridoma production.
4.2.1. The Early Experiments . FE 20-30♦
Infection.
Prior to the commencement of this study infection of the culture
plates by yeast organisms within the first 10 days after fusion
was a major problem within the laboratory. The early experiments
were therefore used firstly to learn the techniques of cell fusion
and cell culturing and secondly to combat the problem of yeast
infection. Before any fusions were done, the CC>2 incubator was
emptied and thoroughly cleaned and all glassware re-sterilised. It
was then planned to investigate the use of Fungizone( Amphotericin
B) to combat yeast infection by adding it to the culture medium in
varying concentrations. These early experiments are summarised as
follows. The plates of FE 20 - 25 were all discarded before day
24, either because of the early development of infection , or
because of a technical error during the fusion experiment. FE
26-30 had fungizone added in varying concentrations to each row of
wells from 0 to 2.5 ug/ml. In each of these plates, when yeast
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infection occurred, it occurred in those wells with either no
fungizone (FE 29/1,29/2.29/3,27/1,27/2,27/3,27/4) or else a low
concentration of fungizone (1.0 ug/ml, FE 29/4). The rest of these
plates succombed to either yeast or mould infection, having
survived longer than 24 days in culture.
No hybrids were obtained from any of these plates.
In these varied early experiments ,fungizone was seen to be of
value in preventing yeast infection in experiments FE26-29.The
only yeast infection occurring in the presence of fungizone was
plate FE29/4, in a fungizone concentration of 1.0ug/ml. Since the
maximum recommended dose of fungizone is 2.5ug/ml for cell culture
work, hybrids obtained from the early fusion experiments were
changed into medium containing fungizone at this concentration.
This did not appear to affect the growth characteristics of these
hybrids at all. In view of these results fungizone was added to
all culture medium at a concentration of 2.5ug/ml to combat yeast
infection. These early experiments are summarised in table 1.
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TABLE 1
SUMMARY OF EARLY FUSION EXPERIMENTS FE20 to FE30.
PLATE FUNGIZONE
CONC. TIME
INFECTING AGENT TIME DISCARDED
{DAYS}
20/1 - Y 15
20/2 - Y 10
20/3 - Y 10
20/4 2.5 12 Y 15
21/1 2.5 4 B 9
21/2 - Y 10
22/1 1 B 5
22/2 - Y 7
23/1-4 } TECHNICAL
25/1-4 } FAILURES.
26/1 ITvC\JO Y 59
26/2 0-1.0 1 M 69
26/3 0-2.5 1 M 69
26/4 0-1.0 1 Y 59
27/1 0-2.5 1 Y 20
27/2 0-1.0 1 Y 27
27/3 LPl•CM1O Y 20








28/1 0-2.5 1 B 28
28/2 0-1.0 1 B 28
28/3 LTiCMO B 28
28/4 0-1.0 1 B 28
29/1 0-2.5 1 Y 12
29/2 0-1.0 1 Y 12
29/3 0-2.5 1 Y 12
29/4 0-1.0 1 Y 39
30/1 LTlCM1O B 17





(fungizone concentration in ug/ml.)
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4.3. Fusion Experiments FE 31-101
4.3.1. Progress in Culture and Incidence of Infection
Table 2 summarises the success of culturing plates of experiments
FE 31-101,which form the main part of this study. The average
survival time of plates in culture in this group was 47.34 days
after fusion, which means that the majority of plates survived
well over the 24 day minimum culture period. Each plate was
ultimately discarded when infection was seen to have occurred in
one or more wells of the plate.
Table 3 summarises the ultimate fate of these plates in terms of
infecting organisms. Frcm this it can be seen that the
introduction of fungizone (and possibly improved technique)was
successful in combating yeast infection. Only 42 plates were
infected with yeast organisms in this group at an average 52.78
days after fusion. Table 4 shows the number of failures as a
percentage of the total plates for each group of 10 fusion
experiments. This demonstrates the impact that improved experience
had in the prevention of infection. Infection by yeast and mould
organisms appeared to occur in epidemic form within the
incubator. In a few days many plates would becane infected
particularly those adjacent to each other in the incubator and
this would be followed by weeks in which virtually no infection
occurred. Most bacterial infections occurred shortly after fusion
and tended to affect groups of plates from the same experiments,
suggesting sane form of direct contamination around the time that
the experiment was performed.
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TABLE 2.
SURVIVAL IN CULTURE OF PLATES OF LATER EXPERIMENTS
FE 31-FE101.
TOTAL NUMBER OF PLATES
"FAILURES" {INCLUDING
5 PLATES WITH NO RECORD}
FAILURE RATE












RECORD OF INFECTION FE31-FE101
INFECTING AGENT NUMBER OF AVERAGE DAYS RANGE
PLATES IN CULTURE
BACTERIA 17 8.12 1- 32
YEAST 42 52.78 19-121
MOULD 213 49.86 11-144







16 {94.12% OF ALL BACTERIAL
INFECTIONS}
3 (7.14% OF ALL YEAST
INFECTIONS}
30 {14.08% OF ALL MOULD
INFECTIONS}
49.
The plate was discarded when infection was seen to
have occurred in one or more of the wells of the plate.
Previous attempts to salvage plates with only one
infected well by aspirating the well and irrigating it




Ratio of "Failures"/Total Plates Divided into Groups of
Ten Fusion Experiments.
Experiment No. Total Failures Failures/ x100
Plates Total Plates
FE 20-30 34 24 70.6%
FE 31-40 42 13 30.9%
FE 41-50 46 20 43.5%
FE 51-60 38 10 26.3%
FE 61-70 29 4 13.8%
FE 71-80 45 3 6.6%
FE 81-90 42 6 14.3%
FE 91-101 34 0 0
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TABLE 5.
EFFECT OF RAISING THE MINIMUM DAYS REQUIRED IN CULTURE
ON THE RATE OF HYTBRIDOMA PRODUCTION.
MINIMUM DAYS PLATES HYBRIDS HYBRIDS/ HYBRIDS/ HYBRIDS/
IN CULTURE PLATE WELL 106 LY.
24 + 231 25 0.108 0.004 0.009
30-39 174 25 0. 143 0.006 0.011
40-49 122 25 0 .204 0.009 0.016
50-59 93 25 0.268 0.01 1 0.022
60-69 70 25 0.357 0.015 0.029
70 + 43 25 0.581 0.024 0.047
SUMMARY OF THE NUMBER OF HYBRIDOMA BEARING PLATES
WHICH WOULD BE COUNTED AS "FAILURES" BY INCREASING THE
MINIMUM REQUIRED DAYS IN CULTURE.
MINIMUM DAYS TOTAL PLATES HYBRID BEARING PLATES
SURVIVING NOT SURVIVING THIS
TIME IN CULTURE.





70 + 43 15
"LY" = Lymphocytes.
4.3.2. Hybridomas.
In this study, 25 hybridomas were obtained from 231 successful
plates(5544 wells). This gives a hybridoma rate of 0.108
hybridomas per 24 well plate, or 0.004 hybrids/well. This may be a
falsely low hybrid rate. Table 5 shows the way in which an
increased "minimum days required in culture"would apparently
improve the hybrid rate by decreasing the number of plates
included in the study. This will be discussed in section
5.2.1..These hybridomas will be discussed further in following
paragraphs.
4.4. Fusion Experiments Using PWM Stimulation
4.4.1. Preliminary Experiments.
Two experiments were initially performed to evaluate the "macro"
technique for PWM stimulation and to assess the value of cell
counting to measure the effects of PWM stimulation.TNLE 184 and
TNLE 178 were stimulated with PWM as described .After nine days in
culture the cells were examined under phase contrast microscopy ,
and counts of both the total and large blast cells made by two
independent observers. The mean counts obtained are recorded on
table 6. As can be seen no definite pattern can be discerned from
these counts and in particular no effect of PWM can be
demonstrated.
The usefulness of the various means described for estimating the
effect of PWM were then assessed over a shorter time period (3
days) using TNLE 205 which was stimulated as described in section
3.3.. The results of this are shown on table 7. From this
experiment it appeared that the technique of tritiated thymidine
v\o
uptake was the preferred method by which to investigate the
effects of PWM stimulation of lymphocytes since this assay most
clearly demonstrated the effects of PWM. Therefore a series of
five experiments were performed using the "micro" system and the
effects of PWM assessed by H3 thymidine uptake. Cells used in
these experiments came from T.N.L.E. 271-5, and PWM was added as
described previously. The results of these experiments are shown
in the graphs in f|(}, S"-^ . Fran these graphs it was observed
that the level of h3 uptake diminished from day 2 to day 10 in
culture. Since no fresh medium was added to these cells during
incubation, it was thought that this may be the result of spent
medium in the wells. Three further experiments were performed
using T.N.L.E. 282,286 and 288 to assess whether regular feeding
of the cultures made a difference. The cells were set up in
identical manner but in duplicate plates. One plate was fed by
removing lOOul of medium and replacing it with fresh medium, the
other plate being fed in like manner but with medium containing
PWM. This was to determine a) whether the replacement of spent
medium would increase the level of Thymidine uptake in the
longer term cultures and b) whether the longer cultures required
the continuous presence of PWM or whether,once stimulated ,the
same level of H3 thymidine uptake would be obtained by feeding
with medium without PWM. The results of these experiments are
shown in figure 10-15. As can be seen TNLE 282 showed a different
result from the others in that the concentration of PWM required
to produce stimulation in this node is higher than for other
nodes and the level of stimulation produced is much lower. It is
thought that this represents a degree of anergy in this node.
TABLE 6.
POKEWEED MITOGEN-PRELIMINARY EXPERIMENTS.
CELL COUNTS AS A MEASURE OF THE EFFECT OF POKEWEED
MITOGEN.
Lymph Node Pokeweed Mitogen Cell Counts (x105/ml)
Concentration Total Large Blast
(ug/ml) Cells (%)
TNLE 178 control 14.1 1 .6 11 .3%
1 6.9 2.2 LO CO
4 6.9 1 .6 23.2%
16 3.1 0.4 12.9%
TNLE 184 control 24 0 0 %
1 54 5.9 10.9%
4 56 2.2 3.9%
16 60 7.6 12.7%
Counts Taken After 9 Days in Culture.
Counts of total cells and large cells morphologically
resembling blast cells were made by two independent
observers. Three counts were made of each suspension and
the mean cell count is recorded. No differences occurred
between the two observers.
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TABLE.7.
POKEWEED MITOGEN. PRELIMINARY EXPERIMENTS.
Comparison of Four Methods For Measuring the Effects of Pokeweed
Mitogen Using TNLE 205 After 3 Days in Culture.
Dose of PWM. Cell Counts Rosette Formation
( ug/ml) Total Large(Blast) %Blast %Rosettes
Control 80 6 15
1 64 13 15
4 85 5 16
16 105 9 22
Dose of PWM Immunoperoxidase (%) Thymidine Uptake
( ug/ml) anti IgG anti IgM (Counts-mean +/-SD)
Control 11.6 21 7071
1 10.0 25 45,918
4 9.8 23.6 46,193
16 5.5 0 47,174
\\T>
The pattern obtained from TNLE 286 and 288 is very comparable to
that obtained from the other experiments, irrespective of whether
the cells were fed with normal medium or medium plus PWM. The
overall conclusion from these studies was that the stimulation of
lymphocytes by PWM forms a plateau type of dose-response curve -ie
there is a level of PWM concentration above which no
further stimulation of lymphocytes occurs. This presumably
represents the point at which all sensitive lymphocytes have been
stimulated and this appears to occur at between 2 and 4 ug/ml of
PWM. It is also interesting that ,of the times tested,the maximal
stimulation occurred at 2 days and decreased thereafter in spite
of feeding the cultures. More frequent sampling would have been
necessary to confirm that two days was the optimum time
period.This pattern is thought to represent the fact that blast
transformation occurs early following PWM stimulation and
following this the cells may go into a resting,small cell stage.
4.4.2. Fusion Experiments with PWM.
The effects of prestimul ating lymphocytes with PWM in the
efficiency of hybrid production were assessed as follows. Firstly
lymphocytes were stimulated with PWM in two regimes- the one at
2ug/ml of PWM for 48 hours and the other at 16ug/ml of PWM for 5
days. Lymphocytes stimulated at 2 ug/ml for 48 hours were fed with
HAT medium, whilst two series of experiments were performed using
lymphocytes stimulated at 16 ug/ml for 5 days, the one series
being fed with HAT and the other with HAzT medium . In all these
series the fusion experiments were performed in matched pairs. At
the time of obtaining the node,one half of the node was fused
immediately, whilst the other half was first stimulated with PWM.
In all other respects the plates were treated in an identical
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manner in order that an accurate assessment could be made of the
effects of PWM. The results of these experiments are shown in
table 8,9 and 10. From table 8 it can be seen that no beneficial
effect was gained through stimulation of lymphocytes with PWM at 2
ug/ml for 48 hours and feeding the fusion cultures with HAT
medium. One problem with this series is the high number of
technical failures due in part to these fusions occurring early
in the series . Thus whilst there were 17 successful plates in
the "HAT only " column and 18 in the"HAT + PWM 2ug/ml" column,
only 10 matched pairs of plates survived long enough in culture to
allow direct comparison. Only one of the two hybrids occurred
within these matched pairs. Thus the comparison of the sum totals
in each column may be slightly inaccurate in that direct
comparison of matched pairs was not made throughout the series..
This problem occurred, although to a lesser extent, in all of the
other groups of fusion experiments.
Table 9 shows the comparison of "HAT only" and "HAT + PWM
16ug/mlfor 5 days". In this series only two plates were failures,
resulting in 16 matched pairs .As can be seen the addition of PWM
in this series conferred no increase in the rate of hybrid
production.
Table 10 shows the comparison between the "HAzT only" and the
"HAzT + PWM16 ug/mlfor 5 days" series of plates. From these
results the number of hybrids was approximately equal in the two
columns but is considerably higher than the equivlent series using
HAT. In the series using HAzT only two hybrids (from plate FE




POKEWEED MITOGEN - FUSION EXPERIMENTS.
1) Effect of Preincubating Lymphocytes with PWM at










21/1 B 9 ) same ( 22/1 B 5
21/2 Y 10 )fusion( 22/2 Y 7
26/3 M 69 26/1 Y 59
26/4 Y 59 26/2 M 69
27/3 Y 20 27/1 Y 20
27/4 Y 19 27/2 Y 27
28/3 B 28 28/1 B 28
28/4 B 28 28/2 B 28
29/3 Y 12 29/1 Y 12
29/4 Y 39 29/2 Y 12
30/3 B 17 3 0/1 B 17
31/4 M 47 31/2 M 25
32/1 Y 52 H 36 32/3 M 48
35/4 M 28 35/2 M 22




37/1 M 26 37/2 Y 41
41/2 M 21 41/3 M 28
41/2A M 21 41/3A M 28
41/4 M 28
41/4A M 28
42/2 M 34 42/4 M 33
43/1 M 38 43/3 M 23
44/1 B 19 44/3 M 25
44/2 M 21 44/4 M 23
45/4 M 68 45/2 M 65
47/2 M 45 47/4 )Unknown
47/2A unknown 47/4A )
48/2 M 90 48/4 Y 5
50/2 B 7 50/4 B 7
55/2 M 19 55/4 M 19
16 Successful Plates 16 Successful Plates
13 "Failures" 13 "Failures"
1 Unknown 3 Unknown
2 Hybrids 0 Hybrids
( 10 successful matched pairs of plates)
(B=Bacteria,M=Mould,Y=Yeast, Time in Days).
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TABLE 9.
POKEWEED MITOGEN- FUSION EXPERIMENTS.
The Effect of Prestimulating Lymphocytes with
PWM at 16ug/ml for 5 Days Prior to Fusion in HAT
Medium.
Control PWM I6ug/ml for 5 Days
Plate Infecting Hybrid Plate Infecting Hybrid






























89/1 M 107 89/3 Y 96
89/2 M 104 89/4 M 24
93/1 Y 19 93/3 M 103
93/2 M 119 93/4 M 103
94/1 M 73 94/3 M 84
94/2 M 66 94/4 M 77
16 Successful Plates 18 Successful Plates
3 "Failures" 1 "Failures"
1 Hybrid 0 Hybrid
( 15 Successful pairs of Matched Plates)
(B=Bacteria,M=Mould,Y=Yeast, Time in Days)
( Time is in Days)
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TABLE 10.
POKEWEED MITOGEN - FUSION EXPERIMENTS.
The Effect of Prestimulation of Lymphocytes
with PWM at 16ug/ml for Five Days Prior to Fusion
in HAzT Medium.
Control PWM 16ug/ml
Plate Infecting Hybrid Plate Infecting Hybrid
Agent (Time) Agent (Time)
(Time) (Time)
49/1 B 10 49/3 M 37
49/2 B 10 49/4 M 37
51/1 M 60 51/3 M 60
51/2 M 25 51/4 Y 45 Hybrid 28
52/1 M 21 52/3 M 39
52/2 M 48 52/4 M 48
53/1 M 51 53/3 M 31 Hybrid 31
53/2 M 31 53/4 M 49 Hybrid 49
54/1 M 12 54/3 M 5 8
54/2 M 31 54/4 M 54 Hybrid 41
56/1 M 42 56/3 M 44
56/2 M 24 56/4 M 42
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TABLE 10 {CONTINUED}
59/1 Y 19 59/3 M 30
59/2 Y 19 59/4 M 42
6 0/1 M 38 60/2 M 38
60/2 M 14 60/4 M 38
63/1 M 24 63/3 M 28
63/2 M 24 63/4 M 24
64/1 M 21 64/3 M 17
64/2 M 97 64/4 M 25
67/1 M 52 67/3 M 106
67/2 M 66 Hybrid 46 67/4 M 77
69/2 M 136 69/4 M 96
71/1 Y 38 Hybridx2 35 71/3 Y 47
71/2 M 74 Hybridx2 38 71/4 M 96
74/1 Y 36 74/3 M 130
74/2 Y 60 Hybridx2 36 74/4 M 60
Day 24
19 Successful Plates 26 Successful Plates
8 Failures 0 Failures
7 Hybridomas 6 Hybridomas
19 Successful Matched Pairs of Plates
(B=Bacteria, Y=Yeast, M=Mould, Time in Days.)
(Time is in Days)
4.5. Feeder Cells.
4.5.1. Monocyte Feeder Cells. Preliminary Experiments.
Monocytes were separated from the lymphocytes by their ability to
adhere to plastic surfaces. This property of monocytes has been
described by Kumagai et al.,(1979),Treves et al.,(1980), Ackerman
et al.,1978, Territo et al.,(1977). These studies have shown that
monocytes adhere to plastic surfaces if incubated for l-2hours at
37°C . If however they are incubated for a prolonged time (greater
than 12 hours) this property is lost.
Preliminary experiments were performed to test this phenomenon.
Cell counts of the number of monocytes (large cells
morphologically resembling monocytes) and total cells were made
of the lymphocyte /monocyte suspension. This suspension was then
distributed over the wells of a 24 well plate (Nunc) at a
concentration of 5x10^ cells/well,and incubated at 37°C for
varying times between 30 min. and 2\ hours. The cells were then
removed from the wells by gentle suction followed by gentle
irrigation of the wells with TCM-A/2%FCS. Cells removed by suction
and irrigation were then centrifuged, resuspended and counted, and
the cells left adherent to the wells calculated by subtraction
from the original counts. Table 11 shows the cell counts obtained
by using this technique and shows that the incubation time
appeared to be of little importance except that the two hour
culture showed fewer cells adherent. The plates were then examined
microscopically after staining the cells with Giemsa stain and
this showed a high density of adherent monocyte cells in the first
three incubation times but a reduced density in the 2 hour plate.
From these results, one hour was adopted as the standard
incubation time for monocyte adherence.
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Further experiments were conducted to determine how many monocytes
needed to be added to leave a minimum of 5x10^ cells adherent to
each well. Table 12 summarises the results of these experiments.
On average approximately 85% of monocytes were found to be
adherent after one hour of incubation. It was decided therefore
that, to leave a minimum of 5x10^ cells/well, lO^monocytes in
suspension would be incubated in each well for one hour prior to
fusion.
On the morning of a fusion experiment a blood sample was prepared
as described, and the mononuclear cell suspension distributed over
the wells of the 24 well culture plate at a concentration of
5x10^ cells/well .The plate was incubated for one hour at 37°C in
the OO2 incubator and then the cell suspension was aspirated and
the wells gently irrigated with TCM-A/2%FCS. Thereafter the plate
was used as previously described for the fusion experiment .
4.5.2. Monocytes - Fusion Experiments.
The effect of adding monocytes to the fusion experiments is
illustrated in table 13 . In addition to the simple addition of
monocytes to these cultures the effects of adding monocytes to
fusion experiments,involving lymphocytes already pre-stimulated
with PWM at 2 ug/ml for 48 hours, was assessed and these results
are shown in table 14. The addition of monocytes did not improve
the efficiency of hybrid production. This series contained a
relatively high number of "failures" -seme of these experiments
were performed in the early part of the study. Neither did the




MONOCYTE FEEDER CELLS - PRELIMINARY EXPERIMENTS.
Effect of Varying Incubation Time on Monocyte
Adherence.
Incubation Time Monocyte Counts (a)
(Minutes) Initial Monocytes Adherent (b)
Count Retrieved Monocytes(%)
30 6.4 0.3 6.1 (95.3%)
60 6.4 0 6.4 (100%)
90 6.4 0 6.4 (100%)
120 6.4 1.2 5.2 (81.3%)
(Monocyte Counts all x10"^/ml)
(a) Monocyte counts are the mean of 3 counts of
each cell suspension.
(b) Adherent monocytes are calculated by
deduction. Preliminary experiments using Giemsa stain
confirmed the presence of many adherent monocytes.
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TABLE 12.
Effect of Varying Monocyte Input on Monocyte
Adherence.
Monocyte Counts
Initial Monocytes Adherent (by
Count Retrieved Monocytes(%) deduction)
3.7 1 2.7 ( 72.9%)
7.4 1 6.4 ( 86.5%)
15 2 13 ( 86.6%)
20 2 18 ( 90.0%)
29 4 25 ( 86.2%)
37 5 32 ( 86.5%)
(All cell counts x104/ml.)
TABLE 13.
MONOCYTE FEEDER CELLS - FUSION EXPERIMENTS.
The Effect of the Addition of Monocyte Feeder
Cells on the Rate of Hybridoma Production Using HAT
Medium.
Control Monocyte Feeder Cells.
Plate Infecting Hybrid. Plate Infecting Hybrid
Agent (Time) Agent (Time)
(Time) (Time)
31/4 M 48 31/3 M 48
32/1 Y 55 Hybrid 35 32/2 M 35
34/4 Y 51 34/3 M 38
35/4 M 28 35/3 M 20
36/2 Y 35 36/1 M 21
40/2 B 3 40/1 B 3
40/2A B 3 40/ 1 A B 3
40/4 Y 41 Hybrid 32 40/3 Unknown
40/4A Y 61 Hybrid 33 40/3A Unknown
42/2 M 34 42/1 Y 68
45/2 Y 60 45/1 B 12
47/2 M 54 47/1 M 54
47/2A Unknown ■47/1A M 61
48/2 Y 89 4 8/1 Y 82
TABLE 13 {CONTINUED}
50/2 B 7 50/1 B 7
55/2 M 19 55/1 M 11
79/1 M 117 79/5 M 131
79/2 M 55 79/6 M 96
80/1 M 110 80/5 Y 73
80/2 M 38 80/6 M 76
83/1 M 33 83/6 M 33
84/1 M 37 84/5 Y 121
84/2 M 97 84/6 M 63
18 Successful Plates 14 Successful Plates
3 "Failures" 6 "Failures"
1 Unknown 2 Unknown
3 Hybridomas 0 Hybridomas
13 Successful Pairs of Matched Plates
(B=Bacteria, Y=Yeast, M=Mould, Time in Days)
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TABLE 14.
COMPARISON OF THE EFFECT OF THE COMBINATION OF MONOCYTE
FEEDER CELLS AND PRESTIMULATION OF LYMPHOCYTES WITH PWM









































10 Successful Pairs of Matched Plates.
(B=Bacteria, Y=Yeast, M=Mould, Time in Days.)
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4.5.3. Thymocytes.
The addition of thymus feeder cells was seen to slightly improve
the rate of hybrid production as shown in table 15. In this series
only 3 plates were failures and 13 matched pairs were successful.
The effect of thymocyte feeder cells and PWM stimulation together
was not assessed in the course of this study.
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TABLE 15.
THYMOCYTE FEEDER CELLS - FUSION EXPERIMENTS.
The Effect of Adding Thymocyte Feeder Cells on the
Rate of Hybridoma Production Using HAT Medium.
Control Thymocyte Feeder Cells
Plate Infecting Hybrid Plate Infecting Hybrid
Agent (Time) Agent (Time)
(Time) (Time)
38/2 M 30 38/1 M 30
38/4 Y 26 38/3 M 28
39/2 M 27 3 9/1 M 27
39/4 M 58 39/3 B 32
41/2 M 21 41/1 M 29
41/2A M 21 41 / 1A M 29
6 5/2 M 42 65/1 M 130
66/3 M 31 66/1 Y 31
66/4 M 52 66/2 Y 31
72/2 M 46 72/1 M 25
75/3 M 17 75/1 M 17
75/4 M 107 75/2 M 28
rs©
TABLE 15 (cont.)
76/3 M 112 76/1 M 69 Hybridx2
53
76/4 M 112 76/2 M 58
85/1 M 64 85/3 M 95







13 Successful Pairs of Matched Plates.
(B=Bacteria, Y=Yeast, M=Mould, Time in Days).
4.6. Selective medium
In this series of experiments matched pairs of fusion plates were
fed with either HAT or HAzT medium. The effect of these selective
media is shown on table 16. Whilst 2 hybrids were obtained from
the HAT group and none from the HAzT group, the number of plates
involved was small and ,as will be discussed the overall analysis
of the hybridomas obtained in this study suggest that HAzT is a
more efficient hybrid producer than HAT
4.7. Cell Numbers.
The effect of varying the lymphocyte/myeloma ratio is shown in
table 17. HAT medium was used in these experiments. From this
series no particular ratio is seen to be more beneficial than any
other, although the number of plates in this series is smaller
than in the others.
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TABLE 16.
SELECTIVE MEDIA - FUSION EXPERIMENTS
Comparison of the Effects of Using Either HAT or
HAzT as Selective Medium on the Rate of Hybridoma
Production.
HAT HAzT
Plate Infecting Hybrid Plate Infect
Agent (Time) Agent
(Time) (Time)
69/1 M 108 Hybrid 60 69/2 M 136
77/1 M 58 Hybrid 36 77/3 Y 35
77/2 Y 36 77/4 Y 35
78/1 M 31 78/3 M 119
78/2 M 17 78/4 M 119
79/1 M 117 79/3 M 40
79/2 M 55 79/4 M 56
80/1 M 110 80/3 M 38
80/2 M 38 80/4 M 76
81/1 M 41 81/3 M 27
81/2 M 34 81/4 Y 41
82/1 M 33 82/3 M 26
83/1 M 33 83/3 M 26
83/2 M 19 83/4 M 33
84/1 M 37 84/3 M 37
84/2 M 97 84/4 M 107
(Time)
TABLE 16 {CONTINUED}
14 Successful Plates 16 Sucessful Plates
2 "Failures" 0 "Failures"
2 Hybridomas 0 Hybridomas
14 Successful Pairs of Matched Plates.
(B=Bacteria, Y=Yeast, M=Mould, Time in Days, HAT=
Hypoxanthine, Aminopterin and Thymidine, HAzT=
Hypoxanthine, Azaserine, and Thymidine.)
TABLE 17




































PLATES 10 10 10
FAILURES 1 2 1
HYBRIDS 1 1 2
( M=Mould, Y=Yeast, H=Hybridoma, Number represents time
in days after fusion at which these events occurred.)
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4.8. Hybridomas.
Table 18 summarises the hybrids obtained, the time after fusion at
which they appeared, the culture conditions under which they were
grown, and their ultimate fate.
Hybrids appeared at widely differing times after cell fusion, the mean
being 42.2 days, the range 24-69 days. No matter how long after fusion
the hybrids appeared there seemed to be no noticeable difference in
their growth rates in culture-ie a hybrid which did not appear until
late after fusion did not appear thereafter to be a slow growing
hybrid.
Table 19 relates the percentage of hybrids obtained compared to the
total number of plates for each set of culture conditions. Frcm these
figures it is seen that plates fed with HAzT produced a higher
percentage of hybrids than plates fed with HAT, whatever other culture
conditions were varied.This was different from the results obtained
when the two were compared directly. This may suggest that HAzT is a
more efficient medium for hybrid production that HAT.
One disappointing aspect of these hybrids was the number which failed
to survive in long term culture. Only 9 hybrids grew well in culture
and could be characterised. Of the remainder, 2 were lost because of
bacterial contamination during medium changing. These hybrids had been
growing well until that point and were being subcultured when the
contamination occurred. The remainding 14 hybrids were lost at the




SUMMARY OF HYBRIDOMAS OBTAINED.
Hybridoma Time After Culture Conditions Progres
Fusion Sel /Cell / PWM /Feeder
(Days) Med. Ratio Cells
32/1/B4 36 HAT / 10:1/ — / - S
40/4/A4 32 HAT / 10:1/ - / - D
40/4A/D3 33 HAT / 10:1/ - / - D
51/4/A6 28 HAzT/ 10:1/ 16 / - D
53/3/A2 31 HAzT/ 10:1/ 16 / - S
53/4 B4 49 HAzT/ 10:1/ 16 / - S
54/4/D4 41 HAzT/ 10:1/ 16 / - S
59/3/A3 24 HAzT/ 10:1/ 16 / - D
59/3/B1 29 HAzT/ 10:1/ 16 / - D
67/2/A3 46 HAzT/ 10:1/ - / - D
69/1/A3 60 HAT / 10: 1/ - / - D
71/1/A6 35 HAzT/ 10:1/ - / - D
71/1/B4 35 HAzT/ 10:1/ - / - D
71/2/A1 38 HAzT/ 10:1/ - / - S
71/2/A2 38 HAzT/ 10:1/ - / - S
71/2/B4 66 HAzT/ 10:1/ - / - D
73/3/B1 65 HAT / 10:1/ 16 / - D
74/2/D2 36 HAzT/ 10:1/ - / - S
7 4/2/D4 36 HAzT/ 10:1/ __ / - S
TABLE 18 (cont.)
76/1 D1 53 HAT / 10:1/ - / T D
77/1/B4 36 HAT / 10:1/ - / - D
95/1/C3 41 HAT / 10:1/ - / - D
96/3/D5 45 HAT / 1:1/ - / - D
98/3/D6 69 HAT / 1:1/ - / - D
Cell Ratios are Lymphocyte/Myeloma.
"T"= Thymocytes
"S"= Survived in Culture
"D" = Died in Culture
"16"= Prestimulation of Lymphocytes in Pokeweed





of the Success Rate




Fusion / Culture Hybridomas Successful Hybridomas/
Conditions Plates PlatesxIOO
HAT 6 72 8.3%
HAzT 8 38 21.0%
HAT/PWM16 1 20 5.0%
HAzT/PWM16 6 26 23.1%
HAT/Thymocytes 2 15 13.3%
HAT/1:1Cell Ratio 2 10 20.0%
"PWM16" = Prestimulation of Lymphocytes with Pokeweed
Mitogen at I6ug/ml for 5 days
All Fusions with a 10:1 Lymphocyte Myeloma Ratio Unless
Otherwise Stated.
Table 20 shows the relationship of the hybrids to the date on
which the corresponding fusion experiment was performed . Whilst
fusion experiments were performed regularly throughout the course
of this study,it appeared that there were clusters of fusion
experiments performed within relatively short time intervals
which produced many hybridomas. The reason for this is unknown and







of Hybridomas to the
t was Performed.



























4.9. Characterisation of Hybrids and Their Supernatants.
As was mentioned previously fusions FE1-19 were not included in
this study, but hybrids from these fusions were characterised in
the course of this study and these results are included in the
data presented. The results of these experiments are now
detailed.
4.9.1. Chromosome Count.
The chromosome count of each hybrid is shown in table 21. Each of
the counts is the mean of at least 3 different cell nuclei,and
were confirmed by an independent observer.In no case did the
results vary by more than 5 from the mean. In each case well
spread out preparations of individual nuclei were selected for
counting to allow as accurate a count as possible. All but one of
the hybrids were found to have a chromosome count of less than 92,
suggesting that some chromosomes were lost at the time of cell
fusion.
Most of the hybrids had their chromosome counts repeated after
several weeks in culture and no changes in the chromosome counts
were noted, suggesting that the hybrids remained stable in culture
over this period in time. A typical chromosome preparation is
shown in plate 1.
4.9.2. Cell Surface Markers.
The cell surface markers were performed to determine whether the
hybrids arose from fusion of a T or B cell with the HmY2 cell.The
results are shown on table 22.In this table also are shown the
\V1
TABLE 21





















Mean Chromosome Count 85.63. Range 74-92.
PLATE 1




Cell Surface Markers of Hybridomas as Defined
Rosetting Reaction Described in Section 3.6.2.
Hybridoma Rosettes
T-cell Sheep anti-human Normal Sheep
Fab Immunoglobulin
32/1/B4 4 17 1
53/3/A2 7 56 6
53/4/B4 2 63 7
54/4/D4 0 31 3
71/2/A1 4 60 4
71/2/A2 1 22 2
7 1/2/B4 0 25 10
74/2/D2 1 41 3
74/2/D4 1 37 2
HMy2 1 75 7
TNLE 192 56 27 0
TNLE 217 48 20 0
TNLE 238 60 25 0
TNLE 240 53 26 0
mimftetu AtvE. the Percentage. of (Idset-tins- Lellj:
V\vS.
results of rosettes formed by SRBC's coated with normal sheep
immunoglobulin. This served as a negative control to ensure that
there were no non-specific rosettes formed. Also included in this
table are the results of rosettes formed from lymphocyte
suspensions from four axillary nodes (TNLE 192,217,238,240.) to
show the normal distribution of T and B cells within these nodes.
It is concluded from this table that the hybrids all arose from
B-lymphocytes and there is no evidence of T-cell hybrids having
been formed.
4.10. Screening of Supernatants.
4.10.1. Measurement of Immunoglobulin Production.
Estimation of immunoglobulin production was made by an
agglutination reaction using SRBC's coated with the appropriate
antibody. When each batch of SRBC's was coupled control
agglutination reactions were performed to ensure that
agglutination was not occurring in a non-specific way. Each batch
of coupled SRBC's was therefore reacted with normal human serum as
a positive control and normal sheep serum as a negative control.
Any batch of coupled SRBC's failing to react appropriately with
either of these controls was discarded.
The results of these agglutination reactions are shown on table
23. Fran this it can be seen that most hybrids as well as HMy2
secrete IgG, although the sub-class of IgG was not determined
using this assay. A few hybrids were found however to secrete
both igG and IgM. Whilst it was not possible to say on the basis of
this assay that the hybrids secreted a different IgG from the HMy2
cell line,the secretion of IgM by seme hybrids is proof that these
hybrids secrete new (and different) immunoglobulin chains from the
HMy2.
This reaction was also used to determine the concentration
of immunoglobulin secreted by the hybrids. Control human
serum was therefore obtained and was found to have an IgG
concentration of 13.7g/l and an IgM concentration of 1.0g/l
(courtesy of the Dept of Clinical Chemistry, Royal Infirmary
of Edinburgh). By using this serum the hybrid supernatants
were found to contain the concentrations of immunoglobulin
shown on table 13 .
\V\
TABLE 23.
Type and Concentration of Immunoglobulin Secreted




1/4/B6 IgG + IgM
1/4/C2 IgG + IgM
4/1/A4 IgG
4/1/B2 IgG + IgM
4/1/C6 IgG



















In each of the assays performed, control wells were included to
ensure that any binding detected in the assay represented a
specific binding of the McAb to the target antigen.
As a negative control,both normal human serum and HMy2 supernatant
were used in place of the hybridcma supernatant, since neither of
these should react specifically with breast carcinoma cells and
would therefore give an indication of the amount of non-specific
binding of human immunoglobulin to the wells of the plate. In
addition the first antibody stage ( either the hybridoma supernatant
or HMy2 supernatant ) was emitted in three wells of each plate to
ensure that no non-specific binding of the other two antibodies was
occurring. The mouse anti human kappa and lambda antibodies were
also emitted frcm three wells to demonstrate the degree of
nonspecific binding of the iodinated rabbit anti-mouse antibody.
An appropriate positive control was more difficult since a human
McAb with specificity for breast cancer cells was not available.
Instead NIBBS (human anti-HLA serum, see apendix 1 ) was used to
bind onto the CLA4 cell line ( a lymphoblastoid cell line) .This
combination would provide a human immunoglobulin bound onto a human
cell line, and could therefore be used as a positive control.
The radioimmunoassay as described was found to produce very high
levels of background counts ( of the order of 400 - 2000 counts per
well). This occurred in control wells where HMy2 supernatant was
used in place of hybrid supernatant, and also in wells in which both
the hybridoma supernatant and the mouse anti human kappa (lambda)
antibodies were omitted. It was concluded that this high background
was caused by non-secific binding of the radioiodinated rabbit
anti-mouse antibody to the plastic of the wells of the plate.
Therefore,instead of merely adding 50ul of blocking buffer (see
page 90 for details) to each well of the plate, the whole plate
was immersed in blocking buffer. This attempt to reduce the high
level of background binding was unsuccessful.
Careful attention was paid to the washing of the plates between
the addition of each of the antibodies. The amount of
radiolabelled antibody added to each well was reduced,but neither
of these measures reduced the degree of background binding. A
total of 28 assays were performed but in none of these could the
level of background be reduced to acceptable levels.
In addition to the high background counts obtained, no difference
was observed in the counts obtained from the positive and negative
control wells. Whilst any difference between these wells may have
been obscured by the high level of background, the experimental
system was further investigated. The mouse anti human kappa and
lambda chain antibodies were conjugated to SRBC's, to determine
whether these conjugated SRBC's would then agglutinate in the
presence of control preparations of human kappa and lambda
chains.However no agglutination was seen to occur.
This agglutination reaction included appropriate controls to
ensure that the coupling reaction had been successful.For these
controls mouse anti rabbit immunoglobulin antibody (Dako) was
conjugated to SRBC's at the same time as the mouse anti human
kappa and lambda antibodies. These control coupled SRBC's were
then found to produce an agglutination reaction in
[SO
the presence of normal rabbit serum. It was concluded that mouse
immunoglobulin satisfactorilycoupled to the SRBC's by the methods
used.
In view of these several difficulties and the theoretical
advantages in favour of the immunoperoxidase technique, no further
use was made of the radioimmunoassay in this study.
4.10.3. The Immunoperoxidase Technique,
a) The Controls
Before the immunoperoxidase technique was used to determine the
binding of hybridoma supernatants to breast cancer cells numerous
control experiments were performed to assess the accuracy of the
technique.
A positive control was difficult to devise as no human McAb with
specificty for breast cancer cells was available. Two different
positive controls, therefore, were used to circumvent this
problem. Firstly a human antibody which would bind to a different
cell type was used as a model on which to work out the appropriate
concentrations of the various antibodies used in the assay. For
this purpose NIBBS ( human anti HLA serum derived from a
multiparous woman (Dept. of Immunology, Cambridge)) was used to
bind onto cytocentrifuge preparations of the CLA4 cell line as
described in the preceding section. Secondly a rabbit antibody
was used which bound onto breast epithelium cells, both normal and
malignant. For this purpose rabbit anti-human epithelial membrane
antigen antibody was used (Sloane et al 1981) . This control was
used when testing hybridoma supernatants against breast cancer
cells.
Using the NIBBS/CLA4 system a number of control experiments were
performed. The first of these aimed to determine whether
nonspecific binding of any of the antibodies used in the
experiment occurred, giving false positive results. This was done
by emitting in sequence first each antibody and then combinations
of antibodies from the process, and the results are shown in table
24. As can be seen , with one exception when one antibody was
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missed out no stain occurred whereas when all antibodies were
present a strong stain of virtually all cells was recorded. With
this one exception no non-specific binding of any of the
antibodies was seen to occur.
The exception occurred when NIBBS alone was cmmitted. It appeared
therefore, that this weakly positive stain (Line 3 table 24) was
due to binding of the rabbit anti human igM to the CLA4 cell
line. To test whether this represented non specific binding of
rabbit immunoglobulin to the cell cytocentrifuge preparation the
antibody was replaced with normal rabbit serum. This produced no
evidence of staining . It was concluded that this staining
represented specific binding of the antibody to the cell
line,which might be expected since the CLA4 cell line expresses
surface immunoglobulin. This binding of the second stage antibody
to human immunoglobulin already present on the slide remained a
problem throughout the course of this study and will be discussed
in greater detail later. A similiar series of controls were
performed replacing the rabbit anti human IgM with rabbit anti
human igG and an identical series of results were obtained.
In each group of immunoperoxidase experiments controls were always
included which involved missing out the hybridoma supernatant.
This allowed the binding of the second stage antibodies (ie the
rabbit anti-human IgG/IgM) to the immunoglobulin already present
within the tumour section or cytocentrifuge preparation to be
demonstrated and compared with the binding pattern obtained from
the hybridoma supernatant.
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In addition HMy 2 supernatant was also tested with each group of
slides to determine whether the immunoglobulin produced by this
cell line produced any non specific binding.
The next series of control experiments investigated the optimal
dilution of each antibody to produce a reliable result with the
minimal background, since too little of any antibody may decrease
the sensitivity of the technique whilst too much may increase the
level of background binding. A series of experiments was
performed in which the concentration of each antibody was varied
keeping all others constant.
A 1/100 solution of the rabbit anti human igG and igM
antibodies and the PAP antibody complex was found to produce
clear staining with minimal background,whilst further dilution
diminished the intensity of the staining. These dilutions were
therefore adopted as standard. The swine anti rabbit antibody was
used in a 1/50 dilution since the assay requires an excess of this
antibody. The hybridoma supernatants were normally used undiluted
because of the low amount of that immunoglobulin they contained.
In sane cases the supernatants ware concentrated X50 in a Minicon
protein concentrator but this did not alter the binding patterns




1) Positive Controls -the Use of HLA Serum and
the CLA4 Cell Line to Assess the Effects of






























(+) = antibody added
(-) = antibody not added
S.A.R. = Swine Anti Rabbit Antibody



































BREAST CANCER TARGET CELLS.
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b) Immunoperoxidase-Results.
Each supernatant was tested against a variety of target cells as
represented on table 25and 26. On this table the numbers in
parenthesis represents the number of times that that supernatant
was tested against that type of target cell-eg if (8) appears
under the "other tumours" column this meant that the supernatant
was tested against tumour sections from 8 different patients.
Supernatants would be tested against numerous sections of each
tumour . Similiarly (3) under the "own tumour" column meant that
the supernatant was tested against sections of tumour from the
patient from which the hybrid arose on three separate occasions.
There was considerable variation in the number of types of target
cellsagainst which each supernatant was tested. FE1/2/B2 and
32/1/B4 were the most widely tested since these hybrids grew very
well in culture and hence a large amount of hybridoma supernatant
was available for testing. These were used, therefore,in the early
experiments establishing the technique. Some supernatants were
obtained only in small volume before the hybrid died (eg 4/3/C2)
and hence the supernatants were only tested against a few
sections. Similiarly the later supernatants eg 72/2/D2 and 72/2/D4
were obtained towards the end of the study and time did not permit
extensive testing of their reactivity. All supernatants were
tested where possible against sections of tumours from which they
were derived except where there was inadequate supernatant
(6/3/A2, 6/1/A3) or where sections of the appropriate tumour were
unavailable(5/1/D5,5/2/D5). Whilst 1/4/C2 and 4/1/B2 showed some
degree of positive binding with an Fc rosette
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preparation of some tumour cells this effect could not be repeated
and was not maintained throughout testing against a variety of
other cell types . This did not therefore seem to represent true
specific binding to breast cancer cells.
Whilst a variety of binding patterns was obtained in many
sections,none of these could be differentiated from the binding
obtained from the appropriate negative control. It is therefore
concluded that using the immunoperoxidase method no selective
binding of McAb to breast carcinoma cells was demonstrated. Each
of the supernatants were then concentrated X50 in a Minicon
protein concentrator and re-tested against sections of their own
tumours, but this also failed to reveal any selective binding of
McAbs to breast carcinoma cells. Some examples of the background
binding patterns obtained are shown in plates 2 and 3.
TABLE 25
Immunoperoxidase Stain.
Summary of the Results of Testing the Hybridoma
Supernatants Against a Variety of Target Antigens.
1) Cytocentrifuge Preparations of Cultured Cell Lines
Hybrid. Target Antigen
MDA MCF 7 CLA4 DET 6
1/2/B2 (5) -ve (5)-ve (4)-ve (4)-ve
1/4/C2 (2) -ve (1)-ve X X
1/4/B6 (1) -ve (1)-ve (1)-ve (1)-ve
4/1/A4 (2) -ve (1)-ve X X
4/1/B2 (2) -ve (1)+ve X X
4/1/C6 (1) -ve X X X
4/2/C2 ( 1 ) -ve * X X
4/3/C2 (1) -ve X X X
5/1/D5 ( 1) -ve (1)-ve X X
5/2/D5 (1) -ve (1)-ve X X
6/1/A2 ( 1) -ve (1)-ve X X
6/1/A3 ( 1) -ve (1)-ve X X
6/3/A2 (1) -ve X X X
6/4/A3 (1) -ve (1)-ve X X
32/1/B4 (5) -ve (5)-ve (3)-ve (3)-ve
53/3/A2 (2) -ve (1)-ve X X
53/4/D4 ( 1) -ve X X X
54/4/D4 ( 1) -ve X X X
71/2/A1 ( 1) -ve X X X
71/2/A2 (1) -ve X X X




Summary of the Results of Testing the Hybridoma
Supernatants Against a Variety of Target Antigens.
2)Preparations Derived from Breast Tumours
a ) Cytocentrifuge preparations of Tumour Cell
Suspensions (C.B.T.) and b) Paraffin Sections of Breast
Tumours (P.B.T.)
Hybridoma C.B.T. C.B.T. P.B.T. P.B.T.
+ Fc Own Other
Rosette Tumour Tumour
1/2/B2 * (2)-ve (1)-ve (10)-ve
1/4/C2 (1)-ve (2)+ve (1)-ve (1)-ve
1/4/B6 (1)-ve (2)-ve (1)-ve (2)-ve
4/1/A4 * (2)-ve (1)-ve (2)-ve
4/1/B2 * (2)+ve (1)-ve (2)-ve
4/1/C6 * (2)-ve (1)-ve (1)-ve
4/2/C2 * (2)-ve (1)-ve (1)-ve
5/2/D5 * (1)-ve * (1)-ve
5/2/D5 * (2)-ve * (2)-ve
6/1/A2 * (2)-ve (1)-ve (3)-ve
6/1/A3 * (2)-ve (1)-ve (2)-ve
6/3/A2 * (1)-ve * (1)weak+ve
6/4/A3 * (2)-ve * (2)-ve
32/1/B4 (3)-ve (7)-ve (2)-ve (13)-ve
53/3/A2 * (2)-ve (1)-ve (7)-ve
53/4/D4 * (2)-ve (1)-ve (5)-ve
54/4/D4 * (2)-ve (1)-ve (5)-ve
(b\
71/2/A1 * * (1)-ve
71/2/A2 * * (1)-ve
74/2/D2 * * (1)-ve
7 4/2/D4 * * (1)-ve







Immunoperoxidase Technique. Negative Controls.
Tissue section of a breast carcinoma in which the hybridoma
supernatant stage of the assay was emitted. Staining of individual
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Iinmunoperoxidase Technique. Negative Controls.
Tissue section of breast carcinoma in which the hybridoma
supernatant stage has been omitted. Staining of the fibrous





Cloning of hybrids was performed by limiting dilution as already
described. Using this technique it was found that hybrids diluted
down to one cell per well could be grown successfully up to large
scale culture again in approximately 14 days. All hybrids which
were growing well at the time of cloning were found to behave in
this way. Similiarly ,those clones which were re-cloned were found
to clone equally well when this was performed repeatedly.
Hybrids grown from fusion of the HMy2 cell line with axillary
lymphocytes clone well by limiting dilution which represents one
advantage of this cell line when used for hybrid production.
Hybrids which were found by agglutination reaction to secrete both
IgG and IgM ( 1/4/C2, 1/4/B6, 4/2/C2, 4/1/B2, 32/1/B4) were cloned
repeatedly to determine whether it was possible to obtain two
different clones, one secreting IgG and the other IgM or whether
it was one hybrid which was producing both classes of
immunoglobulin. These hybrids were cloned six times, and on each
occasion clones were grown from the one cell per well dilution.
These were then grown up in culture, had their supernatant tested
and were then re-cloned. It was found that even after this
procedure the hybrids secreted both classes of immunoglobulin. It
is concluded that these hybrids were truly monoclonal from the




DISCUSSION OF EXPERIMENTAL WORK.
lib
The following section will critically discuss the experimental
work described in this thesis and relate it to published data in
the literature.
5.1. Materials and Methods.
5.1.1 .Lymphocytes.
Successful cell fusion requires as one of the parents a lymphocyte
sensitised by the appropriate antigen. The spleens of inmunised
mice provide a ready source of sensitised lymphocytes. Human McAb
production requires a source of sensitised human lymphocytes.
One possibility as suggested by Reading (1982) is to sensitise
lymphocytes in vitro. Whilst the techniques for this are
described,and may be technically feasible for seme antigens it has
disadvantages in the production of anti-tumour antibodies. This is
because the characterisation of tumour-specific antigens remains
incomplete, and hence it would be difficult to know what antigens
to use in these circumstances. The use of lymphocytes sensitised
in vivo appears to be a more suitable choice.
Peripheral blood lymphocytes are the most easily obtained source
of lymphocytes but according to Eremin et al• (1976) there was
found to be little difference in the lymphocyte subgroups in the
peripheral blood of normal and breast cancer patients, as
assessed by a broad group of phenotypic markers (T,B,Fc,C3),
suggesting that peripheral blood lymphocytes were not greatly
affected by any tumour-host immune reaction. Even if blood
lymphocytes contained tumour-sensitised cells, it would be
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difficult to separate these out from the other non-allergised
cells. Thus lymphocytes from tumour draining nodes or
infiltrating the tumour itself would appear to provide a more
useful source in spite of their relative inaccessability. Whilst
anti-glioma McAbs have been prepared using tumour infiltrating
lymphocytes (Sikora et al 1982(b)) the use of lymphocytes
infiltrating breast tumours for cell fusion was not attempted in
this study. This was because it was found that the techniques
employed to isolate viable lymphocytes from specimens of breast
cancers resulted in an inadequate number of lymphocytes for cell
fusion (Eremin, personal communication).
Axillary nodes on the other hand ,are a suitable source of
lymphocytes for cell fusion work,since they are able to provide
large numbers of lymphocytes sane of which may have been
sensitised by tumour associated antigens. Other workers (Schlan et
al 1980, Sikora 1982(a)) used a similiar strategy. Having accepted
that axillary nodes may be a suitable source of lymphocytes it is
important to ensure that these lymphocytes are in an optimal
biological state for cell fusion.
Two aspects of the preparation of axillary node lymphocytes
require consideration. Firstly, only sensitised B-cells are
required for fusion, although lymphocytes obtained from the
axillary node will contain a mixture of B and T lymphocytes. It
may be advantageous to try to select out the sensitised B
lymphocytes prior to fusion, a point emphasised
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by Sikora et al.1982(c). Whilst it may be very difficult to
isolate the sensitised B lymphocytes from the rest of the B
lymphocytes it may be possible ,and probably desirable,to separate
the B frail the T lymphocytes. The latter may be done in a variety
of ways. Anderson et al. (1983) described a method whereby B
lymphocytes were isolated by a process of immune rosette
depletion. Using this technique,T-cell rosettes were made and
separated from the lymphocyte suspension. The disadvantage of the
technique is that often small numbers of viable B-cells only are
obtained at the end of the procedure. This technique has been used
successfully to prepare enriched B cell populations prior to
fusion (Gigliotti et al.,1984, Littman et al.,1983, Larrick et
al.,1983).
A different approach has been to use a B-cell mitogen in the
mixed lymphocyte culture, in order to expand the B-cell pool. This
approach has the advantage that it will also fulfill the second
requirement of lymphocyte preparation namely, that lymphocytes are
actively growing and dividing at the time of fusion. As has been
discussed in the first section of this thesis successful fusion
requires the presence of two actively dividing cells for nuclear
fusion to occur. This requirement has been emphasised by
Goding(1980). A variety of mitogens may be used in this respect
and in this study pokeweed mitogen was used. Pokeweed mitogen
(PWM), a plant lectin,is described as a specific B cell mitogen,
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although this effect may be dependent on the presence of T cells
(Keightley et al.,1976, Hammarstrom et al.,1979). It has been used
by other workers to improve the rate of human hybrid production by
stimulation of both peripheral blood lymphocytes (Ritts et al.J.983
Shoenfield et al.,1982, olsson et al.> 1983)and node lymphocytes
(Warenius et al1983),and would appear to be an appropriate
mitogen to use.
There are other methods by which B cells may be stimulated and
these perhaps merit further investigation. Kearney et al (1975)
described the way in which bacterial lipopolysaccharide
non-specifically stimulated B lymphocytes and increased
immunoglobulin secretion by these cells. Lamers et al (1982)
discussed how little is known about the mechanisms by which
B-cells are stimulated to proliferate. A murine McAb is described
which bound to the IgG Fc surface receptor on the B lymphocyte
and stimulated B cell proliferation and immunoglobulin
secretion.lt was postulated that this McAb acted in a similiar
manner to lipopolysaccharide.
Another experimental approach is to infect the lymphocyte
suspension with Epstein Barr virus (EBV). EBV has been shown to
specifically infect human B cells (Epstein et al01982) and to
transform them into established cell lines. It was postulated
(Steinitz et all?L979)that all B lymphocytes possessed EBV receptor
sites and when infected were transformed into proliferating cell
lines.B lymphocytes thus transformed did not have the ability to
secrete the virus nor to transform other cell lines. (Epstein et
al 1982) . EBV transformation
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has also been shown to increase the rate of
immunoglobulin secretion by the transformed cell (Rosen et al.,
1977) . The techniques of EBV transformation of lymphocytes is
relatively simple. The virus is secreted by the marmoset blood
leucocyte line B95-8 which can be grown readily in culture (Miller
et 1973). The supernatant of this culture, containing EBV , can be
collected frozen,and stored until required for use. Lymphocytes
can then be transformed by incubating them for one hour at 37°C in
the presence of the EBV containing supernatant (Steinitz et al.j
1979) . The resulting transformed B cells can then be cloned,
grown in culture and have their secreted immunoglobulin measured.
This technique has been used per se to produce human McAbs.
Steinitz et al (1979) demonstrated the feasibility of this by
transforming peripheral blood B lymphocytes of patients with high
natural titre against nitrosonitraphenol. By cloning the resulting
transformed cells a cell line was obtained which produced
immunoglobulin with high anti-NNP activity. Slaughter et al,(1978)
and Steinitz (1980) both used this technique to tranform
peripheral blood lymphocytes from patients with rheumatoid
arthritis in an attempt to produce monoclonal rheumatoid factor.
This technique proved to be successful in their hands. Boylston et
al,(1980) used EBV transformation of peripheral blood lymphocytes
to produce anti-D antibodies. Chiorazzo et al. (1982) used EBV
transformation of enzyme deficient B-cells to provide the myeloma
partner for cell fusion.
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Watson,D.B., et al , (1983) transformed tumour infiltrating
lymphocytes from melanoma tumours with EBV and these produced
antibody with some activity against human melanoma cells. Steinitz
et al .(1984) produced an anti-pneumococcal IgM by EB virus
transformation of peripheral blood lymphocytes of immune
volunteers. This technique appears to have the advantage of
allowing B cells to selectively grow and secrete antibody. Indeed
at first sight it appears to be a much simpler way of producing
monoclonal antibodies than the somewhat complex techniques
involved in cell fusion. It does however have disadvantages.
The transformed B cell cultures, whilst providing proliferating
cultures in the early stages have been found to die after several
months in culture, which wauld be disadvantageous since supplies
of any useful antibody would be limited. (James et al 1984, Kozbor
et al.,1982) .In addition the transformed lymphocytes secrete lower
concentrations of immunoglobulin than the comparable hybridomas.
The technique may be of considerable value if the transformed B
cells are subsequently fused to an appropriate myeloma line, since
the myeloma parent would hopefully increase the rate of
immunoglobulin secretion and also make the B cell stable in
culture. Kozbor et al,(1982) fused EBV transfomed lymphocytes with
a variant of the human myeloma cell line GM1500. This variant was
selected for resistance to oubain. The resulting hybrids were
grown in medium containing oubain as well as HAT so that the
parent transformed lymphocytes would die in culture.Using this
technique antibody secreting hybridomas were obtained which grew
better in culture than the original transformed lymphocytes.
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Thus EB virus appears to be a very useful way to select B cells
out of the lymphocyte suspension ,and to induce these cells to
grow and proliferate prior to fusion. It may even be possible to
select by repeated screening and cloning of the transformed
lymphocytes those lymphocytes which secrete immunoglobulin
reactive with the appropriate antigen prior to fusion. Kozbor et
al »(1984) described the use of EBV transformed peripheral blood
lymphocytes in fusion experiments to produce human monoclonal
anti-tetanus toxin antibody .These lymphocytes were selected out
on the basis of the activity of their secreted immunoglobulin
prior to fusion.In the latter study it was reported that the
transformation of peripheral blood lymphocytes prior to fusion
produces six times more hybrids than lymphocytes stimulated with
PWM and thirty six times more hybrids than unstimulated
lymphocytes. These advantages were obtained at the cost of
introducing further complexity into the fusion system by using
oubain. It has been found to be relatively easy to obtain an
oubain resistant variant of the HMy2 cell line
(T.Alderson,personal communication) and these techniques would
appear to be applicable to the fusion system used in this study.
It is hoped that the merits of EB virus transformation may be
investigated at some time in the laboratory in which this work was
carried out.
It is of interest that the importance of prestimulation of
lymphocytes prior to fusion has only been mentioned in respect to
human-human hybridoma production.This reflects the sources of
m
human lymphocytes used for hybrid production. In murine McAb
production the spleens of immunised animals were used as the
source of lymphocytes. Spleens were removed from these animals
after strong antigenic stimulation and the spleen cells obtained
from these animals have been found to be actively dividing at that
time (Andersson et al 1978).Therefore the lymphocytes obtained
from these spleens are in optimal condition for fusing.
Human lymphocytes used for hybrid production are likely to have a
much lower rate of cell division than the spleen cells of
immunised mice. Peripheral blood lymphocytes have a very low rate
of mitotic activity whilst node lymphocytes may have some degree
of activity especially if the node is being challenged by the
appropriate antigen. One would expect that the higher the rate of
cell division,the greater would be the success rate for obtaining
hybridomas from these lymphocytes .This is confirmed by some
comparisons of the rates of hybrid production compared with the
source of human lymphocytes used.
Olsson et al, (1983) found a lower hybrid rate using peripheral
blood lymphocytes compared with spleen cells. Glassy et al.(1983)
compared the rates of hybridoma production obtained by fusing
human lymphocytes of various types with the myeloma cell line
UC 729-6. In the latter study peripheral blood lymphocytes were
the least efficient hybrid producers, spleen cells and
node lymphocytes less so, and tonsil lymphocytes were found to be
most efficient cells to use. These spleen cells were obtained from
people who had not received an antigenic challenge. Tonsil
lymphocytes from children would be expected to have a high rate of
cell proliferation since the tonsils are constantly undergoing
antigenic stimulation.
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Larrick et al.(1983) found tht B-cell blast fused much more
readily than unstimulated B cells. Thus it appears that the rate
of hybrid production is in part determined by the degree of
proliferation occurring in the parent lymphocyte at the time of
cell fusion. This may be one of the main reasons why murine McAbs
are much easier to produce than autologous human McAbs and further
investigation is required to define the optimum regimes for
stimulating various types of human B-cells to grow and divide
prior to fusion.
Finally Olsson et al.(1983) maintained lymphocytes in HAT medium
during prestimulation with PWM, to induce the enzymes necessary
for the alternative route for purine/pyrimidine synthesis prior to
fusion. This was not done in this study but it may be an important
point of technique and merits further investigation.
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5.1.2. The Myeloma Cell Line.
The HMy2 cell line was kindly donated to the laboratory by the
Ludvig Institute for Cancer Research in Cambridge. The development
of the HMy2 line from the ARH 77 plasma leukaemia cell line has
been described (Edwards et alv1982) . The ARH 77 line was derived
from a patient with plasma cell leukaemia as described by Burk et
al,(1978). The HMy2 line has been found to possess the Epstein-
Barr nuclear antigen suggesting that it may represent an EBV
transformed cell line. The HMy2 line has been found however to
neither secrete the virus nor transform other cells. (Edwards et
al.,1982) . Throughout the course of the study it was found to grow
reliably and readily in culture and to freeze and thaw with little
difficulty. Periodically (every 10 passages) subcultures of the
HMy2 line were grown in HAT medium, to ensure that there were no
spontaneous revertants of the HPRT deficient cells. Every time
this was performed the HMy2 cells died in HAT medium indicating
that no spontaneous reversion had occurred. This same finding has
been reported with other human myeloma cell lines (Ritts et al,,
1983, Glassy et al.p1983)and also with murine myeloma cell lines,
suggesting that clones of myeloma cells selected for resistance to
8 azaguanine are stable mutants and spontaneous reversion is a
rare occurrence.
Reading (1982) mentioned the problem of mycoplasma infection in
these established cell lines. Whilst the HMy2 cell line was
screened for mycoplasma infection prior to the commencement of
this study, routine testing of the HMy2 line and resulting
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hybrids for mycoplasma infection was not performed during this
study. The HMy2 cell line does possess the disadvantage that it
secretes an immunoglobulin (IgG kappa chain) (Edwards et al.,
1982). One advantage of the line , on the other hand,is that it
has been grown in serum-free medium which is an advantage when
analysing the secreted products of resulting hybrids . Growth in
serum free medium was not attempted in the course of this study
but would have been had a McAb been obtained which reacted
specifically with breast cancer cells.
The HMy2 line has been found to produce hybrids
consistently in a number of different laboratories. (Warenius et
al.,1983;Cote et al.,1983). As has been pointed out (Sikora et al
1982(c))this is a feature not shared by some other cell lines.
Several other human myeloma/plasmacytoma cell lines have been
described for use in the production of human hybridomas. Olsson et
al.(1980) described an 8 azaguanine resistant mutant of the U266
myeloma cell line. This cell line secreted an IgE, was used
successfully in cell fusions and given the title SK0-007. Croce et
al. (1980(a)) employed an HPRT deficient variant of the GM1500
myeloma cell line which secreted an IgG. A subline of this ,GM
4672 was used successfully by Shoenfield et al.(1982) to produce
human hybrids. Kozbor et al.(1982) successfully developed an
oubain resistant variant of this line and fused it with EB virus
transformed lymphocytes. The relative efficiencies of the SKO 007,
HMy2 and a murine non secreting cell line were compared as fusion
partners for human lymphocytes by Cote et al,(1983) who concluded
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that the HMy2 cell line compared favourably with the other human
myeloma cell lines but the murine non-secreting myeloma cell line
was the more efficient hybrid producer. Olsson et al.(1983)
compared the properties of the SKO 007,RH L4 and a murine
nonsecreting line. The RH-L4 line was found to produce a higher
percentage of hybrids than the SK0-007 line. It was also found
that the rate of hybrid product ion,produced by the mouse myeloma
line was of the same order as the human lines when peripheral
blood lymphocytes were used as fusion partner, although the
hybridoma production rate of the mouse myeloma line with mouse
spleen cells was much higher. Glassy et al,(1983) have reported a
different myeloma cell line ,U729-6 which is said to form stable
hybrids. This cell line exhibits surface IgM . Experience with
this cell line is as yet limited. There have been two reports of
human non-secreting myeloma cell lines useful for fusion.
Pickering et al, (1982(a)) described an 8-azaguanine resistant
variant of the RPMI 8226 myeloma cell line which was described as
forming stable hybrids when fused to human lymphocytes. This cell
line was said to lack surface Ig and did not secrete
immunoglobulin. Unfortunately, this line was later shown to be of
murine and not human origin(Pickering et al. 1982(b)) .Ritts et al,
(1983) described a nonsecreting human plasmacytoid cell line which
had been shown to possess intracytoplasmic IgG but to have no
Slg or secreted imunoglobulin. This line has been shown to
form hybridomas successfully with human lymphocytyes.
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Further reports about this cell line are awaited to assess its
efficiency for use in hybrid production.
Abram et al • (1983) compared six human myeloma/plasmacytoma
cell lines and one mouse cell line . The human cell lines
used were U 266, RPMI 8226, HMy2, U729-6, HF 2, GM 4672.
These were compared for rate of hybrid production, level of
immunoglobulin secretion, and stability of hybrids. HMy2 was found to
produce a higher percentage of hybrids, and more stable hybrids than
the other lines although these hybrids secreted slightly lower levels
of immunoglobulin.
In conclusion,there is no universally accepted "ideal"
human myeloma cell line for use in cell fusions. Olsson (1985)
reported that there are, as yet, only 15 human myeloma /
lymphoblastoid cell lines freely available for cell fusion. Such a
line would require to be a nonsecretor of immunoglobulin, produce a
high rate of hybridoma formation, and a high level of antibody
secretion by these hybridomas.In the absence of such a line HMy2 was
regarded as a suitable choice for use in this study in spite of its
limitations.
5.1.3. The Fusion Experiment
There appear to be many variations in the way in which fusion
experiments are performed (James et al.,1984) a fact which by
itself suggests that more study is required to evaluate properly
the various methods in use so that the optimum method for fusing
cells may be established. It has been said (Fazekas 1980(b)) that
since the introduction of McAbs by Kohler and Milstein (Kohler et
al., 1975,1976) relatively little attention has been paid to the
mechanisms by which hybridanas are produced, since most workers
have aimed to produce as many McAbs as possible. Whilst this is
understandable, there is a need for the fusion experiment to be
more completely investigated. In this section the fusion
experiment will be discussed to try to determine those areas in
which more study is required.
Choice of Fusogen.
Whilst the initial work of Kohler and Milstein and others
(Yerganian et al.,1966, Harris et al.,1965) used Sendai virus as
the fusogen of choice, there is now wide agreement that
polyethylene glycol (PEG) ,described by Pontecervo (1975), is the
fusogen of choice (Galfre et al.;1977). There are a variety of
ways in which PEG is used and it is interesting in this context to
study Pontecervo's description of the effects of PEG.
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In his work the cells to be fused were first washed and suspended
in serum free solution. It is implied that serum inhibits the
activity of PEG although the mechanism of this is unknown. This
point is emphasised by Sikora et al (1983(a)) and hence all
fusions in this study were performed in the absence of serum.The
strength of the PEG solution and the duration of exposure also
varies. Pontecervo layered on a solution of lOg of PEG in 10 ml of
solution for 5-15 minutes. Olsson et al (1980)0 used 38% PEG,
whilst Edwards et al (1982) used 1 ml of a 50% solution of 1500
PEG in 1-15 medium.
Pontecervo observed that following the addition of PEG in this
manner considerable shrinkage of the cells occurred. PEG exerts a
strong osmotic effect on the cells which may be potentially
damaging . For this reason Fazekas et al (1980(a)) advocated the
addition of DMS0 (dimethyl sulphoxide) to the PEG solution to
prevent osmotic damage. DMS0 was added to the first of the two PEG
solutions used in this study although it is not known whether this
protection against osmotic damage is more important than the
potentially toxic effects of the DMS0 on the growing hybrids.
Osmotic damage may occur particularly when the PEG is removed and
the cells rehydrated. Pontecervo obsered that rapid dilution at
this stage killed the cells. It therefore seems sensible to use a
second more dilute PEG solution before adding medium since this
will protect against rapid dilution of the cells, as described by
Sikora et al (1983(a)). This practice was adopted throughout this
study.
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Relatively little attention has been paid to the temperature and
PH of the fusion mixture. White et al. (1980) emphasised the
importance of a slightly acid pH when Sendai virus was used as
fusogen. Whilst it is thought that PEG exerts its optimal effect
at a slightly alkaline pH there is no definite evidence of what is
the optimum pH. In this study the precise pH of the PEG solutions
were not measured although they were made slightly alkaline as
judged by the colour of the culture medium in which it was
disolved. Likewise while most authors suggest a temperature of
37°C for cell fusion (eg Edwards et altJ1982) there is little
evidence to show t,'ne importance of a particular temperature for
cell fusion. The maintenance of constant temperature in the fusion
experiments in this study was not carried out. Whilst all
solutions of PEG and medium were maintained at 37°C prior to
fusion, the cell suspension and solutions were not maintained in a
37°C waterbath throughout the fusion experiment.Fluctuations of
temperature obviously occurred towards the end of the
experiments. This may in part explain the poor hybrid rate
obtained in this study.
Management after the Addition of PEG.
Most studies agree on the need to dilute the PEG very gently to
avoid osmotic damage to the cells. In this study, care was taken
to add the first 4ml of medium dropwise, after which the cell
suspension was left to stand for 3-4 min. Following this the
next 29ml of medium were again added dropwise. Finally the cell
suspension was very gently aspirated into a wide bore 25ml
pipette. Sikora et al,(1983(a)) is one of the few to mention this
detail.
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Following cell fusion the next point of debate is how to dispose
of the PEG. In this there is a conflict of interests. On the one
hand it is undesirable to leave the fused cells too long in PEG
since this may inhibit hybrid growth, on the other, the newly
fused cells are still very fragile, held together only by the
adhesion of the cell membranes. Over vigorous treatment at this
stage may disrupt this bond.Pontecervo performed the fusion
experiment in a monolayer culture of cells and removed the PEG by
"draining it off". Thus he achieved both aims-to remove the PEG
and not to disrupt the cells. Cell suspensions, however,are not
amenable to this treatment. Many workers have removed the PEG by
centrifuging the cell suspension immediately after fusion and
resuspending the cells in medium (eg Pickering et al 1982(a),
Glassy et al 1983, Warenius et al 1983). Olsson et al (1980) even
washed the newly fused cells before plating them out.
The alternative means of removing PEG is to dilute the PEG out of
the medium by successive changes of medium. This is the technique
described by Sikora et al,, (1983(a)) and used in this study.
Following fusion the 25 ml cell suspension was dispensed into two
24 well plates. Each well was then fed with 1.0ml of fresh
medium.Thus the original 2.0 ml of PEG solution was diluted
approximately 1:47 within 10 min. of being added to the cell
suspension. On the day following fusion one ml of medium was
removed and replaced with fresh medium. This process was repeated
daily for 7 days. It was assumed that by using these techniques
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the amount of PEG left in contact with the hybridomas was
negligible. It is unknown however whether the trauma of
centrifugation is more harmful to the young hybrids than the
prolonged exposure to small amounts of PEG and this requires
further investigation.
d) Feeding and Selective Medium.
The care of hybrids after fusion varies from study to study, in
particular the frequency with which medium changes are made and
the time at which selective medium is added .All authors agree on
the need to change the medium in the culture wells from time to
time but the frequency varies. This is an important point to
establish since each medium change means that the plates are
exposed to the possibility of infection (Fazekas 1980(b)). The
purposes of medium changes appear to be threefold.Firstly fresh
medium provides a source of nutrients for the growing cells. In
the experience of this study this need appeared to occur at two
times during the course of the culture,these being at the
beginning before all the parent cells die , and at the end when
hybridomas were growing briskly and required frequent feeding. In
between these two episodes in the natural history of hybridoma
formation there is a spell when little cell growth is evidentin
the wells and the need for very frequent medium changes at this
time is debatable.
Secondly medium changes provide a means of removing the
potentially harmful remains of the dead cells. The occurrence of
cell fusion has been described as being a relatively rare event
even using PEG. Goding (1980) estimated that fusion between cells
occured approximately once amongst 10^ cells. Hence, there will be
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a lot of cell debris in the well which may inhibit the growth of
young hybrids. On these grounds fairly regular medium changes may
be required,especially early in the study when most cell death
occurs.
Thirdly medium changes provide a means for removing PEG from the
medium if the cells are not centrifuged after fusion,which means
that frequent feeding in the first few days is important.
For these reasons a feeding regime was used which involved
frequent medium changes early and late in the life of the plate,
whilst intermittent rates of feeding were carried out in the
intermediate phase of hybrid growth. There is a large variation in
the feeding regimes used in different studies from daily
(Wunderlich et al.,1981) to weekly (Ritts et al.,1983) to only two
medium changes in the life of the plate (Kennett et al#J1978).
There is a need for a study of the relative beneficial effects of
these regimes.
The addition of selective medium is an important step in selecting
out hybridomas, and there are different methods described in doing
this. In this study selective medium was added 24 hours after
fusion. The reasoning behind this was based on the presumed
pattern of fusion in the emerging hybrid. It was assumed as
described by White et al» (1980) that the initial fusion event
involved only the fusion of the two cell membranes and that
nuclear fusion did not occur until the next stage of cell
division. It seemed , therefore that fusion would not be
185
complete until several hours after the fusion experiment was
performed . Since the survival of hybrids depended upon the
genetic properties of both cells it will take some time before
cellular metabolism is controlled by the fused nucleus ,and hence
it was reasonable not to add the selective medium until this has
occurred. To add selective medium at the time of fusion (Fazekas
et al.,1980(a)) may inhibit division of the myeloma parent and
hence prevent fusion occurring.Other studies have likewise delayed
adding selective medium until 24 hours after fusion (Astaldi
1980). One possible further improvement to this regime was
sugested by Cote et al.(1983) who added Hypoxanthine and Thymidine
at the time of fusion and Aminopterin at day 1. This would provide
the stimulus for the lymphocyte parent to adopt the alternative
pathway of purine/pyrimidine synthesis whilst not inhibiting the
myeloma cell. Equally it may be beneficial to keep the lymphocytes
in HT medium prior to fusion as already mentioned
In conclusion the techniques used in this study have a sound
theoretical basis, but much of this has not been tested by
controlled trial. As the number of laboratories working on McAb
production is increasing rapidly, there is a need for more careful
evaluation of the various steps involved in the fusion process.
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5.1.4, Foetal Calf Serum.
Hybrids were grown in medium, containing foetal calf serum
(Gibco).The importance of testing serum for its efficiency in
producing cell growth has been emphasised (Cote et al.^983)) since
the efficiency of serum has been found to vary widely. Edwards et
al.(1982) tested each batch of serum for its cloning efficiency
and its ability to maitain adequate growth of a HMy2 culture. In
this study each batch of serum was tested for its ability to
support vigorous growth of the stock culture of HMy2 and also for
the growth of whatever hybrids were in culture at that time. Only
one batch sample was found to be inadequate in the course of this
study.
Growing hybridomas in foetal calf serum presents three potential
problems. Firstly,it is expensive,and may be decreasing in
availability (Anderson 1980) both factors which will increase the
production costs of any McAb being prepared commercially in large
scale culture. Secondly, the presence of serum in the supernatant
of hybridomas may complicate the characterisation of these
supernatants. Thirdly, if a McAB is being prepared for clinical
use it is highly undesirable to have foreign proteins mixed in
with the McAb and separation of the two may prove difficult. For
these reasons it may be of value to grow hybrids in serum free
medium as advocated by Goding (1980) although Wunderlich et al»
(1981) found that immunoglobulin secretion by hybridomas decreased
when this was done. A variety of such media are available eg
Iscoves medium (Iscove et al^l978) and attempts have been made to
identify the essential growth factors required in such medium
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(Murakami et al,, 1982) . The HMy2 cell line and resulting hybrids
have been grown in serum free medium in other laboratories as
already described and the method is feasible. This may tie of great
value when producing McAbs for clinical use.
5.1.5. Screening of Supernatants.
The screening of supernatants has two distinct roles.The first of
these is to determine the type and concentration of immunoglobulin
secreted by the hybridoma and the second is to determine the
activity of any McAb produced with the appropriate antigen. Part
of this study was aimed at developing suitable methodology for
the screening of human McAbs for reactivity against breast cancer
cells, which were appropriate both to the type of antigen and to
the facilities of the laboratory. The need to have both an
accurate and reliable method for the screening of hybridoma
supernatants is emphasised by Goding (1980) . There are a large
variety of techniques described for screening McAbs in each of the
above two areas and these are now discussed in turn and their
relative merits compared.
5.1.6. Estimation of Antibody Type and Concentration.
The aim of this part of the screening process was to identify the
type and class of immunoglobulin secreted by the hybridoma. This
is important since it will show whether the hybridoma is secreting
merely the myeloma immunoglobulin or whether it is producing a new
immunoglobulin derived from the lymphocyte parent.(assuming the
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myeloma is an immunoglobulin secretor.) Since both myeloma and
lymphocyte may secrete the same class of immunoglobulin ,analysis
of the light and heavy chains is often required. Knowledge of the
type of antibody secreted will allow the use of appropriate
reagents when assessing the reactivity of the McAbs to the target
antigens. Knowledge of the concentration of antibody produced is
important since it allows comparison of the relative merits of the
various myeloma cell lines and also gives seme indication of the
scale of operation that would be required to produce a McAb
commercially .A variety of mechanisms have been used to determine
the type,class and concentration of MAbs. Underlying these methods
are two distinct principles.
The first involves the use of specific antibodies with reactivity
against different classes of immunoglobulin, and individual light
and heavy chains, whilst the second involves analysis of the
immunoglobulin chains on the basis of their physico-chemical
properties. The use of specific antibody against the
immunoglobulin being tested relies on the fact that there is a
method by which sites of antibody binding can be recognised by an
appropriate indicator , such as a radioactive tracer or an
attached sheep red blood cell. Use of a radioactive tracer in this
context has been widely used in a radioimmunoassay to identify
the characteristics of any McAb present. Olsson et al»(1980) used
jl25 as the tracer and tested for the presence of immunoglobulin
in a radioimmunoasssay using Staphylococcal protein-A.
A similiar technique was adopted by Wunderlich et al,
(1981).Staph.protein A has been shown to bind to certain subgroups
of igG (Kronvall et al.^1969, Goding}1978) . This binding has been
shown to occur at the Fc portion of the heavy chain, binding
occurring to IgG subgroups 1,2 and 4 but not 3. (These subgroups
identify the type of heavy chain present.) Schlom et alv(1980)
used a radioimmunoassay in which the supernatants of hybridomas
were tested for the presence of antibody by their ability to bind
onto rabbit anti-human IgG and igM, which in turn was bound onto
polyacrylamide microspheres. The amount of antibody present could
then be estimated by competitive binding in a column with il25
labelled human IgG and IgM. Pickering et al« (1982(a)) described
the use of the Ouchterlony double diffusion method to test for the
presence of antibody against a variety of anti-immunoglobulin
antibodies. Whilst the technique provided a relatively easy way of
determining the type of antibody present , a radioimmunoassay was
still required to measure the concentration of the antibody.
Sikora et al, (1983(b)) described an radioimmunoassay for the
detection of hybridoma antibody which was sensitive to a
concentration of 20ug/l of immunoglobulin,emphasising how
sensitive a technique the radioimmunoassay can be for measuring
immunoglubulin concentrations.
An alternative means of labelling these antibodies is by an
indirect red cell agglutination reaction. Claflin et al (1978)
described the use of a simple and rapid means of
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detecting immunoglobulin by using sheep red cells coupled with the
appropriate antibody. Sikora et al, (1981) described the way in
which Staph.Protein A can be used in conjunction with an SRBC
lysis test to test for immunoglobulin production. Watson,D.B. et
al, (1983) described the use of an agglutination reaction to
measure the type and concentration of antibody present which was
similiar to that used in this study. The concentration of antibody
could be calculated by comparing the agglutination reaction
pattern of a solution of known immunoglobulin concentration with
the hybridoma supernatant. The concentration at which
agglutination failed to occur should be the same in both instances
and from this the concentration of antibody in the hybridoma
supernatant could be calculated .
The two techniques are both widely used in the screening of
hybridoma supernatants. The radioimmunoassay is a sensitve assay
although background binding caused problems in this study. Its
main disadvantages are that it is a somewhat lengthy procedure
and is also expensive because of the use of the radioactive
tracer. It also requires special equipment to count the
radioactivity. These problems were emphasised by Claflin et al.
(1978).The agglutination assay has the advantages that it is both
quicker to perform and much cheaper. In the experience of this
study the problems of false positive results did not occur
provided that each batch of coupled red cells was properly tested
with positive and negative controls before use. It is also a
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sensitive assay. Using known concentrations of immunoglobulin, IgM
produced an agglutination reaction to a dilution of 10~10 g/1 and
IgG to a dilution of 5.6xl0~12 g/i # This compared favourably with
the sensitivities reported for the radioimmunoassay. Thus the
agglutination reaction seems to possess several advantages over
the radioimmunoassay and in this study was found to be an accurate
and reproducible means of measuring antibody type and
concentration. The disadvantage of both the radioimmunoassay and
the agglutination reaction concerns the antibody reagents used.
Specific antibodies against the type and class of McAb are
required for both assays and the specificity of these antibodies
limits the accuracy of the assay. Having considered this
limitation, the agglutination reaction still represents an easy,
reliable and inexpensive assay for the screening of hybridoma
supernatants for the presence of immunoglobulin. There is, however
, a need for a more accurate way of defining the precise
characteristics of any antibody secreted by hybridomas which does
not rely on the specificity of other antibodies. A suitable
technique for doing this is the technique of isoelectric focusing
which involves the separation of complex mixtures of proteins such
as immunoglobulin chains on the basis of their physico-chemical
properties. The technique was described in some detail by Awdeh et
al,(1968).The distribution of molecules on the polyacrylamide gel
was determined by their isoelectric focusing along a pH gradiant
in a carrier ampholyte ( sodium dodecylsulphate- hence the name of
the technique is abbreviated to SDS-PAGE).
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By this technique groups of immunoglobulin chains could be
analysed accurately. If the hybrid was grown in medium containing
C14 leucine, this label will be incorporated into the secreted
McAbs, and hence when these McAbs undergo SDS-PAGE their positions
on the polyac^lamide gel can be estimated by autoradiography on a
photographic plate.
The technique of SDS-PAGE was further described by
0'Farrell (1973,1975) who advocated it as a an accurate way of
separating mixtures of proteins. Olsson et al (1983) used this
technique as an initial screen of hybrid supernatants.
It is suggested therefore that the agglutination reaction is a
suitable means of screening hybridoma supernatants for the
presence of antibody. Subsequently if any of these antibodies
demonstrate specific binding to the target antigen and thus merit
further investigation, then SDS-PAGE should be applied at that
stage to fully characterise the antibody. In addition the isotype
of this immunoglobulin could be identified using specific
antisera, or, where applicable, protein A affinity chromatography.
A criticism of this study was that it was not established whether
the majority of McAbs produced contained antibody derived from the
parent lymphocyte as well as the myeloma cell. SDS-PAGE of
hybridoma supernatants can be of value in identifying the
immunoglobulin chains secreted by the hybridoma,confirming its
monoclonal ity and comparing the hybridoma chains with those
secreted by the parent lymphocyte and myeloma cells.
5.1.7. Screening The Reactivity of McAbs with the Target Antigen.
A method is required to screen the reactivity of McAbs against the
appropriate antigen, in this study breast carcinoma cells. The
requirements for such an assay may be defined as follows.
It requires a high degree of specificity- that is it requires to
be able to identify sites of McAb/antigen binding without either
an excess of background staining or a poor detection rate of
McAb/antigen binding sites. It is important therefore that
appropriate negative and positive controls are included in the
assay. The assay must also be sensitive -that is it must be able
to detect very low concentrations of McAb/antigen binding.
In addition it is preferable that the results of the assay bear
seme relationship to the possible in vivo activity of the McAb.
Finally the assay should,if possible, be relatively inexpensive
and easy to perform. A wide variety of techniques have been
proposed for the screening of the reactivity of McAbs,their use
depending on the nature of the antigen.The techniques available to
determine sites of McAb binding to tumour cells were summarised by




Of these the radioimmunoassay and immunohistological assays were




The introduction of a reliable positive control in this assay v\as
made difficult in the context of this study by the lack of a human
antibody which would bind selectively onto breast carcinoma
cells. An alternative positive control was used ,utilising the
CLA4 cell line and NIBBS serum as described. Whilst not ideal it
was hoped that this control would show that the assay worked,that
is that it would detect sites where human immunoglobulin was bound
onto human cells. In the latter asssay the main problem
encountered was that of high background binding. This occurred in
all the negative controls described including those in which all
but the il31 labelled rabbit anti mouse antibody was emitted. It
was therefore concluded that this high background was due to
nonspecific binding of this antibody to the wells of the plate.
Not even complete immersion in blocking buffer overcame this
problem. Special attention was paid to ensure that each of the
washing stages was performed very thoroughly but this had no
effect on abolishing non-specific binding. The high level of
background binding remained a problem in this assay and made
assessment of the positive controls impossible. The assay was not




The assay employed in this study was described in detail by Sikora
et al, (1983(b)), who stated that it detected immunoglobulin to a
level of 20 ug/ml and hence is a sensitive assay.The technique
described and used in this assay was made more sensitive by the
introduction of more than one antibody.lt is possible to conjugate
the McAb itself with il25 and then layer this onto the antigen(the
direct method) but the addition of the second and third antibody
stages was shown to increase the sensitivity of the assay by
Warenius et al,(1983) who estimated that the addition of a third
antibody increased the sensitivity of the technique ten-fold
compared with the two stage technique.
c) Relationship to In-Vivo Activity.
One of the main disdvantages of this assay was that it used
cultured cell lines of the appropriate type as target antigen. The
surface antigens of these cells bear an unknown relationship to
those found on tumour cells in actual tumours. This may be
especially true for breast cancer cell lines since breast cancer
cells are difficult to grow in culture and hence there is a
distinct possibility that those cell lines in culture are
atypical and may have deletions or expression of new antigens on
the cell surface. One alternative to this would be to use freshly
prepared suspensions from operative specimens as target cells. It
was, however, difficult to produce pure suspensions of tumour
cells and the presence of a few macrophages expressing
cytophilic immunoglobulin would produce false positive results .
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The relationship of the binding pattern of a McAb to cultured
cell lines used in the radioimmunoassay to the in-vivo binding
pattern of the McAb is unknown. There are therefore several
disadvantages to the use of the radioimmunoassay
d) Time and Cost.
The radioimmunoassay as performed in this study was found to
be a long and somewhat tedious assay to perform. This could
have been improved by the use of multichannel pipettes but the
assay remains time consuming.
It was also quite an expensive assay to perform, requiring
I-*-25 as a tracer and special equipment including a
radioactivity rocm and gamma counter. Whilst the ultimate
failure of the radioimmunoassay in this study may be
attributed to a problem with the mouse anti human kappa and
lambda antibodies there are considerable theoretical and
practical considerations which made the radioimmunassay
unsuitable for this study.
In spite of these disadvantages the radioimmunoassay has been
used quite extensively to determine the activity of McAbs to
a variety of tumour types, including melanoma and colon
(Steplewski, (1980), lung (Sikora et al.,1981), the ZR75 breast
cancer cell line (Hendler et al 1981),breast (
Taylor-Papadimitriou et al.,1981) and melanoma ( Warenius et al,^,
1983 ).It is of interest that while Sikora et al. (1983(a))
found some activity when McAbs were tested against a variety
of cell lines by radioimmunoassay this was not confirmed when
immunoperoxidase staining of sections of the appropriate
tumour were performed. This confirms seme of the above
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criticisms against using a radioimmunoassay for screening the
reactivity of human McAbs to human tumour cells. The assay is of
sane value when McAbs were orignally produced by immunising mice
with cultured tumour cell lines, since one would then anticipate
sane reaction to these cell lines in the assay. The relationship
of this interaction to the in-vivo reactivity of the antibody
remains unclear.
5.1.9. Immunohis tology.
This type of assay allows sites of McAb/antigen binding to be
determined on tissue sections thus allowing the histological sites
of this binding to be visualised. Two methods have been described,
the immunofluorescence technique and the immunoperoxidase
technique. Immunofluorescence is the less useful of the two since
it requires special equipment, is difficult to compare sites of
fluorescence with the standard histology of the slide,and the
fluorescence is not permanent (Taylor, 1978). Whilst techniques
for using immunofluorescence to detect McAb/cell binding have
been described ( Yuan et al.,1982) the technique was not employed
in this study because of its theoretical disadvantages.
5.1.10 . The Immunoperoxidase Technique.
a) Specificity.
The technique shared with the radioimmunoassay the difficulty of
providing a reliable positive control, since this would require a
human McAb with specificity for breast cancer cells. The positive
control used in this study was a rabbit polyvalent antibody
reacting with human epithelial membrane antigen, produced by
immunising rabbits with the human milk fat globule membrane
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( Sloane et al,, 1981) . This antibody was said to bind to the
luminal surfaces of normal breast epithelium and to a variety of
breast tumours. It was found in this study to provide quite
specific staining of both normal and malignant breast epithelial
cells and was therefore regarded as an acceptable control.
Negative controls included the use of the HMy2 supernatant and
normal human serum in place of hybridoma supernatant, as well as
emitting sequentially the various antibodies used in the assay.
Once again background binding was a problem and as previously
mentioned this background staining was coming frcm binding of the
second stage antibodies to immunoglobulin already present in the
tumour tissue section . This background was not seen when the anti
EMA control was used since in this case the second stage
antibodies were omitted.
Several other causes of background binding in the immunoperoxidase
technique have been described. Firstly the presence of endogenous
peroxidase within the tissue section was described as a potential
problem . Many authors (McGee et al.,1982, Wunderlich et al.,1981,
Lansdorp et al.,1980) have advocated treatment of slides with
3%H202 in methanol to prevent this. Heyderman et al.(1977) stated
that 3% H2O2 was inadequate to prevent background binding to
endogenous peroxidase, and advocated the use of 10% H202 instead.
The value of using 10% H2O2 was therefore examined in this study
using a series of matched pairs of slides, the one set being
treated with 3% H2O2 and the other with 10%H2C>2. No difference in
m
the degree of background binding between the two groups could be
identified and therefore pretreatraent of slides with 3%H2C>2 was
continued as standard throughout the course of this study.
A second source of background binding was the nonspecific binding
of protein to the tissue sections. It has been recommended that
slides are pretreated with an appropriate protein solution to
block such binding sites before the assay is performed, Thus
Wunderlich et al.(1981) pretreated slides with normal goat serum,
Douillard et al,(1980) with foetal calf serum and Naiem (1982)
with normal human serum It was important to ensure that the
blocking solution would not itself bind to any of the antibodies
used in the assay ,for which reason the use of both human and
rabbit serum would have been inappropriate in this study. Normal
swine serum was used, therefore, as the blocking solution since
this should not interact with any of the antibodies used (Taylor
1978) .
As has been described the concentrations of all the antibodies
used in the assay were adjusted to reduce background binding.
In spite of these precautions it was difficult to reduce the level
of background staining, which was attributed to the presence of
human immunoglobulin on the tissue sections. This binding occurred
both on the fibrous stroma of the breast and on sane individual
cells which were thought to represent surface immunoglobulin
bearing cells .
The difficulties of interpreting immunohistological staining of
human McAbs on sections of human tissue because of endogenous
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immunoglobulin has been emphasised by Lennox et al.
(1982).Interpretation of all slides stained by the
immunoperoxidase technique depended therefore upon careful
comparison of each slide with the appropriate negative control.
For this reason several negative controls were always produced in
each batch of slides being stained.
b)Sensitivity.
The sensitivity of the immunoperoxidase technique depends on the
method employed (Taylor 1978) . The "direct" technique in which
the peroxidase enzyme is conjugated directly to the McAb provides
a rapid assay system but has the two disadvantages a) it is
much less sensitive than the indirect technique and b) the
conjugation of the peroxidase to the McAb may alter the reactivity
of the McAb. (Field 1983).
To increase the sensitivity of the assay the "indirect" technique
has been recommended. In this technique the peroxidase is
conjugated to a second or subsequent antibody, each additional
step increasing the sensitivity of the method several-fold. There
remains the problem that conjugating the peroxidase molecule onto
one of the antibodies will alter the reactivity of the antibody
and for this reason the PAP technique has been recommended (Taylor,
1978, Weij et alyl983, Field, 1983). This technique uses as its
final antibody an antibody raised against the peroxidase molecule
, and this antibody is then conjugated with its substrate,
peroxidase. This peroxidase-antiperoxidase (PAP) complex can be
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bound onto the site of McAb binding using an excess of the
bridging antibody (in this case the swine anti-rabbit antibody).
The indirect PAP method for performing the immunoperoxidase
assay, whilst more lengthy ,offered considerably increased
sensitivity and was used as standard throughout this study.
Other factors have been described which affect the sensitivity of
the technique. The type of tissue section used may be important.
Curran et al (1977) commented that fixation of tissue sections may
mask tissue antigens which would otherwise be exposed if frozen
sections were used. McGee et al (1982) however performed identical
assays on frozen sections and subsequent paraffin sections of the
same tissue and found no difference in the binding pattern
obtained. This finding was also reported by Hand et al (1983).
Posner et al (1982) used viable cells in an attempt to overcome
this problem.
In this study a variety of target antigens were used but frozen
sections were not used. Paraffin sections of the hybrids "own"
tumour and other tumours were used as well as cytocentrifuge
preparations of suspensions of cultured breast cancer cell lines
and cell suspensions prepared from fresh breast tumour tissues. In
general, the definition of stain obtained on the cytocentrifuge
preparations was not as good as the paraffin sections.Fixed tissue
preparations, or enzyme treated preparations ,do,however, have
limitations in the screening of McAbs, since many antigens may
fail to survive the fixation process, and enzyme treatment may
remove surface antigens and/or expose irrelevant antigens.
The formation of Fc rosettes with tumour cell suspensions was
performed to define tumour infiltrating macrophages and to
characterise human tumour cells. However the problem of background
binding made this technique less successful than was hoped for.
The value of pretreating paraffin sections with trypsin has been
emphasised by Curran et al, (1977).Trypsin unmasked tissue antigens
which were concealed by the fixation process thus increasing the
sensitivity of the technique. This method was employed throughout
this study for paraffin sections although no attempt was made to
confirm the beneficial effects of trypsin.
The choice of reagent used to mark sites of peroxidase binding
may also play a part in determining the sensitivity of the
technique. Whilst diaminobenzidine has been a popular choice
giving a clear brown stain (Schlom et al.,1980,Naiem et al.,1982)
it has the disadvantage of being potentially carcinogenic.
Al-Kaissi et al,(1983) described a variety of potential substrates
for use in the peroxidase technique. Three-amino 9 ethylcarbizole
is not carcinogenic , and was used routinely in this study.
Throughout the study this reagent produced clear red staining
which was easy to identify against the haemotoK/iin counterstain.
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c) Relationship to InVivo Activity.
One great advantage of the immunoperoxidase technique is that it
can tie used to determine the histological site of McAb binding on
tumour sections .This can provide valuable information about the
distribution of the tumour antigens thus recognised within the
tumour and also between various tumours. It can also be used to
test sections of tissue which were fixed in the past thus
allowing wide comparisons of the activity of the McAb to be
made. In addition the record of McAb binding thus produced is
permanent.
Using the method described in this study the only disadvantage
was the problem of background binding and further investigation
is required to overcame this difficulty.
5.1.11. Cytotoxicity Tests.
Cytotoxicity test were not performed in this study. Such tests
require that when the McAb binds to the tumour cell it will cause
cell death in vitro. Such assays can be complex to develop and
often rely on the use of cultured cell lines as targets which is
disadvantageous as has been discussed. Such tests are more likely





At the beginning of this study infection with yeast organisms
presented a major problem within the laboratory, in spite of the
fact that all glassware and reagents were resterilised and the
incubator thoroughly cleaned before the study commenced. Yeast
infection was resolved only by the addition of amphotericin B
(fungizone) into the culture media. Fungizone is widely used in
McAb production (Schlom et al.,1980). A variety of concentrations
of fungizone have been used by different workers eg lug/ml
(Edwards et al,;1982), 2ug/ml (Kearney et ah, 1978). In this study
fungizone did not appear to inhibit hybrid growth at a
concentration of 2.5ug/ml (the manufacturers recommended maximum
concentration) and was therefore included in all media throughout
the study.
Few studies state that infection has been a problem although
Goding (1980) mentioned the problems of mould infection and
Epstein et al. (1982) emphasised the problems of bacterial yeast
and fungal infection. Whilst the addition of fungizone helped
improve the rate of early yeast infection all plates eventually
succumbed to some form of infection. The various factors which
were thought to contribute to infection of plates in this study
fell into two groups, a) those causing bacterial infections and
b)those causing infection by yeasts and moulds..
a) Bacterial Infections.
Bacterial infections tended to occur early (mean 8.12 days after
fusion) and to affect two or more plates from the same fusion
experiment at the same time- eg FE 50/1-4 all developed
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bacterial infection on day 7. Bacterial infection was always
observed the day after fusion or the day after the cells had been
fed, and did not appear to spread to adjacent plates within the
C02 incubator. It did however appear in most if not all of the
wells of the affected plate.
From these observations it was concluded that bacterial infection
was caused by direct contamination of the plate during fusion or
feeding since all plates of each fusion would be fused or fed
together at the same time. The precise source of bacterial
contamination was never identified . Careful attention was paid to
sterile technique whilst fusing and feeding plates. In addition a
continuous suction device was devised for use in removing one ml
of spent medium when the plates were being fed and these measures
reduced the rate of bacterial contamination. This is demonstrated
by the fact that no bacterial infection occurred after FE 51.
b) Yeast and Mould Infection.
The pattern of yeast and mould infection differed from bacterial
infection. Yeast and mould infections occurred relatively late
(mean 52.78 and 49.39 days respectively after fusion), and bore
little relationship to feeding the plates The infection tended to
affect only one or two wells in the plate in the first instance,
and these were usually at the periphery of the plate. Infection
also spread to adjacent plates in the incubator, rather than to
plates of the same fusion. For these reasons it was concluded that
yeast and mould infection occurred because of airborne
contamination within the incubator (although yeast contamination
may also have occurred in sane cases when the plate was being
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fed) . The CC>2 incubator relied for its humidity on a tray of water
placed in the bottom of the incubator . The warm moist conditions
thus produced were an ideal breeding ground for these organisms
which could then spread in droplet form. One infected well would
then act as a source of infection for adjacent wells and plates.
Attempts to arrest established infection and save the plate by
clearing out the infected well and rinsing it several times with
70% alcohol were unsuccessful.
Attempts to prevent infection were only partially
successful.Initially the incubator was emptied and cleaned weekly
but this caused more disturbance of the plates and an increase in
the rate of infection . Regular cleaning of the incubator was
therefore abandoned at an early stage.The plates were stacked in
chronological order in the incubator and the close stacking of
the plates may have facilitated cross infection (plate 4) . It
might have been useful in retrospect to store the plates of each
fusion in separate plastic boxes. The addition of an antiseptic to
the water in the incubator was avoided since this might have
inhibited hybrid growth.
The incidence of infection may also have been related to the
layout of the laboratory. Ideally all work should be carried out
in a clean tissue culture laboratory, with the CO2 incubator and
inverse phase microscope beside the hood so that there would be
minimal disruption of the plates. Whilst all fusion experiments
and cell culturing work were performed in a class II
microbiological safety cabinet this hood was situated in a room
which had a permanent dust problem from the roof (plate 5).The OO2
incubator was situated in a separate roan in the midst of a
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variety of other equipment and so plates would be exposed to
contamination every time the door of the incubator was opened. In
addition plates had to be carried along an outside corridor
between hood,incubator and microscope, again increasing the risk
of contamination (plates 6 ). Thus the physical layout of the
laboratory was somewhat unsuitable for the work of this study but






The Envair Class II microbiological safety cabinet in which all
sterile cell fusion and culture work was performed.
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In this study 25 hybridomas were obtained from 231 successful
plates (5544 wells). This gave a hybrid rate of 0.108 hybrids per
24 well plate, or 0.004 hybrids per well. Alternatively the rate
can be expressed as 0.008hybrids per 10®lymphocytes used. These
various expressions of hybrid rate were all necessary to allow
comparison with other studies some of which are now summarised for
comparison.
Kohler et al (1976) estimated that approximately one hybrid was
obtained for every 10® lymphocytes used for fusion using a
mouse/mouse system. Schlom et al (1980) obtained 301 hybrids from
1460 wells,a rate of 0.206 hybrids per well. However of these only
52 secreted immunoglobulin (0.035 hybrids per well) and only 23
remained stable immunoglobulin secretors(0.015 hybrids per well).
These results were obtained in a human lymphocyte/mouse myeloma
cell fusion. Further experience of this system increased the
number of hybrids to 505 from 2060 wells (0.245 hybrids per well)
although only 62 secreted immunoglobulin (0.03 hybrids per
well)and only 23 were stable in culture (0.011 hybrids per well).
(Wunderlich et al 1981). Yuan et al (1982) using a mouse/mouse
hi
fusion system reported hybrid growth in 80% of the wells seeded.
Papsidero et al.(1983) obtained approximately 3000 hybrids from a
mouse/mouse fusion system although only about 5% of these secreted
immunoglobulin of any interest.
The reported fusion efficiency of the HMy2 cell line in different
hands varies and is sometimes difficult to discern!
Edwards et al,(1982) described a hybrid efficiency of one hybrid
per lO^tolO8 lymphocytes used. Sikora et al. (1982(b)) reported 71
hybrids from 5 patients from the fusion of glioma infiltrating
lymphocytes with the HMy2 cell line. The same author ( Sikora et
al.l983(a)) obtained 55 hybrids from 180 patients by the fusion of
tumour node lymphocytes with the HMy2 cell line. Olsson et al.
(1984) obtained 305 immunoglobulin secreting hybrids from 1436
wells of a human human fusion,fusing PWM stimulated peripheral
blood lymphocytes with the PHL4 cell line, but only one hybrid
secreting immunoglobulin of required specificity survived in
culture. Warenius et al .(1983) described hybrids appearing in
43-55% of wells using HMy2 in which lymphocytes were prestimulated
with pokeweed mitogen compared with only 12-19% of wells when
pokeweed mitogen was not used. However it was then revealed that
only 12 hybrids grew adequately in prolonged in-vitro culture.
Experience with other human myeloma cell lines has been reported
as follows.
Croce et al .(1980(a)) obtained hybrids in 20 out of 24 wells
using the GM1500 cell line and peripheral blood
lymphocytes.Shoenfield et al,(1982) obtained 108 hybrids from 4254
wells (0.02 hybrids per well), using the GM4677 subline of the
GM1500 cell line, and either peripheral blood or spleen
lymphocytes. Kozbor et al , (1982) obtained one hybrid per 105
lymphocytes when these had been transformed with Epstein Barr
virus compared with one hybrid per 107 lymphocytes with no EBV
transformation,using a variant of the GM 1500 cell line. Olsson et
al.(1983) described 39% of 53 fusions producing hybrids with the
RHL4 cell line and 19% of fusions using the SKO 007 cell line.
Overall results however produced only 21 antibody secreting
hybrids from 100 fusions . Glassy et al,(1983) obtained a range of
0.54 to 2.9 hybrids per 106 lymphocytes depending on the type of
lymphocytes used, using the UC729-6 myeloma line. Overall it
appears that mouse/mouse fusions were the most efficient hybrid
producers, and that mouse human fusions were more efficient than
human human fusions at producing hybrids although many of these
resulting hybrids are unstable in culture.
The hybrid rate from human/human fusions is lower than that of
mouse /human or mouse/mouse fusions and it varies considerably.
Experience with the HMy2 cell line suggests that it has a rate of
hybrid production comparable with other human myeloma lines (Cote
et al.;1983). The results obtained in this study compare rather
poorly with other published results confirming the observation by
Sikora et al,(1982(c)) that human hybrid production varied in
efficiency from laboratory to laboratory. The results obtained in
this study compare with the lower end of the hybrid rate reported
by Edwards et al , (1982). Sane of the factors which may be
responsible for this low rate of hybrid production will be
discussed in the following paragraphs.
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5.2.3. Pokeweed Mitogen (PWM).
The use of PWM to prestimulate lymphocytes prior to fusion is
becoming more widespread and the majority of studies suggest that
this step increases the rate of hybrid production. Shoenfield et
al.(1982) described the stimulation of peripheral blood lymphoctes
with a 1/100 dilution of PWM for 48 hours as giving a much
increased rate of hybrid production. Olsson et al, (1983)
stimulated peripheral blood lymphocytes with pokeweed mitogen at
2.5 ug/ml for 5-7 days and this significantly improved the rate of
hybrid production. Warenius et al, (1982) stimulated node
lymphocytes with PWM at 20ug/ml for 5 days ,resulting in improved
rates of hybrid production. Sikora et al . (1983(a)) stated
,however, that PWM did not increase the rate of hybrid production
although no data was given to support this. Olsson et al/(1983(a))
stimulated peripheral blood lymphocytes at 2.5 ug/ml/lO^ cells for
5 days. It is believed that prestimulation of lymphocytes with PWM
is a useful step towards increased hybrid production. The various
regimes used for stimulating lymphocytes suggests that further
investigation is required to decide upon the optimum stimulation
regime and this itself may vary depending on the source of
lymphocytes used.
From this study tritiated thymidine uptake gave reproducible
results when measuring the effects of PWM stimulation and was the
preferred method. Neither of the two regimes used to stimulate
lymphocytes prior to fusion were the optimum regimes
suggested by the data from the tritiated thymidine uptake
experiments. The two regimes selected for use in this study were
chosen on the basis of other mitogen experiments performed
previously in the laboratory (data not presented) . The two
regimes selected were sufficiently different to allow reasonable
comparison between them.The tritiated thymidine uptake experiments
were performed concurrently with the fusion experiments as node
lymphocytes became available. A criticism of this study is that
the tritiated thymidine uptake experiments should have been
performed first before carrying out the fusion experiments , so
that the optimum regime for lymphocyte stimulation could be
selected. This may indicate one cause of the poor hybrid rate
obtained in this study. As has teen discussed the level of
uptake at five days was uniformly lower than at two days in spite
of increasing the feeding regimes. This suggests that many cells
which were dividing at two days were no longer doing so at five
days . This was confirmed by the cell counts which showed a lower
number of cells present at five days than at two. The plateau
effect of the dose-response curve using various concentrations of
PWM appeared to occur at the 8ug/ml level. This is thought to
represent the point at which all lymphocytes capable of being
stimulated by PWM have indeed been stimulated. Fran this data it
appears that a regime of stimulating lymphocytes at 16ug/ml for
two days might be the most beneficial. This regime remains to be
tested in fusion experiments, and to this extent the study of the
effects of FWM remains incomplete. In addition in the experience
of this study and previous wcrk done in the
laboratory , numerous axillary lymph nodes were found to be
hypo-reactive and sometimes totally anergic following PWM
stimulation. This may have contributed to the lack of success
using PWM.
5.2.4. Feeder Cells.
The use of feeder cells to improve hybrid efficiency appears to
have arisen by the chance observation that the wells of a mouse
mouse fusion which produced most hybrids were those in which
active macrophages could be seen (Fazekas et al (1980(a)), these
cells presumably having come from the spleen cell suspension.
Feeder cells have been used widely and successfully to improve the
rate of hybrid production, although the mechanism by which this
occurs remains unclear.
Fazekas (1980(b)) suggested that feeder cells acted first by
phagocytosing the large amount of possibly toxic cell debris from
the large number of dying cells in each well. Thereafter they acted
as feeder cells producing and secreting substances beneficial to
hybrid growth. Reading (1982) suggested that the use of feeder
cells reduced the need for medium changes and that this decreased
the risk of contamination. Lernhardt et al ,(1978) pointed out
that feeder cells can be equally effective if derived from
different species .
Two main types of feeder cells are described as increasing the
success rate of mouse-mouse fusions, these being mouse peritoneal
macrophages and foetal mouse thymocytes although other cell
types have also been investigated.
Mouse peritoneal macrophages were found to increase hybrid
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efficiency in mouse-mouse fusions by a number of authors ( Shulman
et al.,1978, Fazekas et al.,1980 (a)) and also in mouse-human
fusions (Edwards et al.,1980,Lernhardt et al.,1978). Thymocytes
were likewise found to be of value in mouse-mouse fusions and also
in the cloning of murine hybrids (Schlom et al 1980).
Astaldi et al/(1980,1981) compared the efficiency of these cells
with the supernatant of a culture of human endothelial cells
derived from the umbilical cord. In this study using mouse-mouse
fusions , the human endothelial cell supernatant (HECS) was found
to be very efficient at increasing hybrid efficiency. The active
ingredient in HECS was shown to be of molecular weight greater
than 50,000, stable in storage and not a mitogen to peripheral
blood lymphocytes. The active ingredient was thought to bind to
hybridomas and acted equally well on mouse-mouse and mouse-human
hybridomas. This would suggest that part of the activity of feeder
cells is the secretion of growth promoting substances .Less is
known about the effects of feeder cells on human-human hybrids.
Edwards et al (1982) reported that mouse peritoneal macrophage
feeder cells increased the hybrid rate fivefold, but Sikora et al»
(1982(a)) stated that feeder cells did not improve hybrid
production,both studies using HMy2 as parent myeloma. Kennett et
al,(1978) used irradiated human foetal fibroblasts to increase
the hybrid frequency of mouse-human hybrids. Olsson et al, (1983)
reported the benefits of using human monocytes and thymocytes in
human-human fusions using the SK0 007 and RHL4 cell lines
although the data presented is scarce. Brodin et al , (1983)
described the use of peripheral blood monocytes as feeders to
improve the cloning efficiency of human hybridomas.
In this thesis it was decided to investigate the addition of human
feeder cells to hybrid cultures. It was decided that it vould be
inadvisable to use feeder cells of another species since this
study was investigating the production of human human hybrids and
the addition of cells frcm another species may allow overgrowth of
cells of that species.
In choosing feeder cells it was decided to use close equivalents
of those cells which had been found to be beneficial in murine
work . Thus independently of Olsson et al. (1983) peripheral blood
monocytes were chosen since they were readily available, were
known to have phagocytic . ability and resembled the use of murine
macrophages.Thymocytes were likewise chosen because of the
documented benefit of murine thymocytes and a constant supply of
these was available (courtesy of Mr K.Reid, Cardiac Surgeon,Royal
Hospital for Sick Children, Edinburgh). The failure of feeder
cells to improve the rate of hybrid production was disappointing
and suggests that further investigation is required to define the
precise qualities of feeder cells which are important to hybrid
growth, and to investigate more fully those human feeder cells
which are of use. Since the failure of feeder cells in this study
to improve hybrid production may be related to other problems with
the fusion system it is suggested that peripheral blood monocytes
and thymocytes frcm young children are worthy of further
investigation.
5.2.5. Cell Numbers.
The ratio of myeloma and lymphocyte cells in fusion experiments
varies widely in different studies. Indeed it has been suggested
that the initial excess of spleen cells used by Kohler and
Milstein came about more by chance than design. Other studies have
used a large variety of lymphocyte/myeloma ratio. Sikora et al.
(1982(b)) used a 3:1 excess of myeloma cells in the production of
human human hybridomas although this was said to be due to a
relative lack of available lymphocytes. Kozbor et al.(1982), Cote
et al (1983), Gigliotti et al.(1984) used equal numbers of
lymphocytes and myeloma cells .Glassy et al.(1983)_3 used a 2:1
ratio of lymphocyte to myeloma , Wunderlich et al,(1981) a 4:1
ratio. Edwards et al.(1982), Warenius et al<(1983) both used a
10:1 lymphocyte/myeloma cell ratio.
Relatively little attention has been paid to investigating the
benefits of these various ratios, and so it was decided to
investigate the effects of a 1:1, 5:1 and 10:1 lymphocyte:myeloma
ratio on hybridcma production. The following factors may be of
importance in determining the optimum cell ratio .When the two cell
types are mixed in suspension in the PEG solution they will freely
move freely and collide with each other. Successful fusion
requires that one lymphocyte and one myeloma cell collide and fuse
together. Assuming the cells are of equal size one would expect
that a 1:1 ratio would optimise the possibility of successful
collisions.However the HMy2 cell is much larger than the
lymphocyte (plate? ). Hence an excess of lymphocytes may increase
the chances of successful fusion.
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PLATE
Cell suspension of a mixture of HMy2 cells (large cells) and
axillary node lymphocytes (small cells) to demonstrate their
respective sizes.
(Giemsa stain, magnification xlOO).
ox\
In addition successful fusion requires the coming together of two
actively dividing cells. The proportion of lymphocytes actively
dividing at the time of fusion is much less than the HMy2 cell
line and therefore an excess of lymphocytes seem to be required
for successful fusion.
Whilst no advantage was found in this study by altering cell
ratios, there seems to be sound theoretical grounds for using an
excess of lymphocytes and for these reasons a 10:1 lymphocyte:HMy2
e
ratio was used for all subseq^unt fusions in this study.
5.2.6. Selective Medium.
It has been suggested that azaserine may be more appropriate than
aminopterin for use in selective medium (Edwards et al., 1982)
In this series azaserine was shown to be more efficient than
aminopterin when the overall results were compared. Unfortunately
this did not occur when direct comparison between the two was
made. The benficial effect of azaserine was therefore inconclusive
since other factors may have influenced the successful fusions
using azaserine. Whilst accepting this criticism, the data does
suggest that azaserine is more useful in terms of hybrid
production and this requires further controlled investigation. It
may be that the number of plates involved in the controlled series
was too small to demonstrate the difference. The use of azaserine




a) Time of Appearance.
The time after fusion at which hybrids appeared varied widely
(range 24-69 days) but there was no observable difference in the
growth pattern of hybrids obtained either early or late after
fusion. Therefore all plates were maintained in culture for as
long as possible until infection supervened.
The variation in time at which hybrids appear may explain in part
the low hybrid rate of this study. Plates were included in the
results of this study if they survived more than 24 days in
culture (this being the earliest date at which a hybrid
appeared). Thus a plate which developed,say a yeast infection at
day 30 would be scored as negative whereas had the plate survived
it might have produced a hybrid at a later date. Thus a plate
which would have become a positive was scored as a negative,-ie
the scoring system employed in this study allows a potentially
high number of false negative results. The alternative would be
to employ a higher threshold at which plates were included in the
results,which would have the effect of reducing the number of
possible false negatives but of decreasing the number of plates
in the study. This effect is demonstrated on table 5 (page 110) in
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which the effects of adopting different times of scoring plates en
the hybridoma rate are shown. This manner of data presentation can
be misleading in one respect ,in that plates may produce hybrids
and then become contaminated before they reached this threshold,
allowing a falsely high positive error to be introduced. As an
example if plates were to be scored only if they survived forty
days or more in culture and a plate produced 2 hybrids on day 30
and developed yeast contamination on day 35 the hybrids would be
counted but the plate regarded a a technical failure.
Perhaps a more appropriate method of presentation would be to
raise the minimum time in culture to 40 days but to include in
these results any plate which produces a hybrid before this time.
The effect of doing this has been demonstrated in table 5. In
conclusion the criteria by which plates are included in the
results will determine to sane extent the hybrid rate. Whilst the
method adopted in this study allows the maximum number of plates
to be included ,it will produce the highest number of false
negative plates and may artificially reduce the overall hybrid
rate. When compared with other methods of scoring plates however
,it appears to offer the fairest way of collating results. As
table 5 shows altering the results in this way brings the overall
hybrid rate in this study closer to those of other studies already
quoted.
b) Culture Conditions.
The effects of varying the various parameters of the fusion
experiment on the rate of hybrid production have already been
discussed. Of particular interest is the relationship between
hybridoma production and the date on which the corresponding
12 U
fusion experiment was performed. From table XO there appears to be
definite clusters of dates of fusions which were most efficient
at producing hybrids, which is of interest since fusion exeriments
were carried out regularly every week throughout the course of
this study. This would suggest that there may be other factors
operating at these particular times which produce successful
fusion. Such factors may include the quality of the FCS (although
all batches were tested as described), or the quality or the pH of
the particular batch of PEG in use at that time. It has not been
possible to identify in retrospect any particular factor which may
have been responsible for this phenomenon, but it does demonstrate
how little is known of the precise factors necessary for cell
fusion.
c) Hybrid Growth.
Once established,hybrids grew rapidly in culture and could be
frozen and thawed reliably. It was disappointing that so many
hybridcmas failed to survive transfer from the 24 well plates to
the 25ml tissue culture flasks. Strenuous efforts were made with
the later hybrids to dilute them very gently. Most of the
hybridcmas were probably lost at this stage because of the
difficulties of maintaining the pH of a small amount of medium in
these flasks in spite of gassing with C0X, and this was improved
by changing the medium from TCM-B to TCM-A at this stage.
5.2.8. Immunoglobulin Secretion.
From the agglutination assay all hybrids were found to secrete igG
which was to be expected since this is secreted by the HMy2 line.
A few hybrids also secreted igM giving evidence of new
immunoglobulin secretion by these hybrids at least. As has been
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discussed, the agglutination reaction did not provide a means of
accurately defining the immunoglobulin secreted.
In addition the supernatants were only tested for IgG and IgM in
the first instance, on the assumption that they would secrete one
of these classes of immunoglobulin.
Cote et al (1983) detected IgA secreted by hybridomas of axillary
node lymphocytes fused with HMy2 cells. Following this report
attempts were made to identify IgA in the hybridoma supernatants,
but none was found.
The level of immunoglobulin secretion by the hybridomas in this
study was of the order of 0.01-0.82 ug/ml of supernatant.
Edwards et al , (1982) reported an immunoglobulin secretion of
0.5-0.8ug/ml and Sikora et al.(1983(a)) a rate of l-5ug/ml.The
parent ARH-77 line secreted immunoglobulin of the order of 12.1
ug/ml of Ig per 10^ cells .Other human hybridomas are reported as
secreting approximately the same amount of immunoglobulin. Olsson
et al. (1980) obtained 3-11 ug/ml from hybrids of the U266 line.
Kozbor et al,(1983) obtained 3-6ug/ml from hybrids of the GM1500
line. This was described as being 13 to 18 times greater than the
concentration of immunoglobulin secreted by EBV transformed
lymphocytes on their own. Glassy et al. (1983) obtained 3-9 ug/ml
frcm hybrids of the U729-6 line. Human-mouse hybrids are
described as secreting a slightly higher immunoglobulin level
(10-26ug/ml by Schlom et al. 1980, 8.3ug/ml by Nowinski et al
1980). The agglutination assay was found to be a valuable means
of screening hybridoma supernatant and measuring the
concentration of immunoglobulin present. This study confirmed the
low level of immunoglobulin secretion by human-human hybridomas
and this remains a problem.
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The finding that some hybridomas secreted both IgG and IgM on the
basis of the agglutination assay was of interest. Assuming that
each parent cell was committed to the production of only one
antibody this provided evidence that the hybridoma was secreting
antibody derived from both parent cells. It is not possible on the
basis of this assay to ascertain whether the hybridomas were
secreting two different classes (IgG and IgM) of immunoglobulin
simultaneously or whether the agglutination assay was detecting
immunoglobulin chains from both parent cells which had reformed to
produce a new antibody. It is planned to further investigate these
supernatants at a later time to determine whether, in fact, the
hybridomas were secreting two different antibodies
simultaneously.
5.2.9. Cloning.
Hybridomas obtained in this study were found to clone readily by
limiting dilution without the addition of feeder cells, at a
concentration of one to two cells per well. In addition hybrids
which secreted both IgG and IgM were found to do this through
several cloning procedures indicating that hybridomas from the
HMy2 cell line clone satisfactorily.
Whilst the importance of regular cloning of hybridomas to maintain
levels of immunoglobulin secretion is emphasised in many studies,
no hybridoma was kept in continuous culture for longer than 3
months since none of them secreted McAbs of sufficient interest
to merit prolonged investigation. Thus once a hybridoma was grown
in culture and sufficient supernatant gathered for
characterisation the hybridoma was frozen and stored.
5.2.10. The Reactvity of Hybridoma Supernatants.
As has been discussed already in this chapter, the
radioimmunoassay was found to be an unsatisfactory method of
assessing the reactivity of McAbs and was abandoned. The
immunoperoxidase method was developed therefore as the technique
of choice for testing the reactivity of McAbs to breast cancer
cell s.
Whilst the staining obtained using the immunoperoxidase technique
on cytocentrifuge preparations of tumour cells was not very
clearly defined there was no discernible selective binding of
McAbs to these cells.
The interpretation of staining on tumour sections was difficult
since this required careful comparison of each slide with the
corresponding negative control slides. This background staining
presented in three ways. Firstly moderate staining was seen in
much of the fibrous connective tissue of the breast , this
presumably being due either to the presence of free immunoglobulin
or possibly a non-specific reaction to the antigenic epitopes on
the connective tissue. This staining tended to be spread uniformly
throughout the connective tissue. Secondly isolated cells within
tumour cell collections were seen to stain very darkly around the
cell membrane. This was presumed to indicate the presence of
surface immunoglobulin bearing cells possibly macrophages or
plasma cells within the tumour. These cells are difficult to
distinguish histologically from tumour cells. Thirdly staining was
occasionally seen in some areas at the luminal edge of normal
ep ithelium. The reason for this part of the background stain is
unclear. These three forms of background staining often made
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the interpretation of McAb staining difficult. This was
particularly true of the cells within tumour cell
aggregates which stained darkly. However no McAb staining
pattern resembled the positive anti EMA stain and after careful
and repeated examination of the slides, no McAb was seen to bind
selectively to the breast cancer cells.The pattern of distribution
of immunoglobulin found within breast tumours was demonstrated by
Richman (1976) using immunofluorescence to demonstrate the
binding of anti-human immunoglobulin antibodies to sections of
both benign and malignant breast tissue. The pattern of
immunoglobulin binding in that study was similiar to that





The production of human McAbs with reactivity against human tumour
cells raised expectations that these antibodies would provide new
avenues for treating cancer. Whilst initial studies concentrated
on the production of murine McAbs, these may be unsuitable for
clinical use because of their relative lack of specificity and
because of possible hypersensitivity reactions with repeated
usage. This study has explored the production of autologous human
monoclonal antibodies with reactivity against human breast
carcinoma cells. It has demonstrated both the feasibility of
producing such McAbs and the problems associated with their
production.
There appear to be two main problems which are currently limiting
the clinical application of monoclonal antibodies, these being 1)
the technical difficulties associated with cell fusion and human
monoclonal antibody production, and 2) the lack of precise
knowledge of the nature and distribution of tumour antigens within
tumour cell populations. This study aimed to investigate the
technical problems of monoclonal antibody production, and also
reviewed the available evidence about tumour antigens.
The difficulties of producing human monoclonal antibodies
because of the low rate of hybridoma production and the low rate
of immunoglobulin secretion has been well documented. The low rate
of hybridoma production by cell fusion was investigated in this
study, by studying various factors involved in
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the fusion experiment. The factors studied were a) the
prestimulation of lymphocytes with pokeweed mitogen ,b) the
addition of feeder cells into the fusion experiment, c) the use of
azaserine in place of aminopterin in the selective medium, and d)
the alteration of the cell numbers used for the fusion
experiment. Prestimulation of lymphocytes with PWM did not , in
this study, improve the rate of hybridoma production. This was
disappointing since other studies had demonstrated benefit from
PWM. The failure of PWM in this study may be due to the regimes
used, or the overall hybridoma rate was to low to allow any
discernible benefit to be demonstrated. In future it is planned to
use EBV transformation of lymphocytes prior to fusion to stimulate
selective growth of the B-cell population. The addition of feeder
cells also produced no improvement in the hybridoma rate in this
system. Very little is known about the mechanisms by which feeder
cells have produced their beneficial effect in murine McAb
production and feeder cells require further detailed
investigation. The use of azaserine in place of aminopterin did
produce an overall improvement in the rate of hybridoma production
in this study and is recommended for routine use. A 10:1
lymphocyte/myeloma ratio was used routinely since no benefit was
obtained from altering this ratio. Of particular interest was the
finding that hybridomas arose in clusters from fusion experiments
performed within short periods of time. The factors essential for
successful fusion are reviewed in the text and it is concluded
that there is little information available about the mechanisms
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involved in cell fusion. There is a need for more basic research
to improve our understanding of cell fusion so that the rate of
human hybridoma production may be improved. The rate of
immunoglobulin secretion by hybridomas is a function primarily of
the myeloma cell parent and was not further investigated in this
study.
Problems were encountered with both the radioimmunoassay and the
immunoperoxidase method used in this study to determine sites of
binding of the McAb to breast carcinoma cells. Whilst the
immunoperoxidase method was the method of choice in this study,
there remains a need for the more accurate detection of sites of
McAb binding to breast carcinoma cells which closely resembles the
in-vivo activity of the McAb.
The nature and distribution of tumour antigens within breast
carcinoma cell populations remains unclear. It has been documented
in the literature that there is a heterogeneity of antigenic
expression as detected by McAbs within breast carcinoma cell
populations and that there is seme antigenic cross- reactivity of
antigens between tissues from benign and malignant breast
tumours. It is concluded that the ultimate clinical value of
human anti-breast carcinaoma antibodies will be determined by the
nature and distribution of these antigens. For the foreseeable
future it appears that the main role of anti-breast cancer McAbs




MATERIALS AND REAGENTS USED.
1. Tissue Culture Media.
a) Tisssue Culture Medium (TCM) A





Distilled Water to Make 1000ml.
b) TCM-B






Non Essential Amino Acids:-10 ml of xlOO solution.
Distilled water to make 1000ml.
2. Foetal Calf Serum (FCS) (Gibco)
Heat inactivated at 56°C for one hour.
3. Polyethylene Glycol (PEG)
Sigma cat. no p3515. Molecular Weight 1000.
23S
PEG Solution 1.
PEG 2.5g autoclaved at 15 psi for 20 minutes,
Solution cooled to 60°C
0.75ml of Dimethyl Sulfoxide (DMSO) and 2.75 ml of TCM-B
added.
5% Na HCO3 use<3 to adjust pH to 7 .8.
PEG Solution 2.
PEG 2.5g autoclaved at 15 psi for 20 minutes
Solution cooled to 60°C.
7.5ml of TCM-B added
5% NaHC03 used to adjust pH to 7.8.
(DMSO - Sigma cat. no D5879).











0.01N NaOH to make 100ml.
Radio immunoassay.
Poly-L-Lysine Sigma cat.no.Pi399.
Mouse anti huma kappa and lambda chain antibodies.
Bethseda Research Lab cat.no. 31030 & 31040.





Distilled water to make 1000ml. (Density 1.0770)










Distilled water to make 1000ml.
Acetate Buffer
1M Sodium Acetate 50ml
IN HC1 10ml
Distilled water to make 200ml.
Aminoethyl Carbizole
AEC 40mg
N,N Dimethyl Formamide 10ml
Antibodies (all DAKO,Denmark)
Rabbit anti Human IgG cat no A290
Rabbit anti Himan IgM cat no A091
Swine anti Rabbit cat no Z196
Rabbit peroxidase/antiperoxidase cat. no.Z113.
2V7
Swine serum obtained from local abbatoir and heat
inactivated at 56°C for one hour.
. Miscellaneous
Collagenese la Sigma cat. no C9891
Trypsin Difco.
Trypsin Inhibitor Sigma cat. no T9003.
Cultured Cell Lines.
LICR/L0N/HMy2
Myeloma cell line used for cell fusions.
Reference Edwards et al 1982.
MCF-7
Breast carcinoma cell line derived from pleural effusion of
patient with breast carcincma.
Reference Soule et al 1973.
MDA-MB 231
Breast Carcinoma cell lineobtained from pleural effusion of
patient with metastatic breast cancer.
Reference Cailleau et al 1974.
CLA4
Human lymph&l.astoid cell line
Reference Steel 1972.
DET 6.





Summary of patients from whom axillary node
lymphocytes were obtained for use in this study.
Number of Patients = 70.
Mean Age 51.75 years (Range 33-81).
Axillary Operation Performed (in Conjunction with
Surgery to the Breast Tumour).
Axillary Sampling ( Lowest 5 Axillary Lymph Nodes
Removed) 13.
Lower Axillary Dissection (Clearance of Axillary Nodes
up to the level of the Axillary Vein) 20.
Axillary Clearance ( Removal of All Axillary Lymph
Nodes) 37.
Patients in Whom Subsequent Histological Examination
Demonstrated The Presence of Axillary Node Metastases
in One or More Nodes 23.
Patients with No Axillary Metastases 47.
Screening Procedures.





Haematological and Biochemical Profile.
In all these patients the above investigations were




Pokeweed Mitogen Stimulation of Lymphocytes.
Preliminary Experiments.
Tritiated Thymidine Uptake Experiment using T.N.L.E. 1~l I
Pokeweed Mitogen Concentration (ug/ml)
2.4 O
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Pokeweed Mitogen Stimulation of Lymphocytes.
Preliminary Experiments.
Tritiated Thymidine Uptake Experiment using T.N.L.E.
Pokeweed Mitogen Concentration (ug/ml)
F\<son.E 1
Pokeweed Mitogen Stimulation of Lymphocytes.
Preliminary Experiments.


























Pokeweed Mitogen Concentration (ug/ml)
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Pokeweed Mitogen Stimulation of Lymphocytes.
Preliminary Experiments.













Pokeweed Mitogen Stimulation of Lymphocytes.
Preliminary Experiments.
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Pokeweed Mitogen Concentration (ug/ml)
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Pokeweed Mitogen Stimulation of Lymphocytes.
Preliminary Experiments.
Tritiated Thymidine Uptake Experiment using T.N.L.E.
10% FCS + PWM Feeds.
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Pokeweed Mitogen Stimulation of Lymphocytes.
Preliminary Experiments.
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Pokeweed Mitogen Concentration,
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Pokeweed Mitogen Stimulation of Lymphocytes.
Preliminary Experiments.
Tritiated Thymidine Uptake Experiment using T.N.L.E. "2.#£>
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Pokeweed Mitogen Stimulation of Lymphocytes.
Preliminary Experiments.

















Pokeweed Mitogen Stimulation of Lymphocytes.
Preliminary Experiments.
Tritiated Thymidine Uptake Experiment using T.N.L.E.
10% FCS + PWM Feeds.
Pokeweed Mitogen Concentration (ug/ml)
Pi&uae IS'.
Pokeweed Mitogen Stimulation of Lymphocytes.
Preliminary Experiments.
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